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1 SUMMARY 
1.1 Scope of the submission 
The remit of the Evidence Review Group (ERG) is to comment on the clinical and cost-
effectiveness evidence submitted to the National Institute for Health and Care Excellence 
(NICE) as part of the single technology appraisal (STA) process. Clinical and economic 
evidence have been submitted to NICE from Boehringer Ingelheim in support of the use of 
nintedanib (Vargatef) for previously treated locally advanced or metastatic non-small cell 
lung cancer (NSCLC) of adult patients with adenocarcinoma tumour histology. 
1.2 Critique of the decision problem in the company’s submission 
The population specified in the scope is adults with locally advanced or metastatic NSCLC 
that has progressed following prior chemotherapy. The decision problem addressed by the 
company is patients with locally advanced, metastatic or locally recurrent NSCLC of 
adenocarcinoma tumour histology who had previously received first-line chemotherapy. This 
is in line with the anticipated full marketing authorisation for nintedanib which differs to that of 
the scope by including the term “locally recurrent” and restricting NSCLC to 
adenocarcinoma. The ERG notes that to be classified as locally recurrent, a patient would 
initially present with early stage disease (stage I, II or IIIA) and be treated with surgery or 
radical radiotherapy and then relapse in the same area without metastases. Since the 
anticipated license also stipulates patients must have previously received first-line 
chemotherapy, then all patients would have locally advanced or metastatic disease at the 
time of second-line treatment. Treatment for locally advanced (be it recurrent or present 
since diagnosis) or metastatic disease at this point in the disease course is identical. 
The anticipated license also specifies that nintedanib should be administered in combination 
with docetaxel. Both docetaxel monotherapy and erlotinib monotherapy are considered as 
comparators in the company’s submission (CS). However the company states that erlotinib 
is not a relevant comparator to nintedanib plus docetaxel and this is only considered a 
comparator by the company for secondary analyses. The ERG agrees with the company that 
erlotinib is not a relevant comparator. A preliminary recommendation by NICE in February 
and August 2014 is that erlotinib should not be recommended for treating locally advanced 
or metastatic NSCLC that has progressed after non-targeted chemotherapy in people with 
tumours that are EGFR-negative. Furthermore, in clinical practice the ERG notes that the 
majority of patients with EGFR-positive disease will already have received erlotinib (or 
another tyrosine-kinase inhibitor [TKI]) as first-line treatment so would not receive erlotinib as 
a second-line treatment. Finally, patients who would be considered fit enough (i.e. Eastern 
Cooperative Oncology Group [ECOG] performance status [PS] 0 to 1) to receive nintedanib 
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would also need to be considered fit enough to receive docetaxel (since docetaxel is 
administered in combination with nintedanib). Hence only docetaxel is considered to be a 
relevant comparator by the ERG.  
Clinical evidence is presented for all outcomes specified in the scope and cost-effectiveness 
results are expressed in terms of incremental cost per quality adjusted life year (QALY) 
gained. No subgroups were specified in the decision problem and no equality issues were 
identified. 
1.3 Summary of clinical effectiveness evidence submitted by the 
company 
Direct evidence is presented for nintedanib plus docetaxel vs placebo plus docetaxel from 
one phase III double-blind randomised controlled trial (RCT) (LUME-Lung 1). The company 
states that as not all patients in LUME-Lung 1 had histology of adenocarcinoma but that as 
patients who did not have adenocarcinoma are expected to be outside the licensed 
population only data for patients with adenocarcinoma are presented. While some of these 
patients had locally recurrent, as opposed to locally advanced or metastatic disease at 
diagnosis, the vast majority (94.2%) had metastatic disease at screening. 
The findings from LUME-Lung 1 suggested that nintedanib plus docetaxel significantly 
improve progression-free survival (PFS) and overall survival (OS) in comparison to placebo 
plus docetaxel. The gain in median PFS is 1.2 months (4.0 months vs 2.8 months; hazard 
ratio [HR] 0.77, 95% confidence interval [CI]: 0.62 to 0.96) based on the primary analysis 
with a median follow-up of 7.1 months. Based on the final analysis, after a median follow-up 
of 31.7 months, the gain in PFS is 1.4 months (4.2 months vs 2.8 months; HR 0.84, 95% CI: 
0.71 to 1.00). The gain in median OS is 2.3 months (12.6 months vs 10.3 months; HR 0.83, 
95% CI: 0.70 to 0.99). Pre-specified and post-hoc subgroup analyses for both PFS and OS 
support the findings for the population of patients with adenocarcinoma as a whole. 
Specific adverse events (AEs) occurring more often in the nintedanib plus docetaxel arm 
than in the placebo plus docetaxel arm and considered to be AEs of special interest (AESIs) 
were diarrhoea (43.4% vs 24.6%), nausea (28.4% vs 17.7%) and vomiting (19.4% vs 
12.3%). These AEs were successfully managed by dose reduction, dose interruption and/or 
symptomatic treatment and led to permanent nintedanib discontinuation in <1% of patients. 
Other reported AESIs associated with nintedanib treatment included increases in alanine 
aminotransferase (ALT) (37.8% vs 9.3%) and aspartate transaminase (AST) (30.3% vs 
7.2%). These were reported to be generally reversible and led to permanent nintedanib 
discontinuation in <2% of patients. The incidence of Common Terminology Criteria for 
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Adverse Events (CTCAE) grade ≥3 AEs and CTCAE grade ≥3 SAEs were greater in the 
nintedanib plus docetaxel arm (75.9% and 31.3%) than the placebo plus docetaxel arm 
(68.5% and 26.6%). The AEs of greatest concern were fatal AEs and some imbalances were 
reported between treatment arms; fatal AEs being more common in the nintedanib plus 
docetaxel arm (6.3%) compared to the placebo plus docetaxel arm (2.4%). However, the 
company considers that these figures may be partially confounded by a longer median 
duration of treatment with nintedanib/placebo (4.2 months vs 3.0 months respectively) and 
docetaxel (median 5 and 4 cycles in the intervention and comparator arms respectively).  
There was no significant difference over time, or between arms, in global health 
status/quality of life (QOL) or self-reported health related quality of life (HRQoL) 
assessments for cough, dyspnea or pain in LUME-Lung 1. Statistically significant 
improvements were observed for three individual pain items (‘have pain’, ‘pain in chest’ and 
‘pain in arm and shoulder’) in favour of nintedanib plus docetaxel, while time to deterioration 
(TTD) for diarrhoea was significantly worsened in this arm. 
Additional evidence is presented for nintedanib plus docetaxel compared to docetaxel and 
erlotinib by means of mixed treatment comparisons (MTCs) and, where possible, Bucher 
indirect comparisons. Compared to docetaxel, the base-case MTC analyses (which include 
four trials) report significant improvements in OS (HR 0.83, 95% CI: 0.70 to 0.99) and PFS 
(HR 0.77, 95% CI: 0.62 to 0.96) with the addition of nintedanib. The base-case MTC 
analyses also report significant improvements in OS (HR 0.64, 95% CI: 0.46 to 0.90) and 
PFS (HR 0.70, 95% CI: 0.50 to 0.998) for nintedanib plus docetaxel compared to erlotinib. 
The Bucher indirect comparisons (which includes two trials) support these findings (OS HR 
0.56, 95% CI: 0.38 to 0.82; PFS 0.58, 95% CI: 0.39 to 0.87). Scenario analyses (including 
three of the trials from the base-case plus an additional trial) and sensitivity analyses of the 
base-case (including eight trials) and scenario analyses (including eight trials) were also 
conducted. These analyses all broadly support the base-case findings. For overall response 
rate (ORR), the base-case results suggest that there was no significant difference between 
nintedanib plus docetaxel in comparison with docetaxel or erlotinib. 
1.4 Summary of the ERG’s critique of clinical effectiveness evidence 
submitted 
The ERG is satisfied with the search strategy employed by the company to identify clinical 
effectiveness studies. It is not aware of any additional relevant ongoing or completed studies 
relevant to the decision problem. 
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The ERG is of the opinion that the LUME-Lung 1 study is well-designed and conducted, with 
low risk of bias. However, eligibility criteria mean that the patient population may not be 
representative of patients generally seen in clinical practice in England. Specifically, the trial 
excludes patients with any major pleural effusion or evidence of cavitary or necrotic tumours 
and therapeutic anticoagulation (except low dose heparin) or antiplatelet therapy (except for 
chronic low-dose therapy with acetylsalicylic acid ≤325mg/day). In addition, the proportion of 
patients aged ≥65 years is relatively small (28.3%) and such patients may have a poorer 
prognosis than younger patients. Given the focus of the decision problem on patients with 
adenocarcinoma, the ERG agrees it was appropriate for the company to only present data 
from LUME-Lung 1 for this patient population. Notwithstanding the exclusions of certain 
types of patients referred to above, the patient population is similar to the adenocarcinoma 
population likely to be treated for locally recurrent, locally advanced or metastatic disease in 
clinical practice in England. However, perhaps as a result of the eligibility criteria, it is noted 
that the rate of post-study therapy is relatively high (55.8%) which suggests this is an 
atypically fitter patient population than would be found in clinical practice in England. This is, 
however, not uncommon in clinical trials.  
The ERG does not consider a comparison of nintedanib plus docetaxel to erlotinib is 
appropriate to decision problem. However, this was specified in the NICE scope and the 
company has therefore undertaken such a comparison via MTCs. The ERG has identified a 
number of methodological limitations related to the conduct of the MTCs (explored below in 
section 1.9.2) and advises that results from the MTCs should be treated with caution.  
1.5 Summary of cost effectiveness evidence submitted by the company 
The company developed a de novo partitioned survival Markov model that comprises three 
health states: progression-free (on or off treatment), progressive disease (PD) and death. All 
patients enter the model in the progression-free state. The model, when projecting PFS and 
OS data from LUME-Lung 1, fits a variety of standard parametric functions to the available 
trial data. Variants of this model structure have been used in the modelling of metastatic 
oncology for a number of previous NICE STAs. The model has been developed in Microsoft 
Excel using a 3-weekly cycle length. It includes a half-cycle correction and the time horizon 
is set at 15 years. As recommended by NICE, a discount rate of 3.5% has been used for 
both costs and outcomes; outcomes are measured in QALYs. The model perspective is that 
of the UK NHS. Resource use, costs and utilities were estimated based on information from 
LUME-Lung 1, published sources and clinical experts.  
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For the comparison of nintedanib plus docetaxel vs docetaxel, the company’s incremental 
cost-effectiveness ratio (ICER) per QALY gained is £50,776. For the comparison of 
nintedanib plus docetaxel vs erlotinib, the company’s ICER per QALY gained is £27,008. 
The company carried out a wide range of deterministic sensitivity analyses for these two 
comparisons. The results from the ten parameters that had the most influence on the ICER 
per QALY gained ranged from £44,034 to £59,711 for nintedanib plus docetaxel vs 
docetaxel and from £17,721 to £238,678 for nintedanib plus docetaxel vs erlotinib (in the 
latter comparison, the HR for OS was the single most influential variable). The results of the 
company’s probabilistic sensitivity analysis (PSA) suggest that for nintedanib plus docetaxel 
vs docetaxel, there is a 2% and a 50% chance of nintedanib plus docetaxel being cost-
effective at willingness to pay thresholds of £30,000 and £50,000 per QALY gained 
respectively; and a 65% and 94% chance of nintedanib plus docetaxel being cost-effective 
compared to erlotinib using the same thresholds. 
1.6 Summary of the ERG’s critique of cost effectiveness evidence 
submitted 
The ERG is satisfied with the search strategy employed by the company to identify cost-
effectiveness studies and is reasonably confident that no other relevant published articles 
exist.  
Overall, the ERG found the company’s model to be well structured. For most functions the 
assumptions and options are labelled and annotated where necessary; however, in some 
cases, the ERG has found it difficult to confirm details of the data sources employed (e.g. 
analyses related to Surveillance, Epidemiology and End Results program [SEER] and 
the National Lung Cancer Audit database [LUCADA]). The ERG identified eleven factors that 
limit confidence in the reliability of the company’s model and/or results. These relate to: 
inappropriate methods used to project time-to-event outcomes (OS, PFS and time-on-
treatment); mid-cycle adjustment error; inappropriate methods used to estimate cost of 
treatment doses; underestimate of true cost of febrile neutropenia; monitoring costs; non-UK 
standard approach to discounting; overall average disutility estimate for fatigue used for both 
regimens; error in stable disease costs and erroneous restriction of docetaxel to four cycles. 
The ERG is concerned by the number of implementation errors that have been identified, 
some of which have important consequences for the size of the estimated ICER per QALY 
gained for the comparison of nintedanib plus docetaxel vs docetaxel. 
The ERG does not consider a comparison of nintedanib plus docetaxel to erlotinib is 
appropriate to decision problem. However, this was specified in the NICE scope and the 
company has therefore undertaken such a comparison. The ERG considers that this is 
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seriously flawed due to inconsistencies apparent in the available time-to-event data leading 
to conflicting results from the MTC. The ERG has applied other relevant amendments to the 
submitted model for this comparison, but the uncertainty in OS, PFS and time on treatment 
(ToT) probably far outweighs all other effects but cannot be quantified. 
1.7 Summary of company’s case for end of life criteria being met 
The company makes a case that nintedanib plus docetaxel meets the criteria set by NICE for 
end of life treatment. Namely: 
• The life expectancy of the patient population was short (< 24 months). Patients with 
advanced NSCLC have a short life expectancy of less than 24 months on average. 
Using the extrapolated results from the LUME-Lung 1 trial data implemented in the 
cost effectiveness model, the median OS of patients on docetaxel monotherapy 
(current standard of care) is 10.23 months and the mean OS is 15.96 months.  
• The number of patients who would be eligible for the treatment is small. The total 
eligible population in England for nintedanib plus docetaxel based on the anticipated 
marketing authorisation is estimated to be 703.  
• The increase in OS is >3 months. Extension to life due to nintedanib plus docetaxel 
vs docetaxel monotherapy in the target population with the base-case assumptions 
within the model is a mean of 3.96 months. The extension in OS over erlotinib is a 
mean of 5.16 months.  
 
1.8 ERG commentary on end of life criteria 
The ERG agrees that patients with advanced NSCLC have a life expectancy of less than 24 
months. It also agrees that only a small number of patients would be eligible for treatment 
with nintedanib plus docetaxel. By applying the Kaplan-Meier (K-M) trial results using the 
area under the curve (AUC) method until the long-term OS trends were established and then 
projecting remaining estimated survival using exponential trends, the ERG calculated the 
extension in mean OS to be 3.05 months for nintedanib plus docetaxel compared with 
docetaxel. It was not possible for the ERG to derive a mean estimate for OS gain for 
nintedanib plus docetaxel vs erlotinib. 




The ERG considers LUME-Lung 1 presents good quality evidence of clinical effectiveness 
which is directly relevant to the decision problem.  
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Cost-effectiveness 
The company presented comprehensive and very detailed economic sections both within the 
CS and in the supplementary evidence. The company attempted to fully address the NICE 
scope. The ERG’s requests to the company for additional economic analyses and further 
information were completed on time and to a high standard. 
1.9.2 Weaknesses and areas of uncertainty 
Clinical effectiveness 
The ERG considers the MTCs are unnecessary because erlotinib is a comparator of no 
relevance to the vast majority of the patient population that would be considered for 
treatment with nintedanib plus docetaxel. The ERG further observes that LUME-Lung 1 is 
the only trial in which any patients (18.8%) received pemetrexed as a first-line treatment, as 
is now typically the case in clinical practice in England and so, arguably, all of the other trials 
included in the MTCs are of limited relevance to the decision problem. There are also other 
major methodological weaknesses and areas of uncertainty with the conduct of the MTCs, 
namely: 
1. the proportional hazards assumption is not supported by the LUME-Lung 1 trial data 
for PFS or OS. Thus any estimation of the relative effectiveness of nintedanib plus 
docetaxel vs erlotinib (i.e. a calculated HR) will lack credibility and be effectively 
meaningless  
2. differences in trial and patient characteristics mean that there is heterogeneity across 
trials which suggests that comparing data from these trials is inappropriate 
Methodological issues also exist, namely: the use of both unadjusted and adjusted PFS and 
OS data, the use of PFS assessed by central independent review and local investigators and 
the use of primary PFS as opposed to updated PFS from LUME-Lung 1. However, these are 
not considered by the ERG to have major importance, particularly given the weaknesses and 
areas of uncertainty identified previously. 
A greater number of fatal AEs have been observed in the nintedanib plus docetaxel arm than 
in the placebo plus docetaxel arm of the LUME-Lung 1 trial. However, the numbers are small 
and the company is using ongoing surveillance to monitor this issue. 
Whilst LUME-Lung 1 is directly relevant to the decision problem, specific exclusion criteria 
employed in this trial may have excluded some patients who would ideally be considered for 
treatment in clinical practice in England. These are patients with major pleural effusion, 
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evidence of cavitary or necrotic tumours, or receiving therapeutic anticoagulation (except low 
dose heparin) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic 
acid ≤325mg/day). This may also partially explain why a higher proportion of patients in the 
trial than would be expected in clinical practice in England received third-line treatment. 
Cost-effectiveness 
The ERG identified a number of weaknesses and areas of uncertainty in the company’s 
model for the comparison of nintedanib plus docetaxel vs docetaxel. The ERG considers that 
the high number of implementation errors is a major weakness of the model. These errors 
are present in estimates of both costs and benefits and therefore influence the size of the 
base-case ICER per QALY gained in a number of ways (mostly resulting in increasing the 
size of the ICER).  
The most important area of uncertainty identified by the ERG is related to OS estimation. 
The company used a Log-Logistic survival model, whereas the ERG used the unadjusted 
trial data directly for the majority of patients, followed by projecting long-term survivors using 
trends evident in the data set. The company used data from the SEER and LUCADA to 
support the parametric survival modelling applied in the model. However, it was not possible 
for the ERG to assess whether this approach was valid; the analyses reported by the 
company did not provide references for the specific data sets used, nor did the company 
present sufficient explanation of the data employed. When the ERG replaced the company’s 
preferred OS model with the ERG’s preferred OS model, there was a major impact on the 
size of the ICER per QALY gained; it increased substantially as the size of the ERG’s 
estimated OS incremental gain was reduced. 
The ERG does not consider the company’s comparison of nintedanib plus docetaxel vs 
erlotinib to be relevant to the decision problem. Furthermore, even if the comparison was 
considered to be relevant, the ERG has noted a number of flaws in the company’s MTCs 
that render the clinical effectiveness results unreliable. The ERG considers that these 
problems are so fundamental that it is not possible to rectify them and modify the company’s 
model to provide improved estimates of OS, PFS and the relative cost-effectiveness of 
nintedanib plus docetaxel and erlotinib. 
1.10 Summary of exploratory and sensitivity analyses undertaken by the 
ERG 
For the comparison of nintedanib plus docetaxel vs docetaxel, the company’s base-case 
ICER (£50,776 per QALY gained) would increase to £85,292 per QALY gained if all 11 ERG 
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recommended revisions were applied and would increase to £82,995 per QALY gained if all 
but the limit on the number of cycles of docetaxel treatment were applied.  
The ERG has been unable to estimate an ICER for the comparison of nintedanib plus 
docetaxel vs erlotinib for the reasons stated in the ERG’s critique of the clinical effectiveness 
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2 BACKGROUND 
2.1 Critique of company’s description of underlying health problems 
section 2.1 of the CS1 provides a brief overview of NSCLC.sections 2.1 and 2.2 of the CS1 
provide data on the number of patients with NSCLC and section 2.3 provides details about 
the life expectancy of people with NSCLC in England. These sections appropriately present 
the key issues relating to the underlying health problems of patients with NSCLC and are 
summarised as presented in the CS1 in Box 1.  
Box 1 Lung cancer disease course and epidemiology 
Types of lung cancer 
• [Non-small cell lung cancer (NSCLC) is] the most common type, accounting for 85% to 90% of cases 
• Adenocarcinoma is the most common [40%] histological sub-type of NSCLC2 
• Patients with NSCLC have a poor prognosis that has not changed significantly in the past decades  
 
The disease course 
• Lung cancer does not usually cause noticeable symptoms until it is locally advanced or has spread 
through much of the lungs or into other parts of the body (i.e. metastatic lung cancer) 
• This means that the outlook for lung cancer is poor compared with other types of cancer3 
 
Epidemiology 
• Lung cancer is the second most common cancer in the UK; there are around 41,500 new cases 
diagnosed each year, with 35,406 new cases in England and Wales in 2010, and more than one in five 
cancer deaths (22%) in the UK are from lung cancer4 
• Smoking causes more than 8 in 10 lung cancers in the UK5 
• At diagnosis, 10 to 15% of patients have locally advanced cancer, i.e. stage IIIB and 40% of patients 
have metastatic cancer i.e. stage IV6,7  
• Moreover, patients with stage IIIB and stage IV NSCLC have the lowest 5-year survival rate, at 5% and 
1%, respectively2,8-10 
 
In relation to epidemiology, the ERG adds that the LUCADA database audit published in 
2012 reported approximately 57% of patients with NSCLC were stage IIIB or stage IV.11 This 
figure is consistent with the estimates presented by the company in Box 1 (50% to 55%). A 
recent National Institute for Health Research Horizon Scanning Centre document12 states 
that the incidence of stage III/IV NSCLC is 78%. This implies an incidence of stage IIIA 
disease of around 20% to 30% if the estimates for stage IIIB and IV cited by the company 
and ERG are subtracted.  
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2.2 Critique of company’s overview of current service provision 
As stated in section 2.1 of the CS,1 the type of treatment that patients with locally advanced 
or metastatic NSCLC receive depends on several factors, including, but not limited to, 
tumour histology and EGFR mutation status. Patients with mutation free (i.e. EGFR-
negative) locally advanced or metastatic lung cancer usually receive platinum doublet 
chemotherapy in the first-line setting, typically pemetrexed plus cisplatin for patients with 
adenocarcinoma.3 As stated in section 2.5 of the CS,1 TKIs - erlotinib, gefitinib or afatinib - 
are all NICE recommended options13-15 for patients with EGFR-mutations. At present all 
three of these drugs have been made available to NHS patients at discount prices, as set 
out in patient access schemes.  
According to the company, approximately 30%16 to 50%17 of patients with locally advanced 
or metastatic NSCLC receive second-line treatment. The current options for second and 
subsequent lines of treatment, as stated in sections 2.1 and 2.5 of the CS,1 are summarised 
in Box 2. The company’s advisory board, which comprised five clinical experts, estimated 
that xxxx of all patients who had received second-line treatment would go on to receive third-
line treatment, with approximately one third of these patients receiving this treatment as part 
of an ongoing clinical trial.1 The company’s own data on file18 that reports on data from the 
final quarter of 2012 appears to support this view. These data show that 13.33% of patients 
who received second-line treatment also received third-line cytotoxic treatment. 
Box 2 Current service provision for patients with NSCLC following first-line treatment 
Second-line treatment 
• The major goal of second-line treatment is to prolong life without worsening HRQ[o]L 
• There are a number of new therapies that target patients with relatively rare mutations (e.g. EGFR), but 
patients with adenocarcinomas and without actionable mutations [e.g. EGFR] who progress following 
first-line chemotherapy have limited therapy options 
• Following failure of first-line chemotherapy, treatment options are limited to docetaxel monotherapy or 
erlotinib 19,20 
• Docetaxel monotherapy can be considered for second-line treatment of locally advanced or metastatic 
NSCLC when cancer has relapsed after previous chemotherapy  
• Erlotinib is recommended, within its licensed indication, as an alternative to docetaxel as a second-line 
treatment option for patients with NSCLC only on the basis that it is provided by the manufacturer at an 
overall treatment cost (including administration, AEs and monitoring costs) equal to that of docetaxel  
 
Third-line treatment and subsequent lines of therapy  
•  Currently, there are no NICE-recommended technologies 
 
In section 2.6 of their submission,1 the company notes that the use of erlotinib as a second-
line treatment is being reviewed by NICE and presents recommendations issued by NICE in 
February 2014. The ERG notes that this guidance is in the process of being replaced, with 
draft guidance published on the NICE website on 7 August 2014. One of the Appraisal 
Committee’s preliminary recommendations21 from both February and August 2014 is that 
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erlotinib should not be recommended for treating locally advanced or metastatic NSCLC that 
has progressed after non-targeted chemotherapy in people with tumours that are EGFR-
negative. Furthermore, erlotinib is only recommended in second-line treatment for patients 
with tumours that are EGFR-positive, or of unknown status, in limited circumstances (Box 3). 
 
In addition, the ERG notes that as the recommended first-line treatment for patients with 
tumours that are EGFR-positive is a TKI,13-15 there are unlikely to be many patients with 
EGFR-positive tumours for whom erlotinib is considered an appropriate second-line 
treatment. Furthermore, as noted on page 35 of the CS,1 the opinion of clinical experts is 
that patients who are sufficiently fit to allow them to tolerate treatment with docetaxel receive 
docetaxel rather than erlotinib. It is, therefore, unlikely that the same group of patients who 
would be eligible to receive erlotinib is the same as that who would be considered for 
docetaxel.  
Box 3 Draft NICE guidance on the use of erlotinib as second-line treatment, 7th August 2014 
• Erlotinib should not be recommended for treating locally advanced or metastatic NSCLC that has 
progressed after non-targeted chemotherapy in people with tumours that are EGFR-negative 
• Erlotinib is recommended as an option for treating locally advanced or metastatic non-small-cell lung 
cancer that has progressed in people who have had non-targeted chemotherapy because of delayed 
confirmation that their tumour is epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation-
positive, only if the manufacturer provides erlotinib with the discount agreed in the patient access 
scheme 
• Erlotinib is recommended as an option for treating locally advanced or metastatic non-small-cell lung 
cancer that has progressed after chemotherapy in people with tumours of unknown epidermal growth 
factor receptor tyrosine kinase (EGFR-TK) mutation status, only if: 
o the result of an EGFR-TK mutation diagnostic test is unobtainable because of an inadequate 
tissue sample or poor quality DNA and 
o the treating clinician considers that the tumour is very likely to be EGFR-TK mutation-positive 
and 
o the person’s disease responds to the first 2 cycles of treatment with erlotinib and 
o the manufacturer provides erlotinib with the discount agreed in the patient access scheme 
 
According to the company: “Nintedanib fits well in the existing clinical pathway and can 
complement docetaxel treatment as an effective second-line option for patients with locally 
advanced/metastatic or recurrent NSCLC of adenocarcinoma tumour histology, previously 
treated with one line of chemotherapy.” (page 34 of the CS1) As highlighted in the CS,1 
nintedanib is a potent, orally-administered small molecule triple angiokinase inhibitor 
targeting three receptor classes: vascular endothelial growth factor receptors (VEGFR), 
fibroblast growth factor receptors and platelet-derived growth factor receptors α and β.22-24 
These receptors have a key role in the formation and maintenance of new blood vessels 
(angiogenesis) and tumour growth.25-27 Suppression of neo-angiogenesis via inhibition of 
VEGFR is considered a promising strategy for the treatment of human solid tumours, 
impacting tumour growth and spread.25-27 The simultaneous targeting of all three pathways 
may be more effective than inhibition of angiogenesis via the VEGF pathway alone. 
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Largely based on the findings from the pivotal trial comparing nintedanib plus docetaxel to 
placebo plus docetaxel (LUME-Lung 124), nintedanib is expected to be licensed in 
combination with docetaxel. Indeed, a positive opinion was received by the European 
Medicines Agency (EMA) on 25 September 2014 as follows: "Vargatef [nintedanib] is 
indicated in combination with docetaxel for the treatment of adult patients with locally 
advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of 
adenocarcinoma tumour histology after first-line chemotherapy.”28 As noted above, the group 
of patients who would be eligible to receive second-line docetaxel - and therefore nintedanib 
- is not likely to be the same as those who would be eligible to receive second-line erlotinib. 
Therefore the ERG considers with only very few exceptions, nintedanib plus docetaxel would 
fit into the existing treatment pathway as a comparator to docetaxel rather than erlotinib. 
The ERG notes that the aforementioned positive opinion includes patients with locally 
recurrent NSCLC. In order to be classified as locally recurrent, a patient would initially 
present with early stage disease (stage I, II or IIIa). The company does not provide 
information on the service provision for these patients, presumably because the NICE scope 
is focussed on patients with locally advanced or metastatic disease. However, since the 
scope also focussed on second-line treatment following chemotherapy, the ERG considers 
these patients will have locally advanced or metastatic cancer by this stage. The ERG notes 
that patients with stage I, II or IIIa will initially be treated with surgery or radical radiotherapy 
and subsequently receive first-line chemotherapy when their disease has relapsed and/or 
spread.29 The choice of chemotherapy will again depend on several factors, including, but 
not limited to, tumour histology and EGFR mutation status. 
The estimated number of patients with locally advanced or metastatic adenocarcinoma 
potentially eligible for second-line treatment with nintedanib plus docetaxel in England is 
reported by the company to be 703. The ERG agrees with the company that a similar 
number of patients are likely to be eligible for treatment with nintedanib plus docetaxel. 
Based on data from the pivotal LUME-Lung 124 in which the median number of cycles with 
docetaxel was five (see also section 4.5) and given the norm in clinical practice in England is 
to provide a maximum of four cycles of docetaxel, the ERG considers the majority of patients 
would receive nintedanib in combination with four cycles of docetaxel.  
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3 CRITIQUE OF COMPANY’S DEFINITION OF DECISION 
PROBLEM 
Table 1 displays the decision problem presented in the CS1 and that addressed by the 
company. Each parameter is discussed in detail in the text following the table. 
Table 1 Decision problem specified by NICE and addressed in the company’s submission 
Parameter Final scope issued by NICE 
Decision problem 
addressed in the 
company’s submission 
Population  Adults with locally advanced or metastatic non-small 
cell lung cancer (NSCLC) that has progressed following 
prior chemotherapy 
Patients with locally 
advanced, metastatic or 
recurrent NSCLC of 
adenocarcinoma tumour 
histology after first-line 
chemotherapy 
Intervention  Nintedanib in combination with docetaxel As per final scope 
 
Comparator(s)  Docetaxel monotherapy 
Erlotinib 
Primary analysis:  
docetaxel monotherapy 
 
Secondary analysis:  
erlotinib monotherapy 
Outcomes  The outcome measures to be considered include: 
• overall survival  
• progression-free survival  
• response rates 
• adverse effects of treatment 
• health-related quality of life 
As per final scope 
 
Economic analysis  The reference case stipulates that the cost 
effectiveness of treatments should be expressed in 
terms of incremental cost per quality-adjusted life year. 
The reference case stipulates that the time horizon for 
estimating clinical and cost effectiveness should be 
sufficiently long to reflect any differences in costs or 
outcomes between the technologies being compared. 
The availability of any patient access schemes for the 
intervention or comparator technologies should be 
taken into account  
As per final scope 
 
Subgroups to be 
considered  
None Not applicable 
Special considerations 
including equity or 
equality issues  
None Not applicable 
Source: adapted from Table 5 of the CS1 
3.1 Population 
The population addressed in the CS1 differs to the population specified in the scope. The 
scope states the population is adults with locally advanced or metastatic NSCLC that has 
progressed following prior chemotherapy. The decision problem addressed by the company 
is patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma 
tumour histology who had previously received first-line chemotherapy. This is in line with the 
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anticipated full marketing authorisation for nintedanib which also specified nintedanib should 
be administered in combination with docetaxel (expected in December 2014). The ERG 
notes that to be classified as locally recurrent, a patient would initially present with early 
stage disease (stage I, II or IIIA) and be treated with surgery or radical radiotherapy and then 
relapse in the same area without metastases. Since the anticipated license also stipulates 
patients must have previously received first-line chemotherapy, then all patients would have 
locally advanced or metastatic disease at the time of second-line treatment regardless of 
their initial diagnosis. The ERG notes that while the scope makes no specification about the 
EGFR mutation status of tumours, in the UK the majority (85% to 90%) of patients have 
EGFR wild-type tumours (EGFR-negative).30-32 The ERG further notes that as patients who 
receive nintedanib also receive docetaxel, the vast majority of eligible patients will be 
required to have ECOG PS 0 to 1. 
3.2 Intervention 
The intervention described in the CS1 is nintedanib. Nintedanib does not currently have a full 
UK Marketing Authorisation. It does however have a positive opinion from the EMA and it is 
anticipated that it will be licensed in December 2014 in combination with docetaxel (the 
specified intervention in the final NICE scope). Nintedanib is provided orally at a dose of 
200mg twice daily (BD) and dose adjustments are permitted in patients who experience AEs. 
The first dose reduction is to 150mg BD and, if required, the dose may be further reduced to 
100mg BD. Docetaxel is administered intravenously alongside nintedanib on day 1 of a 21 
day cycle at a dose of 75mg/m2. If necessary, docetaxel doses may be reduced to 60mg/m2 
as per the docetaxel summary of product characteristics (SmPC)33 and standard clinical 
practice. Nintedanib may be provided as monotherapy after discontinuation of docetaxel. In 
the pivotal LUME-Lung 124 trial, this was only permitted after four cycles of treatment with 
docetaxel. The ERG notes that in England, clinicians rarely administer more than four cycles 
of docetaxel due to the toxicity associated with this drug.  
3.3 Comparators 
Both docetaxel monotherapy and erlotinib monotherapy are considered as comparators for 
locally advanced or metastatic disease in the CS.1 These are the same comparators that are 
specified in the scope. The company considers docetaxel monotherapy to be the comparator 
for the primary analysis and considers erlotinib to be the comparator for secondary analyses. 
This is because as stated on page 184 of the CS,1 based on feedback from clinical experts, 
it does not believe that erlotinib is a relevant comparator. The ERG agrees with the 
company. As noted in section 2.2, the ERG notes that one of the NICE Appraisal 
Committee’s preliminary recommendations21 is that erlotinib should not be recommended for 
Confidential until published 
 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 23 of 139 
treating locally advanced or metastatic NSCLC that has progressed after non-targeted 
chemotherapy in people with tumours that are EGFR-negative. Furthermore, the 
characteristics of patients who are considered suitable for second-line erlotinib treatment are 
different from those who are considered suitable for docetaxel treatment. Given that erlotinib 
is likely to be preferred when patients have a poorer ECOG PS and/or have EGFR-positive 
tumours, docetaxel is the most appropriate comparator to nintedanib plus docetaxel in the 
second-line setting. The company notes that no other agents are licenced or routinely used 
for this indication (pemetrexed is licensed but not NICE approved). Therefore, no other 
comparisons are presented (although as reported in section 4.4, there were other 
comparators employed in the MTCs). The ERG agrees that this is appropriate. 
3.4 Outcomes 
Clinical evidence is reported in the CS1 for all outcomes specified in the scope: OS, PFS, 
response rate (reported as ORR]and disease control rate), AEs of treatment and HRQoL.  
3.5 Economic analysis 
Results are expressed in terms of incremental cost per QALY gained. Various time horizons 
are presented with lifetime (15 years) being that of the primary analysis (appropriate for a 
condition such as lung cancer, with low survival rates). Costs are considered from the 
perspective of the NHS. No patient access scheme has been submitted.  
3.6 Subgroups 
No subgroups were specified by NICE or identified by the company. 
3.7 Other relevant factors 
The company states on page 37 of the CS1 that it does not consider there will be any 
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4 CLINICAL EFFECTIVENESS 
4.1 Introduction 
This section provides a structured critique of the methods and clinical evidence submitted by 
Boehringer Ingelheim Ltd in support of the use of nintedanib in combination with docetaxel 
for the treatment of adult patients with locally advanced, metastatic or recurrent NSCLC of 
adenocarcinoma tumour histology after first-line chemotherapy. The key components of the 
clinical evidence presented in the CS1 are (i) a report of the pivotal trial (LUME-Lung 124 ) 
which compared nintedanib plus docetaxel to placebo plus docetaxel (ii) a report of the 
company’s MTC which was conducted in order to compare nintedanib plus docetaxel to 
erlotinib. 
4.2 Critique of the methods of review(s) 
The company conducted a systematic literature review to identify RCTs of patients with 
previously treated second-line NSCLC. The review was designed to identify evidence for any 
drug, not limited to nintedanib plus docetaxel, erlotinib or docetaxel. 
4.2.1 Searches 
Sections 6.1.1 and Appendices 1 and 4 of the CS1 describe the search strategies employed 
for the systematic review (direct evidence) and the multiple treatment comparison (MTC) 
(indirect evidence), respectively. While the ERG notes some potential minor limitations with 
the search strategy employed by the company (as outlined in Appendix 1), the ERG 
considers that the search strategies employed by the company were appropriate and 
sufficiently comprehensive to identify relevant studies.  
In order to ascertain whether the company had missed any relevant studies or not, the ERG 
also conducted its own searches, as summarised in Appendix 1. However, the ERG did 
identify four additional conference presentations34-37 for the pivotal LUME-Lung 124 trial not 
cited in the CS.1 
4.2.2 Eligibility criteria 
Although the same search strategy was employed to identify studies for inclusion in the 
systematic review (direct evidence) and MTC (indirect evidence), different eligibility criteria 
were appropriately employed for each. These are described in detail in Table 6 (pages 44 to 
45) and Table 25 (pages 106 to 107) respectively of the CS1 and summarised in Appendix 2. 
In general the ERG considers the criteria for both reviews were appropriate although notes 
that the eligibility of studies for inclusion into the MTC was limited to include only results with 
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abstracts, an unusual exclusion criterion which could potentially have removed relevant 
results. However, as noted in section 4.2.1, the ERG conducted its own searches and did 
not identify any additional eligible studies. 
Although the same search was conducted to identify studies for both the systematic review 
and the MTC, it is unclear if the eligibility criteria for both reviews were simultaneously 
employed. The ERG notes from an examination of Figures 1 (page 46) and 19 (page 109) in 
the CS1 that the number of records screened in the systematic review differed from the 
number screened in the MTC, suggesting this was not the case.  
4.2.3 Quality assessment 
The company conducted an assessment of the risk of bias of LUME-Lung 1,24 the only study 
to meet the inclusion criteria for the systematic review, and all studies included in the MTC. 
This assessment included elements of the tool for assessing risk of bias, as recommended 
by the Cochrane Collaboration.38 The ERG agrees this is an appropriate tool for assessing 
the quality of RCTs.  
4.2.4 Evidence synthesis 
One trial (LUME-Lung 124) was identified by the searches for inclusion into the systematic 
review and hence the findings were appropriately presented narratively. This trial24 
compared nintedanib plus docetaxel to placebo plus docetaxel. In order to compare 
nintedanib plus docetaxel to erlotinib, the other comparator specified in the final NICE scope, 
the company conducted a MTC. The ERG’s critique of the company’s MTCs is presented in 
section 4.3. 
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4.3 Critique of the direct evidence 
4.3.1 Identified studies 
Only one RCT (LUME-Lung 124) that presented direct evidence relevant to the decision 
problem was identified by the systematic review. The ERG is not aware of any additional 
relevant ongoing or completed studies. The company also referred to LUME-Lung 239 which 
compared nintedanib plus pemetrexed to placebo plus pemetrexed. However, data from 
LUME-Lung 239 were solely used to inform the pre-specified statistical analysis of LUME-
Lung 1.24 
As well as being published in a peer reviewed journal,24 data from LUME-lung 1 were also 
provided by the company in two clinical trial reports (CTRs): primary PFS40 and final OS41 
since analyses were conducted at both these time points (see section 4.3.4). Selected 
appendices to the CTR for final OS were also provided.42 The company also provided the 
trial statistical analysis plan (TSAP),43 the TSAP addendum44 and the summary of clinical 
efficacy.45 Three conference presentations were also cited, two poster presentations,46,47 and 
an oral presentation, the slides of which were provided;48 one of the poster presentations46 
also included data from LUME-Lung 2,39 the focus of the presentation being to identify 
potential clinical biomarkers for second-line treatment. These findings are not presented by 
the company it the CS.1 The ERG’s search also identified four conference presentations not 
referred to by the company;34-37 these do not appear to contain any additional data to that 
included in the CS.1 
4.3.2 Trial characteristics 
The key characteristics of LUME-Lung 124 are summarised in Table 2. The study was 
conducted internationally and randomised 1,314 patients in a 1:1 ratio to nintedanib plus 
docetaxel or placebo plus docetaxel. Randomisation was stratified by ECOG PS (0 vs 1), 
previous bevacizumab treatment (yes vs no), histology (squamous vs non-squamous) and 
presence of brain metastases (yes vs no). The ERG is of the opinion that the LUME-Lung 
124 study is well-designed and conducted. A large number of patients were recruited to the 
study and the length of trial follow-up means that the data collected are mature and allow 
reasonable conclusions to be drawn from the data. 
The ERG notes that some of the participating treatment centres were located in the UK 
although it is not known how many centres or numbers of patients were recruited (this was 
reported in Appendix 16.1.4 of the CTRs,40,41 an appendix not included with the CS1). 
However, the ERG notes that the eligibility criteria for entry into this trial (see Appendix 3 for 
the full eligibility criteria as provided in the CS,1 pages 58 to 59) do mean the patient 
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population was likely to be different to that of standard clinical practice in England in a 
number of different ways. Specifically the trial excludes, patients with clinically significant 
pleural effusion or evidence of cavitary or necrotic tumours and therapeutic anticoagulation 
(except low dose heparin) or antiplatelet therapy (except for chronic low-dose therapy with 
acetylsalicylic acid ≤325mg/day). In clinical practice these patients are likely to have a poorer 
prognosis than patients included in the trial49-52 although it is recognised that cavitation may 
be less of a strong prognostic factor49 than pleural effusions50,51 or venous 
thromboembilsm.52 
The ERG further notes that previous treatment with docetaxel is a specific exclusion criterion 
to entry in LUME-Lung 1.24 Docetaxel is licensed for first-line treatment of NSCLC. However, 
this is rarely used in clinical practice in England, pemetrexed being the preferred choice for 
adenocarcinoma patients (see also section 2.2). 
Table 2 Trial characteristics of LUME-Lung 1 
Characteristics of LUME-Lung 124 
Location 211 locations in 27 countries (Austria, Belarus, Belgium, Bulgaria, China, Croatia, Czech 
Republic, Denmark, France, Georgian Republic, Germany, Greece, India, Israel, Italy, 
Lithuania, Poland, Portugal, Romania, Russia, Slovakia, South Korea, South Africa, Spain, 
Switzerland, Ukraine, United Kingdom)  
Design Phase III multi-centre, randomised, parallel-group, double-blind, placebo-controlled RCT  




23 December 2008 to 15 February 2013 (data cut-off date) 
Intervention and 
comparator  
Nintedanib + docetaxel (n=655) 
Nintedanib 200mg twice daily, orally, on days 2 to 21 of a 21-day cycle in combination with 
docetaxel 75mg/m2 IV on day 1 of a 21-day cycle 
Matched placebo + docetaxel (n=659) 
Matched placebo twice daily on days 2 to 21 of a 21-day cycle in combination with docetaxel 
75mg/m2 IV on day 1 of a 21-day cycle 
Primary 
outcomes  
PFS by central independent review 
Secondary 
outcomes  
OS (key secondary endpoint) 
PFS by local investigator review 
Tumour response by central independent review and local investigator assessment, 
including: confirmed objective response; disease control; time to confirmed objective 
response; duration of confirmed objective response; duration of disease control; change in 
tumour size; clinical improvement 
HRQoL 
Pharmacokinetics 
safety and tolerability 
Duration of 
follow-up 
Median follow-up at the primary PFS analysis (2 November 2010) was 7.1 months 
(interquartile range: 3.8 to 11.0) and 31.7 months (interquartile range: 27.8 to 36.1 months) 
at the time of the final OS analysis (15 February 2013) 
AE=adverse event; HRQoL=health related quality of life; NSCLC=non-small-cell lung cancer; OS=overall survival; 
PFS=progression-free survival; RCT=randomised controlled trial 
Source: adapted from Table 8 of the CS1  
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4.3.3 Participant characteristics 
Not all patients in LUME-Lung 124 had histology of adenocarcinoma. As the expected 
marketing authorisation for nintedanib plus docetaxel is specifically for patients with 
adenocarcinoma, the company only presented data for the overall population of patients with 
NSCLC where the results were of relevance to statistical testing (see section 4.3.4). The 
ERG agrees that this is appropriate. The participant characteristics of 658 (50.1%) patients 
with adenocarcinoma in LUME-Lung 124 are summarised in Table 3. While some patients 
(15.8%) had early stage disease at diagnosis, at the time of treatment the ERG considers all 
would have locally advanced or metastatic disease since patients had all received first-line 
treatment and were now being treated second-line. Indeed, 94.2% of all patients had 
metastatic disease at screening. The mean time from diagnosis to randomisation into the 
trial reported in Table 15.1.8: 3 of the CTR41 was 12.84 months (median 8.74 months).  
The company comments that demographic and baseline disease characteristics are well 
balanced between the two arms of the trial, and that the population is largely representative 
of patients typically diagnosed with adenocarcinoma although it is noted by the ERG that the 
proportion of patients aged ≥65 years is relatively small (28.3%). The ERG agrees that the 
patient characteristics are well balanced.  
Data on EGFR mutation status was not routinely collected in LUME-Lung 124 although in 
response to a query from the ERG during the clarification process, the company stated these 




Notwithstanding the exclusions of certain types of patients identified in section 4.3.2, the 
patient population is similar to the population who would be treated in clinical practice in 
England with the exception that a smaller proportion (18.8%) of patients than would be 
expected today had received prior pemetrexed. Additionally, perhaps as a result of the 
eligibility criteria, it is noted that post-study therapy is relatively high (55.8%) which suggests 
this is a fitter patient population than in clinical practice England in Wales. As noted in 
section 2.2, in England, in clinical practice around *** of all patients who receive second-line 
treatment subsequently receive third-line treatment (including a third of patients who are 
enrolled into trials).  
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Table 3 Participant characteristics of patients with adenocarcinoma in LUME-Lung 1 
Characteristic Nintedanib + docetaxel (N=322) 
Placebo + docetaxel  
(N=336) 






Age, years Mean (SD) 
Median (range) 
58.5 (10.1) 
60.0 (29 to 80) 
58.6 (9.5) 
59.0 (30 to 80) 
Age ≥65 years, n(%) 90 (28.0) 96 (28.6) 




























Local recurrence without metastases at screening 22 (6.8) 16 (4.8) 













Platinum-based therapy 308 (95.7) 323 (96.1) 
Non-platinum-based therapy 10 (3.1) 10 (3.0) 
Prior pemetrexed, n 
(%) 
As platinum therapy 





Prior bevacizumab, n (%) 24 (7.5) 21 (6.3) 
Brain metastases at 































ECOG=Eastern Cooperative Oncology Group; EGFR-TK=epidermal growth factor receptor tyrosine kinase; SD=standard 
deviation 
† Including one patient in the nintedanib arm who had an ECOG PS of 2 at screening and at randomisation (i.e. at baseline) 
Source: adapted from Table 10 of the CS1 with additional information taken from Table 15.1.8:2 of the CTR41 
 
4.3.4 Description and critique of the statistical approach 
Information relevant to the statistical approach taken by the company to analyse data from 
the pivotal study LUME-Lung 124 are taken from the TSAP,43 trial protocol,53 CTRs40,41 and 
the CS.1  
Sample size calculation  
Details of the sample size calculation performed by the company are reported in the CS1 
(page 71). The study was powered (at the 90% level) to detect a HR for centrally 
independently assessed PFS for the comparison of nintedanib plus docetaxel vs placebo 
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plus docetaxel of 0.7843. This would require 713 PFS events. The ERG is satisfied that the 
company’s pre-specified sample size calculation is correct. However as noted in section 3.1 
above, only patients with adenocarcinoma were considered relevant to this STA. The 
company therefore only presents data for the adenocarcinoma population. The ERG notes 
that although around half of the patients in LUME-Lung 124 had adenocarcinoma (see 
section 4.3.3) this was not a stratification factor (see section 4.3.2) and so patients with 
adenocarcinoma were not strictly a randomised subgroup although they do constitute the 
majority of non-squamous patients which was a stratification factor. However, as noted in 
section 4.3.3, baseline characteristics were well balanced between the two groups 
suggesting the analyses were valid. 
Protocol amendments 
A list of changes implemented after a protocol amendment (dated 15 May 2009) is included 
in the CTR40 (pages 120 to 121). The changes included slight adjustments to the exclusion 
criteria, clarification of ongoing safety evaluations, and timings of the screening period. All 
changes were made before analyses began, and so were not driven by the results of the 
trial. The ERG considers that it is very unlikely that any of the changes would influence the 
outcomes or analyses of LUME-Lung 1,24 or would be a cause for concern. 
Clinical endpoints and statistical analyses 
The company provides a list of outcome measures used in LUME-Lung 124 in Table 13 
(page 66) of the CS1 (also summarised in Appendix 4 of the ERG report). The ERG is 
satisfied that all outcomes were pre-specified in the TSAP43 and reported in full in the 
CTRs.40,41  
The intention-to-treat (ITT) population was used in all efficacy analyses. The primary 
outcome of PFS by central review was analysed using the K-M method, and a stratified log-
rank test. Cox regression analyses were also carried out to estimate treatment effect, 
including adjustment for stratification factors. 
Secondary outcomes relevant to the decision problem included OS, PFS by local 
investigator review, best tumour response, HRQoL and AEs. OS, the key secondary 
outcome of the trial, was also analysed using a stratified log-rank test. Tumour response was 
reported for both central independent review and local investigator review according to 
modified Response Evaluation in Solid Tumours (RECIST) criteria and analysed using 
logistic regression.  
Confidential until published 
 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 31 of 139 
Within clinical trials, time-to-event data like PFS and OS are commonly reported as HRs, 
derived from the Cox proportional hazards model. Such a model does not appear to be 
appropriate for the PFS and OS results of this trial since hazards are not independent of time 
(see Appendix 7) and the HR (and 95% CIs) presented for PFS and OS offer inaccurate 
estimates of relative efficacy. Instead of assuming proportional hazards, alternative 
approaches may be more appropriate to better reflect relative efficacy in the data.. 
The CS1 (page 71) describes the stages of analyses in Table 14. These are summarised in 
Appendix 4 of the ERG report. The ERG is satisfied that each of these stages was pre-
specified in the trial protocol.53 
Following the hypothesis-generating trial LUME-Lung 2,39 an amendment to the statistical 
plan of LUME-Lung 124 was implemented such that statistical testing of OS would only be 
conducted if a significant difference had been observed for the primary analysis of PFS and 
had been confirmed by the updated analysis of PFS. If this condition was satisfied, OS 
analyses would then be conducted in a sequential fashion, i.e. the null hypothesis was to be 
tested in each population only if a significant treatment effect had been shown in the 
previous population. This hierarchical method was utilised to control the type 1 error rate 
(detecting an effect when one is not present), which can be high when performing a large 
number of statistical tests. The sequence of populations was: 
1. Adenocarcinoma patients who had progressed within 9 months of starting first-line 
therapy (i.e. the T<9m adenocarcinoma population) 
2. Adenocarcinoma population 
3. Overall trial population 
The CS1 clarifies that the amendment to the TSAP43 was made before database lock and 
unblinding of data used in the final OS analysis; the ERG considers that this amendment is 
unlikely to bias the results from LUME-Lung 1.24 
Subgroup analyses 
A number of pre-specified analyses for the primary endpoint of PFS assessed by central 
review and for the secondary outcome OS were pre-specified in the protocol. The company 
also conducted post-hoc subgroup analyses and a number of baseline characteristics (CS,1 
page 77) were also investigated for subgroup effects. The subgroup types analysed are 
summarised in Appendix 5 of the ERG report. The ERG notes that there is a large number of 
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subgroup analyses but is satisfied that the results of all of the pre-specified and post-hoc 
subgroup analyses are provided in the CS.1  
Sensitivity analyses 
A number of sensitivity analyses for the primary endpoint of PFS assessed by central review 
and for the secondary outcome OS were pre-specified in the protocol.53 These are 
summarised in Appendix 5 of the ERG report. However, no sensitivity analysis of PFS in the 
adenocarcinoma population was performed. The ERG is satisfied that the results of all of the 
pre-specified and post-hoc sensitivity analyses are provided in the CTR.41 
4.3.5 Risk of bias 
The company conducted an assessment of the risk of bias using the criteria recommended 
by NICE in the Guide to the Methods of Technology Appraisal.54 The risk of bias assessment 
is presented in Table 4. The ERG is satisfied with the risk of bias assessment presented in 
the CS1 and agrees that the study has an overall low risk of bias.  
Table 4 Assessment of risk of bias conducted by company for LUME-Lung 1trial 
Criteria Response 
Was randomisation carried out appropriately? Yes 
Was the concealment of treatment allocation adequate? Yes 
Were the groups similar at the outset of the study in terms of prognostic factors? Yes 
Were the care providers, participants and outcome assessors blind to treatment allocation? Yes 
Were there any unexpected imbalances in drop-outs between groups? No 
Is there any evidence to suggest that the authors measured more outcomes than they reported? No 
Did the analysis include an intention-to-treat analysis? If so, was this appropriate and were 
appropriate methods used to account for missing data? 
Yes 
Source: Table 17 of the CS1  
4.3.6 Results 
The focus of the results section in both the CS1 and this ERG report is the adenocarcinoma 
population from LUME-Lung 1,24 as this is the population relevant to the decision problem.  
However, results of the primary PFS analysis for the overall trial population and OS for the 
T<9m adenocarcinoma population have been presented wherever necessary (and are 
clearly labelled), due to the fact that these populations were part of the previously described 
hierarchical OS statistical analysis (section 4.3.4). By presenting these results, the 
justification for conducting the analysis of OS for the patients with adenocarcinoma has been 
demonstrated. 
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Progression-free survival 
The CS1 reports that median follow-up was 7.1 months at the time at the primary PFS 
analysis (2 November 2010), the results of which are presented in Table 5.  









HR vs placebo arm 
(95% CI)† p-value 
Risk 
reduction 
PFS in overall ITT population  3.4 months 2.7 months 0.79 (0.68 to 0.92) 0.0019 21% 
PFS in adenocarcinoma 
population§ 
4.0 months 2.8 months 0.77 (0.62 to 0.96) 0.0193 23% 
CI=confidence interval; HR=hazard ratio; ITT=intention-to-treat; PFS=progression-free survival 
* Based on unadjusted Kaplan-Meier estimates for each treatment arm 
† A proportional hazards model stratified by three factors (ECOG PS at baseline, presence of brain metastases at baseline, 
prior bevacizumab therapy) was used to derive the HR, 95% CI, and p-value (corresponding to the stratified log-rank test p-
value) 
§ Analysis conducted retrospectively 
Source: Table 18 of the CS1  
 
 
The results suggest that the use of nintedanib plus docetaxel significantly improved PFS in 
comparison to placebo plus docetaxel in both the overall trial population and in the subgroup 
of patients with adenocarcinoma. However, the ERG suggests that these results should be 
interpreted with caution, due to the violation of the proportional hazards assumption (see 
section 4.3.4). In particular, it is evident that the trial survival arms converge within the 
duration of the trial indicating that PFS gain from use of nintedanib is restricted to the first 12 
months of treatment (see Figure 12 in section 5.5.3) and that the hazard ratio is not time-
invariant (Figure 19 in Appendix 7). 
The CS1 reports that median follow-up was 31.7 months at the time of the updated PFS 
analysis (15 February 2013), the results of which are summarised in Table 6.  









HR vs placebo 
arm (95% CI)† p-value 
Risk 
reduction 
PFS in the overall trial 
population 
3.5 months 2.7 months 0.85 (0.75 to 0.96) 0.0070 15% 
PFS in adenocarcinoma 
population§ 
4.2 months 2.8 months 0.84 (0.71 to 1.00) 0.0485 16% 
CI=confidence interval; HR=hazard ratio; PFS=progression-free survival 
* Based on unadjusted Kaplan-Meier estimates for each treatment arm 
† A proportional hazards model stratified by three factors (ECOG PS at baseline, presence of brain metastases at baseline, 
prior bevacizumab therapy) was used to derive the HR, 95% CI, and p-value (corresponding to the stratified log-rank test p-
value) 
§ Analysis conducted retrospectively 
Source: Table 19 (page 89) of the CS1 
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The CS1 states that the results obtained in the updated analysis support the findings from 
the primary PFS analysis. The ERG agrees that the results are consistent across both 
analyses as nintedanib plus docetaxel is shown to significantly improve PFS in comparison 
to placebo plus docetaxel in both the overall trial population and the adenocarcinoma 
population at the updated analysis. 
Progression-free survival by local investigator review  
The ERG notes that the PFS results as assessed by local investigator review were very 
similar to those obtained by central review. The treatment effect for the adenocarcinoma 
population significantly favoured nintedanib plus docetaxel over placebo plus docetaxel (HR 
0.78, 95% CI: 0.62 to 0.97, p=0.0246). 
Progression-free survival subgroup analyses 
Subgroup analyses were performed at the time of the final OS analysis (15 February 2013). 
Results from the PFS (central review) subgroup analyses of baseline characteristics for 
adenocarcinoma patients are provided by the company in Figure 17 of the CS1 (page101). 
The majority of pre-specified and post-hoc subgroup analyses show the effect of nintedanib 
plus docetaxel to be consistent with the treatment benefit observed in the primary analysis. 
The only exceptions to this are two subgroups (i) more than 9 months since start of first-line 
treatment and (ii) Asian region where there was a trend in favour of placebo plus docetaxel.  
The results of tests for interaction were also provided to identify whether any subgroup of 
patients experienced a significantly greater treatment benefit than the remaining population. 
Significant interactions were observed for ‘time since start of first-line therapy’ (p=0.0032) 
and metastases in ‘adrenal glands’ (p=0.0336); these results suggest that patients who 
progressed within 9 months of first-line therapy, and those with metastases in the adrenal 
glands, experience a greater treatment effect than the remaining population.  
Progression-free survival sensitivity analyses 
Sensitivity analyses were only performed for PFS in the whole trial population, not only for 
those with adenocarcinoma.  
Overall survival  
Nintedanib plus docetaxel significantly improved median OS in comparison to placebo plus 
docetaxel in the population of adenocarcinoma patients who progressed within 9 months of 
first-line therapy (10.9 months vs 7.9 months respectively; HR 0.75, 95% CI: 0.60 to 0.92, 
p=0.0073). Therefore, analysis of OS in the population of interest, all adenocarcinoma 
patients, was permitted and the results are summarised in Table 7. Median OS was 
significantly longer with nintedanib plus docetaxel than with placebo plus docetaxel in the 
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adenocarcinoma population. However, the ERG is concerned that survival hazards appear 
not to be time invariant (see Figure 20, Appendix 7) and therefore may be misleading. 
Table 7 OS in the adenocarcinoma population in LUME-Lung 1 trial (February 2013) 
Outcome Nintedanib + docetaxel (median)* 
Placebo + docetaxel 
(median)* 
HR vs placebo 
arm (95% CI)† p-value 
Overall survival 12.6 months 10.3 months 0.83 (0.70 to 0.99) 0.0359 
CI=confidence interval; HR=hazard ratio; OS=overall survival 
* Based on unadjusted Kaplan-Meier estimates for each treatment arm 
† A proportional hazards model stratified by three factors (ECOG PS at baseline, presence of brain metastases at baseline, 
prior bevacizumab therapy) was used to derive the HR, 95% CI, and p-value (corresponding to the stratified log-rank test p-
value) 
Source: Table 20 of the CS1 
 
Overall survival subgroup analyses 
Subgroup analyses were performed at the time of the final OS analysis (15 February 2013) 
in the adenocarcinoma population.  
Results from the pre-specified and post-hoc OS subgroup analyses of baseline 
characteristics for adenocarcinoma patients are provided by the company in Figure 18 of the 
CS1 (page102). The subgroup analyses also show treatment effects in favour of nintedanib 
plus docetaxel, supporting the findings of the primary analysis. The only exceptions to this 
are two baseline characteristics: (i) presence of brain metastases and (ii) below stage IIIB 
disease at diagnosis. The company notes that a significant interaction was observed for 
‘best response to first-line treatment’ (p=0.0766), indicating that patients whose best 
response to first-line therapy was PD would benefit more in terms of OS than the rest of the 
population. The ERG agrees with the company that this subgroup has a relatively small 
sample size (n=117) and the results should therefore be interpreted with caution.  
The ERG is satisfied that all pre-specified subgroups were reported and show a consistent 
effect for OS across the majority of baseline characteristics.  
Overall survival sensitivity analyses 
The results of the two sensitivity analyses performed for OS in the adenocarcinoma 
population are presented in the text of the CS1 and summarised here in Table 8. 
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Table 8 Sensitivity analyses of OS in the adenocarcinoma population in LUME-Lung 1 
(February 2013) 
Analysis HR (95% CI) p-value 
Main OS analysis 0.83 (0.70 to 0.99) 0.0359 
Sensitivity analysis 1 - Cox proportional hazards model with three of 
the stratification factors used at randomisation as covariates (ECOG 
PS at baseline, prior bevacizumab treatment, presence of brain 
metastases at baseline) 
0.83 (0.70 to 0.98) 0.0295 
Sensitivity analysis 2 - Model included the stratification factors and 
the baseline sum of the longest diameters (SLD) of the target lesions 
(mm) as covariates 
0.81 (0.69 to 0.97) 0.0186 
CI=confidence interval; HR=hazard ratio; OS=overall survival 
Source: Text (page 99) of the CS1 and Table 11.4.1.2.1.7: 2 of CTR41 
 
The sensitivity analyses show that the results of the OS analysis remain very similar when 
including three of the stratification factors (ECOG PS at baseline, prior bevacizumab 
treatment and presence of brain metastases at baseline), or the stratification factors and 
baseline sum of the longest diameters of the target lesions as covariates in the model.. 
Tumour response based on central independent review 
The results from the tumour response assessment (central independent review) are 
summarised in Table 9. No significant difference in ORR between nintedanib plus docetaxel 
patients and placebo plus docetaxel patients (4.7% vs 3.6%, odds ratio 1.32 [95% CI 0.61 to 
2.93], p=0.4770) was observed. The ERG considers the ORRs in both arms to be lower than 
would be anticipated in typical clinical trials (see also section 4.4.5). 
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Table 9 Tumour response and disease control in the adenocarcinoma population in LUME-
Lung 1 (February 2013)  
Type of response (according to modified 








Odds ratio*  
(95% CI) 
Patients with objective tumour response, 
ORR [n (%)] 
15 (4.7) 12 (3.6) 1.32 (0.61 to 2.93) 
p=0.4770 
Complete response, n (%) 0 0 - 
Partial response, n (%) 15 (4.7) 12 (3.6) - 
Unconfirmed complete/partial response n (%) 10 (3.1) 7 (2.1) - 
Median duration of confirmed objective 
response (months) 
4.9 4.3 - 
Median time to confirmed objective response 
(months) 
1.6 5.1 - 
Stable disease† n (%) 179 (55.6) 136 (40.5) - 
Patients with disease control§ n (%) 194 (60.2) 148 (44.0) 1.93 (1.42 to 2.64) 
p<0.0001 
Median duration of disease control (months) 5.7 6.3 - 
Progressive disease‡ n (%) 87 (27.0) 147 (43.8) - 
Other¥ n (%) 41 (12.7) 41 (12.2) - 
CI=confidence interval; ORR=overall response rate 
* Odds ratios were obtained from logistic regression model adjusted for baseline ECOG PS 
† stable disease was assumed if a follow-up imaging indicated stable disease at least once and at least 6 weeks after 
randomisation (i.e. at or after Day 43). 
§ A patient was considered to have disease control if he/she had a best objective response of stable disease or better. 
‡ Including patients with stable disease from a radiological imaging earlier than Day 43 followed by progressive disease 
¥ Including patients with stable disease from a radiological imaging earlier than Day 43 followed by a non-evaluable response 
Source: Table 21 of the CS1  
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4.4 Critique of the indirect evidence 
4.4.1 Included studies in the MTC and statistical approach  
Nine trials24,55-62 were included in the review of the indirect evidence. The ERG did not 
identify any additional studies that met the company’s eligibility criteria. However, not all nine 
studies were incorporated in any single MTC analysis. Four studies48,56,59,62 were included in 
the base-case analyses, three24,59,62 of which were also included in scenario analyses 
alongside a fifth study.60 The remaining four studies55,57,58,61 were only included in sensitivity 
analyses alongside those included in the base-case (sensitivity analyses i) or scenario 
analyses (sensitivity analyses ii); hence there were only ever a maximum of eight studies 
included in any given analysis. 
The features of the types of analyses are as follows: 
1. Base-case: includes all trials that meet eligibility criteria but excludes studies in which 
a high proportion (>20%) of patients have EGFR-positive adenocarcinoma and 
studies which include ‘chemotherapy’ as a single comparator where chemotherapy 
could be one or more possible regimens i.e. it must be possible to compare the 
intervention to all included comparators separately. The base-case analysis network 
diagram is reported in Figure 1.  
2. Scenario analysis: assumes docetaxel and pemetrexed are of equal efficacy. The 
CS1 states that this assumption was used to allow as many treatments to be 
compared with nintedanib plus docetaxel as possible. Hence the TITAN60 study, 
excluded from the base-case, could be included in the scenario analysis because 
chemotherapy (docetaxel or pemetrexed) was the comparator. However the JMEI56 
study could not be included since this trial compared docetaxel to pemetrexed. 
3. Sensitivity analyses: studies in which >20% of patients had EGFR-positive 
adenocarcinoma were also included in a MTC alongside  
i. the trials included in the base-case or  
ii. the trials included in the scenario analyses.  
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* Trial included only patients with adenocarcinoma 
† Subgroup of patients with adenocarcinoma 
Figure 1. Network diagram for MTC base-case analyses 
Source: adapted from Figure 20 of the CS1 
 
The company explains that the rationale for excluding patients with EGFR-positive 
adenocarcinoma from all but the sensitivity analyses was to enable a comparison between 
nintedanib plus docetaxel and other TKIs in a population similar to the patient population in 
LUME-Lung 1.24 The majority of patients in LUME-Lung 124 would be expected to have 
EGFR-mutation negative adenocarcinoma ******************************************************* 
*************************************** (see also section 4.3.3 and Table 14, section 4.4.3). 
For each analysis, the company attempted to compare efficacy and safety. Efficacy 
outcomes were OS, PFS and ORR and safety outcomes were AEs for the following: fatigue, 
nausea and diarrhoea. However, for AEs, it was not possible to conduct a MTC for the base-
case because none of the AE outcomes were reported in a sufficient number of trials in the 
base-case in order to be able to conduct a MTC.  
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Table 10 Studies included in the review of indirect evidence identified by the company  
Trial name Intervention Comparator Analyses included in 
LUME-Lung 124 Nintedanib + docetaxel Placebo + docetaxel Base-case, scenario and sensitivity 
TAILOR59 Erlotinib Docetaxel  Base-case, scenario and sensitivity 
WSY00162 Erlotinib Pemetrexed Base-case, scenario and sensitivity 
JMEI56 Pemetrexed Docetaxel Base-case and sensitivity 
TITAN60 Erlotinib Chemotherapy  
(docetaxel or pemetrexed) 
Scenario and sensitivity 
GEF-ERL55 Gefitinib Erlotinib Sensitivity 
KCSG-LU08-0157 Gefitinib Pemetrexed  Sensitivity 
V-15-3261 Gefitinib Docetaxel Sensitivity 
S10358 Pemetrexed + erlotinib Pemetrexed or erlotinib Sensitivity 
Source: adapted from Figure 20 and Figure 21 of CS1 
 
Table 11 Comparisons with nintedanib plus docetaxel in the MTCs undertaken by the 
company 






Overall response rate 




Overall response rate 
Safety 




Pemetrexed + erlotinib 
Overall survival 
Progression-free survival 
Overall response rate 
Sensitivity ii Chemotherapy (docetaxel and/or pemetrexed) 
Erlotinib 
Gefitinib 
Pemetrexed + erlotinib 
Overall survival 
Progression-free survival 
Overall response rate 
Safety 
Sensitivity i: sensitivity analyses for base-case; sensitivity II; sensitivity analyses for scenario analyses 
Source: adapted from Table 36 and Table 37 of CS1 
 
For efficacy and safety outcomes, the company conducted MTCs and, where possible, 
Bucher indirect comparison results using the methods described in Appendix 6. The ERG is 
satisfied that the modelling approach was suitable. The ERG considers that conducting 
Bucher indirect comparisons is an effective method of assessing consistency within the 
network and therefore the reliability of the MTC results. If results from the MTC for any given 
comparison are considerably different to those obtained by the Bucher indirect comparison, 
it is likely that the MTC is not measuring the treatment effect accurately. 
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However, the ERG does not consider conducting any MTC was appropriate. There are 
multiple reasons for this, the primary reasons relating to the appropriateness of the MTC to 
the decision problem: 
1. Erlotinib is not an appropriate comparator for the population of patients who would 
potentially be eligible to receive nintedanib plus docetaxel. As noted earlier in 
sections 0 and 3.3, the NICE Appraisal Committee’s preliminary recommendations21 
are that erlotinib should not be recommended for treating locally advanced or 
metastatic NSCLC that has progressed after non-targeted chemotherapy in people 
with tumours that are EGFR-negative. Furthermore the characteristics of the vast 
majority of patients who are considered suitable for second-line erlotinib treatment 
are different from those who are considered suitable for second-line docetaxel 
treatment, most notably in terms of ECOG PS, EGFR mutation status and previous 
treatment received. Therefore the comparison with docetaxel is most appropriate and 
direct evidence for this is available from LUME-Lung 1.24  
2. The ERG further observes that LUME-Lung 124 is the only trial in which any patients 
received pemetrexed as a first-line treatment as is now typically the case in clinical 
practice in England. In this trial, 19.1% of patients were previously treated with 
pemetrexed, more than in any other included trial. 
In addition, there are methodological issues:  
3. Although this is still an issue of some academic debate, the ERG considers that the 
proportional hazards assumption is not supported by LUME-Lung 124 trial data for 
PFS or OS. As LUME-Lung 124 is the only trial providing evidence for nintedanib plus 
docetaxel, any comparison also including evidence from this trial will incorporate this 
HR, which affects the robustness of these other comparisons. Thus any estimation of 
the relative effectiveness of nintedanib plus docetaxel vs erlotinib (i.e. a calculated 
HR) will lack credibility and be effectively meaningless. A full assessment of this 
issue is provided by the ERG in Appendix 7.  
4. Differences in trial and patient characteristics (as described in detail in sections 4.3.2 
and 4.3.3) suggest there is heterogeneity across trials which may mean MTCs are 
inappropriate: 
a. In the base-case analyses, while LUME-Lung 124 and TAILOR59 both report 
similar median follow-up times, JMEI56 and WSY00162 report much shorter 
follow-up times. This heterogeneity may mean that the trials are too dissimilar 
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to allow a valid comparison of outcomes in an MTC. Additional sources of 
heterogeneity have also been identified in terms of differences in eligibility 
criteria across trials (see section 4.4.2) and participant characteristics (see 
section 4.3.3). 
b. There also appears to be heterogeneity across the trials included in the 
scenario analyses.24,59,60,62 TITAN60 includes many more patients with ECOG 
PS 2 (20%) than would be expected in a patient population considered for 
treatment with nintedanib plus docetaxel. Furthermore, unlike any of the other 
trials in the base-case, TITAN60 also permitted treatment crossover following 
disease progression. Hence the median OS for the chemotherapy arm may 
be inflated. It also compares erlotinib to chemotherapy in which 
chemotherapy consists of docetaxel or pemetrexed, thereby assuming the 
two treatments to be of equal efficacy. The ERG is not aware of any evidence 
that supports this assumption specifically in an adenocarcinoma population. 
Finally, by including this trial, the MTC is no longer making comparisons to 
docetaxel but to chemotherapy. However the chemotherapy arm includes 
pemetrexed which is not a second-line treatment option in England. Taking 
these factors into account, the ERG considers that the efficacy and safety 
results generated by the scenario analyses are neither relevant nor robust. 
c. Trials included only in the sensitivity analyses55,57,58,61 appear to be different to 
those in the base-case and scenario analyses, in particular these trials have 
high proportions of patients with EGFR-positive mutations and are based in 
Asia. Combining data from these trials with data from trials in the base-case 
and scenario analyses appears to be inappropriate as patients from Asia may 
have different tumour biology and comorbidities to those in the UK and EGFR 
mutation status is known to be related to the efficacy of some drugs. The 
ERG considers that the efficacy and safety results generated by the 
sensitivity analyses are not robust.  
d. For the MTCs of safety outcomes, the company explains that due to low 
event rates, and the fact that only a small number of trials reported these 
outcomes, a network could only be formed when assuming equal tolerability 
of docetaxel and pemetrexed (scenario analysis). However, the findings from 
JMEI,56 which compared these two drugs, albeit in a broader NSCLC 
population (52.9% had adenocarcinoma), reported differences between the 
two drugs, with a more favourable safety profile for pemetrexed. Therefore 
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this assumption does not hold. Furthermore, as identified above, the ERG 
considers there are differences in trial and patient characteristics between the 
trials included in the base-case, scenario and sensitivity analyses. The ERG 
considers that none of safety results generated by the MTC analyses are 
robust. 
For all of the reasons outlined above, the ERG does not consider the comparison of 
nintedanib plus docetaxel with erlotinib is relevant to this STA. 
4.4.2 Trial characteristics of included studies 
The characteristics of trials included in the base-case and scenario analyses are 
summarised in Table 12 as well as the characteristics of those trials included in the 
sensitivity analyses only. The ERG notes that only TAILOR59 was conducted solely in 
Europe whereas four trials55,57,61,62 were conducted solely in Asia; three55,57,61 of the Asian 
studies were included only in the sensitivity analyses. The location of trials is likely to be 
important because patients may have different tumour biology and comorbidities depending 
on their ethnic origin and where they live. 
The company argues that all of the included trials had similar eligibility criteria. However, the 
ERG notes that there were some differences.  
The ERG considers that two eligibility criteria (ECOG PS and complications such as brain 
metastases and pleural effusions) may be the main drivers of outcome in patients with 
adenocarcinoma. In the base-case and scenario analyses, only LUME-Lung 124 restricted 
trial entry to ECOG PS ≤1. Six trials explicitly stated they excluded patients with brain 
metastases: three in the base-case: LUME-Lung 1,24 WSY00162 and JMEI;56 TITAN60 in the 
scenario analyses and KCSG-LU08-0157 and S10358 in the sensitivity analyses. It is however 
noted by the ERG that LUME-Lung 124 excluded patients with active brain metastases and 
so this exclusion criterion may have enabled patients with a poorer prognosis to have been 
included than in the other trials in this respect. Two trials (LUME-Lung 124 and JMEI56), both 
in the base-case, excluded clinically significant or uncontrolled pleural effusions. Therefore 
patients in LUME-Lung 124 and JMEI56 in particular may be expected to have slightly better 
prognoses than patients in the other trials although similar exclusion criteria may have been 
employed in the other trials but were not reported; for example TAILOR,59 GEF-ERL55 and V-
15-3261 reported only limited eligibility criteria. The ERG acknowledges that existence of 
brain metastases is a relatively common exclusion criteria for entry into trials. Nevertheless, 
such exclusions do result in a patient population different to those who would be treated in 
clinical practice. In this instance, because patients who receive nintedanib do so in 
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combination with docetaxel, the exclusion of patients with ECOG PS≥2 is however 
appropriate. 
Additional eligibility criteria which could also impact on patient outcomes include EGFR 
mutation status, previous treatment and smoking status. WSY00162 included only patients 
with EGFR wild type disease (EGFR-negative) whereas GEF-ERL55 included only patients 
with EGFR activating mutations (EGFR-positive). Patients in the latter study would be 
expected to perform better when treated with a TKI or chemotherapy than patients in the 
former study. Furthermore, it should be noted that the majority of patients treated in clinical 
practice in England would be EGFR-negative. KCSG-LU08-0157 and V-15-3261 only 
permitted entry to never-smokers whereas the majority of patients with NSCLC treated in 
England are current or ex-smokers. Prior pemetrexed (or drugs directed at pemetrexed 
molecular targets) or TKIs were explicitly not permitted in three trials in the base-case 
(WSY00162 and JMEI56 and S10358), TITAN60 in the scenario analyses and three trials 
(TAILOR,59 GEF-ERL55 and KCSG-LU08-0157) in the sensitivity analyses. These are 
potentially important exclusion criteria as not only may these affect outcomes but in clinical 
practice in England today, as noted in section 2.2, these are the first-line treatments of 
choice: pemetrexed for EGFR-negative disease and a TKI for EGFR-positive disease.  
Alongside differences in eligibility criteria, the ERG also observes that in V-15-32,61 
docetaxel was administered every 3 weeks as a one-hour intravenous infusion of 60 mg/m2 
(the approved dosage in Japan). This trial,61 alongside KCSG-LU08-0157 and TITAN,60 also 
permitted treatment crossover, unlike any of the other trials. This is an important 
consideration because treatment crossover could confound OS in these trials. Finally, it 
should also be noted that the median follow-up times varied considerably in the trials (range 
7.5 to 33 months). This is important because if follow-up is not similar across trials, bias may 
be introduced into studies with shorter follow-up and less mature data as a result of 
increased censoring.  
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Table 12 Trial characteristics of trials included in only the MTC base-case and scenario analyses  





• Histologically or cytologically confirmed stage IIIB-IV or 
recurrent NSCLC of any histology, following relapse or 
failure of one previous first-line chemotherapy (in the 
case of recurrent disease one additional previous 
regimen was allowed for adjuvant, neoadjuvant, or 
neoadjuvant + adjuvant therapy) 
• Life expectancy of ≥3 months 
• At least one target lesion measurable according to 
RECIST criteria 
• ECOG PS 0 to 1 
• Prior docetaxel or VEGF/VEGFR inhibitor (other than 
bevacizumab) usage 
• Radiographic evidence of cavitary or necrotic tumours, 
centrally located tumours with radiographic evidence (CT 
or MRI) of local invasion of major blood vessels, or a 
recent history (<3 months) of clinically significant 
haemoptysis or a major thrombotic or clinically relevant 
major bleeding event in the past 6 months 
• Active brain metastases or leptomeningeal disease 
• Pre-existing ascites and/or clinically significant pleural 
effusion 
31.7 months 
TAILOR59 Italy • Patients with wild-type EGFR advanced NSCLC, who 
had recurrence or progression after failing platinum-
based chemotherapy  
• Adequate vital functions 
• ECOG PS ≤2 
• Previous treatment with taxanes or anti-EGFR drugs or 
drugs directed at pemetrexed molecular targets (i.e., 
thymidylate synthase and dihydrofolate reductase 
inhibitors) 
33 months 
WSY00162 China • Aged 18 to 75 years 
• Pathologically or cytologically confirmed stage IIIB or 
IV lung adenocarcinoma or postoperative recurrent 
lung adenocarcinoma incurable by surgery or 
radiotherapy within 6 months of neoadjuvant or 
adjuvant chemotherapy 
• EGFR wild-type and EGFR FISH-positive disease 
• Received 1 prior platinum-based chemotherapy 
(including neoadjuvant or adjuvant chemotherapy) 
• Adequate bone marrow function 
• Adequate liver function  
• Adequate renal function  
• Presence of 2-dimensional measurable disease 
• Life expectancy of ≥3 months 
• ECOG PS 0 to 2 
• Prior treatment with TKI or pemetrexed 
• Symptomatic brain metastases 
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Trial Location Inclusion criteria Exclusion criteria Median follow-up 
JMEI56 Not reported • Histologically or cytologically confirmed stage III or IV 
NSCLC not amendable to curative therapy 
• Received treatment with only one prior chemotherapy 
for advanced disease (one prior additional therapy 
allowed for neoadjuvant, adjuvant, or neoadjuvant + 
adjuvant therapy) 
• Adequate bone marrow function 
• Adequate hepatic function  
• Adequate renal function  
• ECOG PS 0 to 2 
• Patients with prior docetaxel or pemetrexed treatment 
• CTCAE ≥grade 3 peripheral neuropathy 
• An inability to interrupt nonsteroidal anti-inflammatory 
drugs 
• Uncontrolled pleural effusions, symptomatic or 
uncontrolled brain metastases, or significant weight loss 
(≥ 10% body weight in the preceding 6 weeks) were 
ineligible. 
7.5 months 
TITAN60 International • Histologically documented locally advanced, recurrent, 
or metastatic NSCLC  
• Disease progression while receiving four cycles of a 
standard first-line platinum-based chemotherapy 
doublet (representing a population with poor 
prognosis); patients who had disease progression 
during the four cycles of a standard platinum-based 
chemotherapy doublet could enrol once they had 
recovered from any toxic effects of the chemotherapy 
treatment 
• Adequate haematologica function 
• Adequate hepatic function  
• Adequate renal function  
• Ability to comply with study and follow-up procedures 
• ECOG PS 0 to 2 
• Previous exposure to anti-human-EGFR-directed drugs 
or drugs directed at pemetrexed molecular targets (i.e., 
thymidylate synthase and dihydrofolate reductase 
inhibitors) 
• Prior chemotherapy or systemic anti-neoplastic therapy 
other than the permitted platinum-based regimens 
• Uncontrolled or untreated brain metastasis 
• Spinal cord compression or other malignancies within 
the past 5 years (except carcinoma in situ) 
24.8 months 
(chemotherapy arm) 
 27.9 months 
(erlotinib arm) 
CTCAE= Common Terminology Criteria for Adverse Events; ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor; FISH=fluorescence in situ 
hybridisation; NSCLC=non-small-cell lung cancer; PS=performance status; RECIST=Response Evaluation Criteria in Solid Tumors; TKI=tyrosine-kinase inhibitor; VEGFR=vascular endothelial 
growth factor receptor 
Source: adapted from Tables 9, 26 and 36 of the CS1 with additional criteria added from cited source publications (For JMEI56 eligibility criteria were reported in Hanna et al63)  
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Table 13 Trial characteristics of trials included in only the MTC sensitivity analyses  
Trial Location Inclusion criteria Exclusion criteria Median follow-up 
GEF-
ERL55 
South Korea • Histologically confirmed stage IIIB or IV NSCLC including recurrent or 
metastatic disease following failure of first-line chemotherapy 
• WHO performance status of 0 to 2 
• Presence of either an activating EGFR mutation, or two of three clinical 
factors associated with higher incidence of EGFR mutations.  
• Brain metastasis permitted if treated at least 4 weeks before entry and 
clinically stable without steroid treatment for 1 week 
• Previous treatment with EGFR 
signalling inhibitors and radiation 
therapy within the preceding 4 weeks 
16.3 months  
KCSG-
LU08-0157 
Korea • Histologically or cytologically confirmed pulmonary adenocarcinoma that 
progressed after just 1 previous platinum-based chemotherapy regimen 
for advanced disease (stage not reported) 
• Never-smoked (a total of ≤100 cigarettes in their lifetime) 
• ECOG PS 0 to 2 
• Patients with prior TKI or pemetrexed 
treatment  
• Symptomatic or uncontrolled brain 
metastases were ineligible. 
15.9 months 
V-15-3261 Japan • Histologically or cytologically confirmed stage IIIB or IV NSCLC not 
amenable to curative surgery or radiotherapy, or postoperative recurrent 
NSCLC 
• Failure of prior treatment with one or two chemotherapy regimens (≥1 
platinum-based regimen) 
• WHO PS 0 to 2 
• Protocol amendment allowed recruitment of patients without measurable 
lesions 
• Not reported 21 months 
S10358 Not reported • Histologically or cytologically confirmed, locally advanced or metastatic 
non-squamous NSCLC following failure of first-line chemotherapy 
regimen  
• ECOG PS 0 to 2 
• Only never-smoking patients (<100 lifetime cigarettes) were eligible. 
• Prior exposure to agents directed at 
the human EGFR axis or at 
pemetrexed molecular targets (e.g. TS 
or DHFR inhibitors) 
• Brain metastasis (unless treated and 
stable after radiotherapy ≥2 weeks)  
• Concurrent administration of any other 
antitumour therapy. 
14.7 months 
DHFR= dihydrofolate reductase; ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor;; NSCLC=non-small-cell lung cancer; PS=performance status; TKI=tyrosine-
kinase inhibitor; TS= thymidylate synthase; VEGFR=vascular endothelial growth factor receptor; WHO=World Health Organisation 
Source: adapted from Tables 27 and 36 of the CS1  
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4.4.3 Participant characteristics of included studies 
Baseline characteristics of patients summarised in the CS1 are reported in Table 14 (for trials 
included in the base-case and scenario analyses) and Table 15 (for trials included in the 
sensitivity analyses). The ERG considers that the baseline characteristics that are the main 
drivers of outcomes in patients with adenocarcinoma are ECOG PS, response to prior 
therapy and EGFR mutation status. 
Narratively, the company only focuses on ECOG PS, noting that in TITAN60 and GEF-ERL,55 
which were included only in the scenario and/or sensitivity analyses, there were a higher 
proportion of patients (20.0% and 14.6% respectively) with ECOG PS 2 than any of the trials 
in the base-case. Because patients receive docetaxel with nintedanib, then the ERG 
considers that the vast majority of patients included in studies should all have ECOG PS≤1. 
While it is difficult to quantify the proportion, a minimum of 85% would seem reasonable. 
TITAN60 (included only in the scenario analyses) does not meet this criterion. 
The ERG notes that the proportion of patients with adenocarcinoma ranged from 50% to 
100% in the base-case. The three studies (LUME-Lung 1,24 JMEI56 and TAILOR59) with 
<75% are appropriately included because they do report subgroup analyses for patients with 
adenocarcinoma. The ERG further notes that while LUME-Lung 124 included some patients 
with early stage disease at diagnosis, the majority (91.2%) of patients with adenocarcinoma 
had stage III/IV disease at diagnosis and even more (94.2%) had metastatic disease at 
screening. In WSY00162 71.5% were reported to have stage III/IV disease, the remainder 
(28.5%) described as having recurrent disease. In JMEI56 all adenocarcinoma patients were 
reported to have stage III (18%) or IV (82%) disease at baseline. No information about 
staging is provided in TAILOR,59 it being stated patients with metastatic disease were 
enrolled who “had recurrence or progression after failing platinum-based chemotherapy.” 
Response to prior therapy differed across the trials. The proportion of patients with a 
complete or partial response or stable disease to previous treatment varied from 56.1% in 
WSY00162 to 70.7% in JMEI;56 in LUME-Lung 124 it was 70.7% and in TAILOR59 was 63.9%. 
As noted in section 4.3.6, in LUME-Lung 124 a significant interaction was observed for ‘best 
response to first-line treatment’ indicating that patients whose best response to first-line 
therapy was PD would benefit more in terms of OS than the rest of the population. However, 
as noted by both the company and ERG, this subgroup has a relatively small sample size 
(n=117) and the results should be interpreted with caution.  
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With regard to other baseline characteristics, in studies included in the base-case, the ERG 
observes that median age varied from 54.3 to 60 years, proportion of females from 27.3% to 
39.2%, patients with wild-type mutations (EGFR-negative) ranged from xxx  to 100% and the 
proportion of never smokers from 17.4% to 35.7%. However, data were not presented for 
mutation status or never smokers for JMEI56 and data were incomplete for mutation status 
for LUME-Lung 1;24 it is assumed the majority of patients in both trials would be EGFR-
negative, an assumption apparently supported by the limited data available from LUME-Lung 
1.24  
In some respects, the characteristics of TITAN,60 which is included only in the scenario 
analyses, is like those included in the base-case. There were again a high proportion of 
patients with unknown EGFR status but it appears from the data available, if it is assumed 
the ratio of EGFR-positive to EGFR-negative patients in the patients with unknown mutation 
status is the same as that in the known mutation status, that the majority were EGFR-
negative. Arguably what makes this trial most unlike those in the base-case, however, is the 
aforementioned higher proportion of patients with ECOG PS 2 suggesting a greater 
proportion of patients with more severe disease in this trial. The ERG further notes that all 
patients in this trial had stage IIIB (21.7%) or stage IV (88.3%) disease at baseline.  
With regard to the trials included only in the sensitivity analyses, it is apparent from Table 15 
that three trials appear similar to each other in most respects (GEF-ERL,55 KCSG- LU08-
0157 and S10358) whereas the fourth (V-15-3261) appears to be different as it has fewer 
numbers of female patients, never smokers and patients with adenocarcinoma. The ERG 
notes that in all trials, EGFR-mutation status is only available from a minority of patients. If it 
is assumed the ratio of EGFR-positive to EGFR-negative patients in the patients with 
unknown mutation status is the same as that in the known mutation status patients, then the 
data appear to support the company’s assertion that the proportion of patients with EGFR-
positive disease ≥20%; indeed, in each trial there would be a majority of patients with EGFR-
positive disease. All patients had stage IIIB and IV disease at baseline in S10358 and KCSG-
LU08-01.57 In GEF-ERL55 the proportion was 84.4% with the majority of other patients 
described as having recurrent disease (13.5%). In V-15-3261 all patents had stage III/IV 
disease or were described as being recurrent (83.0% and 17.0% respectively). 
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Table 14 Patient characteristics of trials included in only the MTC base-case and scenario analyses 





Age (years) Wild-type mutations (EGFR-negative) (%) 
ECOG PS 0 to 1 
(%) Female (%) Never smokers (%) % N 
LUME-Lung 124 1314 50.1 658   100.0   
Nintedanib + 
docetaxel 
655 49.2 322 Median: 60 
Range: 53 to 67 
******************** 100.0 27.3 35.7* 
Placebo + 
docetaxel 
659 51.0 336 Median: 60 
Range: 54 to 66 
******************** 100.0 27.3 34.2* 
TAILOR59 219 69.4 152   92.7   
Erlotinib 109 63.3 69 Median: 66 
Range: 40 to 81 
100 93.6 29.4 17.4 
Docetaxel 110 75.5 83 Median: 67 
Range: 35 to 83 
100 91.7 33.6 27.2 
WSY00162 123 100 123   94.3   
Erlotinib 61 100 61 Median: 54.3 
Range: 30 to 74 
100 93.4 34.4 24.6 
Pemetrexed 62 100 62 Median: 55.1 
Range: 33 to 75 
100 95.2 37.1 27.4 
JMEI56 571 52.9 302   86.8*   
Pemetrexed 283 55.8 158 Median: 57.4* 
Range not reported 
Not reported 84.8* 39.2* Not reported 
Docetaxel 288 50.0 144 Median: 56.7* 
Range not reported 
Not reported 88.9* 34.0* Not reported 
TITAN60 424 49.5 201   80.0   
Erlotinib 203 47.3 96 Median: 59 years 





80.8 20.7 14.8 
Chemotherapy 221 51.6 114 Median: 59 years 





79.2 27.6 19.9 
* Subgroup of patients with adenocarcinoma only. *************xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx*******       
Source: adapted from Table 26 with additional data on EGFR mutations and ECOG PS taken from the cited source publications 
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Table 15 Patient characteristics of trials included in only the MTC sensitivity analyses  





Age (years) Wild-type mutations (EGFR-negative) (%) 
ECOG PS 0 to 1 








   
Gefitinib 48 91.7 44 Median: 60 
Range: 37 to 83 
25.0 
Missing: 56.3 
85.4 85.4 91.7 
Erlotinib 48 89.6 43 Median: 56 
Range: 32 to 81 
41.7 
Missing: 41.7 
85.4 85.4 95.8 
KCSG-LU08-0157 
 
135† 100.0 135   91.1   
Gefitinib 68† 100.0 68 Median: 58 
Range: 40 to 77 
22.1 
Missing: 50.0 
91.2 85.3 100.0 
Pemetrexed 67† 100.0 67 Median: 64 
Range: 30 to 78 
23.9 
Missing: 44.8 
91.0 85.1 100.0 
V-15-3261 489¥ 77.7 380  5.3 
Missing: 88.3 
95.7   
Gefitinib 
 
244¥ 78.4 191 ≤64 years: 56.3  95.5 38.4 29.0 
Docetaxel 
 
239¥ 77.0 184 ≤64 years: 55.3  95.9 38.1 35.7 
S10358 240 93.8 225  7.9 
Missing: 82.1 
92.9   
Erlotinib + 
pemetrexed 
78 92.3 72 Median: 55.8 
Range not reported 
 91.0 74.4 100.0 
Erlotinib 82 92.7 76 Median: 53.9 
Range not reported 
 92.7 65.9 100.0 
Pemetrexed 80 96.3 77 Median: 55.9 
Range not reported 
 95.0 56.3 100.0 
Source: adapted from Table 27 with additional data on EGFR mutations and ECOG PS taken from the cited source publications 
† Population analysed for safety and efficacy analyses 
¥ Population evaluated for safety (described as intention-to-treat population in source paper) 
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4.4.4 Risk of bias 
The company conducted an assessment of the risk of bias of the studies included in the 
base-case MTC, the results are presented in the CS1 and shown in Table 16. The ERG 
considers that the conclusions drawn by the company are valid and that the included studies 
have an overall low risk of bias.  
Table 16 Company’s assessment of risk of bias for trials included only in the MTC base-case 
analyses 
Criteria LUME-Lung 124 TAILOR
59 WSY00162 JMEI56 
1. Was randomisation carried out 
appropriately? Yes Yes Yes Yes 
2. Was the concealment of treatment 
allocation adequate? Yes Yes Not clear Not clear 
3. Were the groups similar at the outset 
of the study in terms of prognostic 
factors? 
Yes Yes Yes Yes 
4. Were the care providers, participants 
and outcome assessors blind to 
treatment allocation? 
Yes Yes No Not clear 
5. Were there any unexpected 
imbalances in drop-outs between 
groups? 
Not clear No No No 
6. Is there any evidence to suggest that 
the authors measured more outcomes 
than they reported? 
No No No No 
7. Did the analysis include an intention-
to-treat analysis? If so, was this 
appropriate and were appropriate 
methods used to account for missing 
data? 
Yes Yes Yes Yes 
Overall quality (" +  + ", " + ", "-")  +  +   +  +   +  +   +  +  
Source: Appendix 5 (Table 155) of the CS1 
Information for LUME-Lung 124 taken from trial protocol53 
 
Trials in the scenario and sensitivity analyses were also assessed for risk of bias (Appendix 
5 of the CS1). These were considered to be of similarly low risk of bias with the exception of 
KCSG-LU08-0157 which was deemed to be at higher risk of bias because of unexpected 
imbalances in drop-outs between treatment arms. 
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4.4.5 Individual study findings 
Efficacy results from the studies included in the base-case analyses are provided in Table 
17. The findings from the studies included in the scenario and sensitivity analyses are not 
presented here because the patient characteristics of these trials are considered by the ERG 
to be too different to those of the patient population relevant to the decision problem.  
Significant improvements in OS were reported for nintedanib plus docetaxel compared to 
placebo plus docetaxel in LUME-Lung 124 and erlotinib vs pemetrexed in TAILOR.59 
Significant improvements in PFS were only reported in LUME-Lung 124 for nintedanib plus 
docetaxel vs placebo plus docetaxel. In patients treated with adenocarcinoma, median OS 
varied from 9.2 months (adjusted OS in JMEI56) to 13.4 months (pemetrexed arm of 
WSY00162); the OS for nintedanib plus docetaxel therefore appears to compare favourably 
in LUME-Lung 124 (12.6 months). Median PFS ranged from 2.8 months (placebo plus 
docetaxel arm in LUME-Lung 124 to 4.2 months (nintedanib plus docetaxel arm in LUME-
Lung 124).  
Although median OS was not presented for the adenocarcinoma population in TAILOR,59 the 
ERG notes that for the overall population median OS was 8.2 months in the erlotinib arm as 
compared to 11.7 months for erlotinib in WSY00162 in which all patients had 
adenocarcinoma. The median OS for docetaxel in the overall population of TAILOR,59 was 
5.4 months and was lower than the adjusted median OS reported for the adenocarcinoma 
subgroup of patients treated with docetaxel in JMEI56 (9.2 months) and OS for the placebo 
plus docetaxel arm in the adenocarcinoma subgroup of LUME-Lung 124 (10.3 months). The 
median PFS for the erlotinib arm in the overall population in TAILOR59 (2.9 months) was also 
slightly lower than for the erlotinib arm in WSY00162 (4.1 months). Median PFS for the 
docetaxel arm in the overall population in TAILOR,59 (2.4 months) was however similar to 
that of the placebo plus docetaxel arm of adenocarcinoma patients in LUME-Lung 124 (2.8 
months) and slightly less than the adjusted PFS in the docetaxel arm of JMEI56 (3.5 months). 
These findings may be indicative that the trials included different patient populations, as 
suggested by the ERG in 4.4.1.  
Response rates were only reported for three of the trials.24,56,62 The ERG notes that the ORR 
for patients treated with docetaxel in JMEI56 (9.9%) was much greater than reported for 
placebo plus docetaxel in LUME-Lung 124 (3.6%). For patients treated with pemetrexed it 
was also higher (12.8%) in JMEI56 than in WSY00162 (8.1%). The highest ORR was reported 
for erlotinib (19.7%) in WSY001.62 The findings for ORR were lowest for either arm in LUME-
Lung 1.24  
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Table 17 Individual study findings (inputted into the MTC base-case analyses by the company) 
Outcomes 




docetaxel Erlotinib Docetaxel Erlotinib Pemetrexed Pemetrexed Docetaxel 
N efficacy 322 336 69 83 61 62 158 144 
Unadjusted OS Months 12.6 10.3 NR¥ NR¥ 11.7 13.4 NR NR 
HR (95% CI) 
p-value 
0.83 (0.7 to 0.99) 
p=0.0359 
0.67 (0.48 to 0.95); reported as 
significant 




Adjusted OS† Months NR NR NR NR NR NR 9.0 9.2 
HR (95% CI) 
p-value 
0.81 (0.69 to 0.97) 
p= 0.0186 (two-sided) 
NR NR 
0.92 (0.69 to 1.22) 
p=0.551 
Unadjusted PFS Months 4.0 2.8 NR¥ NR¥ 4.1 3.9 NR NR 
HR (95% CI) 
p-value 
0.77(0.62 to 0.96) 
p= 0.0193 
0.76 (0.54 to 1.05) 
 




Adjusted PFS† Months 4.2 2.8 NR NR NR NR 3.5 3.5 
HR (95% CI) 
p-value 
0.84 (0.71 to 1) 
p= 0.0485 (two-sided) 
NR NR 
0.83 (0.65 to 1.06) 
p= 0.135 
Response Criteria RECIST NR RECIST Southwest Oncology Group Criteria 
Objective response Definition Objective tumour response (CR + PR) NR PR + CR CR, PR* 
ORR N evaluated 322 336 NR NR 61 62 158 144 
N 15 12 NR NR 12 5   
% 4.7 3.6 NR NR 19.7 8.1 12.8 9.9 
CI=confidence interval; CR=complete response; HR=hazard ratio; NR=not reported; ORR=overall response rate; OS=overall survival; PFS=progression-free survival; PR=partial response 
† No study reported what variables were adjusted for except LUME-Lung 124 for OS: ***********xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx********* 
ǂ For the LUME-Lung 124 trial adjusted OS, PFS, and ORR data for the adenocarcinoma subgroup are available from CTR41 
¥ For TAILOR, median OS and median PFS are only reported for overall population, not adenocarcinoma subgroup 
* Complete response: complete disappearance of all measurable and evaluable disease; Partial response: ≥50% decrease in the sum of products of perpendicular diameters of all measurable 
lesions 
Source: adapted from Table 32 of the CS1 with additional data taken from the source papers 
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4.4.6 Results from mixed treatment comparisons 
As noted in sections 2.2, 3.3 and 4.4.1 above, the ERG does not consider a comparison of 
nintedanib plus docetaxel to erlotinib is appropriate to decision problem. Furthermore, the 
ERG also considers there are a number of methodological issues with the MTC and taken 
together, the ERG does not therefore consider a comparison of nintedanib plus docetaxel 
with erlotinib is relevant to this STA. Nevertheless, for completeness, a brief description of 
the results and critique follows. 
The following analyses were conducted by the company: 
• Base-case analyses 
• Sensitivity analyses for base-case (sensitivity analysis i) 
• Scenario analyses 
• Sensitivity analyses for scenario analyses (sensitivity analysis ii) 
 
While only comparisons of nintedanib plus docetaxel to docetaxel and erlotinib are 
considered relevant to the NICE scope, some results are presented relative to other 
comparators included in the MTCs for completeness.  
Summary of company’s results: overall survival 
The results from the base-case analysis for OS are presented in Table 18 and the 
probabilities of each treatment being the best at improving OS are presented in Table 19. 
The results from the base-case analysis suggest that nintedanib plus docetaxel is 
significantly more effective than either docetaxel alone or erlotinib alone. Results from the 
Bucher indirect comparisons support the findings from the MTC. Nintedanib plus docetaxel is 
most likely to be the best treatment, suggesting superiority over docetaxel and erlotinib.  
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Table 18 Summary of OS findings from MTC base-case analysis  
Treatment HR (95% Cl) to fixed-effects 
Nintedanib + docetaxel vs docetaxel 
 
Result from MTC 0.83 (0.70 to 0.99) 
Result from Bucher indirect comparison Not applicable 
Nintedanib + docetaxel vs pemetrexed  
Result from MTC 0.82 (0.60 to 1.11) 
Result from Bucher indirect comparison 0.90 (0.65 to 1.26) 
Nintedanib + docetaxel vs erlotinib  
Result from MTC 0.64 (0.46 to 0.90) 
Result from Bucher indirect comparison 0.56 (0.38 to 0.82) 
Deviance information criterion 0.4095 
OS=overall survival; HR=hazard ratio; CI=confidence interval 
Notes: The results from the base-case analysis do not feature the random-effect model as there were no instances of two trials 
with the same comparison 
Source: adapted from Table 38 of the CS1 
 
Table 19 Probabilities of each treatment being the best at improving OS in base-case 
analysis 
Treatment Probability of being best 




Source: adapted from Table 39 of the CS1 
 
The findings from the scenario and sensitivity analyses broadly support those of the base-
case analyses. Nintedanib plus docetaxel also had the highest probability of being the best 
treatment in the sensitivity analysis (i) of the base-case (49.2%), followed by erlotinib plus 
pemetrexed (37.17%), a comparator that was not included in the original base-case. In the 
scenario analysis that assumes equivalent efficacy of docetaxel and pemetrexed, nintedanib 
plus docetaxel also had the highest probability of being the most effective treatment 
(78.95%). In the sensitivity analysis (ii) for the scenario analysis, erlotinib plus pemetrexed 
(54.39%), a comparator that was not included in the base-case analysis, had the highest 
probability of being the most effective, followed by nintedanib plus docetaxel (34.21%). 
Summary of company’s results: progression-free analyses 
The results from the base-case analysis for PFS are presented in Table 20. The probabilities 
of each treatment being the best at improving PFS are presented in Table 21. The results 
suggest that nintedanib plus docetaxel significantly improves PFS in comparison to 
docetaxel and erlotinib. Results from the Bucher indirect comparisons support the findings 
from the MTC. Nintedanib plus docetaxel was most likely to be the best treatment, 
suggesting superiority over docetaxel and erlotinib.  
Confidential until published 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 57 of 139 
Table 20 Summary of PFS findings from MTC base-case analysis 
Treatment HR (95% Cl) to fixed-effects 
Nintedanib + docetaxel vs docetaxel 
 
Result from MTC 0.77 (0.62 to 0.96) 
Result from Bucher indirect comparison Not applicable 
Nintedanib + docetaxel vs pemetrexed  
Result from MTC 0.84 (0.61 to 1.15) 
Result from Bucher indirect comparison 0.93 (0.67 to 1.29) 
Nintedanib + docetaxel vs erlotinib  
Result from MTC 0.70 (0.50 to 1.00)¥ 
Result from Bucher indirect comparison 0.58 (0.39 to 0.87) 
Deviance information criterion 1.568 
PFS=progression-free survival; HR=hazard ratio; CI=confidence interval 
The results from the base-case analysis do not feature the random-effect model as there were no instances of two trials with 
the same comparison 
¥ The estimate for the upper bound of the 95% credible interval was 0.9958, making the result statistically significant 
Source: adapted from Table 40 of the CS1 
 
Table 21 Probabilities of each treatment being the best at improving PFS in base-case 
analysis 
Treatment Probability of being best 




Source: adapted from Table 41 of the CS1 
 
 
The findings from the scenario and sensitivity analyses broadly support those of the base-
case analyses although not to the same extent as for the OS analyses. Erlotinib plus 
pemetrexed, a comparator not in the original base-case, had the highest probability of being 
the best treatment in the sensitivity analysis (i) of the base-case (61.99%), followed by 
nintedanib plus docetaxel (25.01%). In the scenario analysis that assumes equivalent 
efficacy of docetaxel and pemetrexed, nintedanib plus docetaxel had the highest probability 
of being the most effective treatment (83.57%). In the sensitivity analysis (ii) for the scenario 
analysis, erlotinib plus pemetrexed (72.23%), a comparator that was not included in the 
base-case analysis, had the highest probability of being the most effective, followed by 
nintedanib plus docetaxel (16.42%). 
Summary of company’s results: overall response rate 
Table 22 shows the results of the base-case analysis for ORR. The results suggest that 
there was no significant difference in ORR between nintedanib plus docetaxel in comparison 
with docetaxel or erlotinib.  
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Table 22 Summary of ORR findings from MTC base-case analysis 
Treatment HR (95% Cl) to fixed-effects 
Nintedanib + docetaxel vs docetaxel 
 
Result from MTC 1.33 (0.61 to 2.95) 
Result from Bucher indirect comparison Not applicable 
Nintedanib + docetaxel vs pemetrexed  
Result from MTC 0.98 (0.33 to 2.84) 
Result from Bucher indirect comparison 0.98 (0.34 to 2.83) 
Nintedanib + docetaxel vs erlotinib  
Result from MTC 0.33 (0.07 to 1.56) 
Result from Bucher indirect comparison Not applicable 
Deviance information criterion 37.47 
CI=confidence interval; ORR=overall response rate 
The results from the base-case analysis do not feature the random-effect model as there were no instances of two trials with 
the same comparison.  
Source: adapted from Table 42 of the CS1 
 
In the sensitivity analysis (i) for the base-case, nintedanib plus docetaxel was statistically 
inferior to erlotinib, gefitinib and erlotinib plus pemetrexed using a fixed-effects model. The 
findings from the random-effects model also suggest nintedanib plus docetaxel to be inferior 
although the wider confidence intervals mean that the difference is no longer statistically 
significant. The scenario analysis found nintedanib plus docetaxel shows no significant 
difference in ORR compared with chemotherapy (docetaxel or pemetrexed) or erlotinib. The 
sensitivity analysis (ii) for the scenario analysis found nintedanib plus docetaxel was not 
significantly different from chemotherapy (docetaxel or pemetrexed) or erlotinib but was 
significantly inferior to gefitinib and erlotinib plus pemetrexed.  
Summary of company’s results: adverse events 
The safety outcomes of any grade fatigue, nausea and diarrhoea were only able to be 
analysed as part of the sensitivity analysis where docetaxel and pemetrexed were assumed 
to be of comparable efficacy. Although LUME-Lung 124 reported additional AEs, including 
CTCAE grade ≥3 fatigue and nausea, these outcomes could not be compared as either no 
other linked trial reported equivalent data, or the event rates in one or more of the treatment 
arms were zero. 
ERG critique of the company’s results from the mixed treatment comparisons 
If the problems with the appropriateness and conduct of the MTCs highlighted in section 
4.4.1 are ignored, the ERG makes a number of further observations in relation to the findings 
reported from the MTCs: 
1. Results from the Bucher indirect comparisons support the findings from the MTCs 
suggesting that inconsistency in the network is not a concern, as additional evidence 
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from the wider treatment networks corroborate the evidence from simple indirect 
comparisons. 
2. It is stated that unadjusted data were used wherever possible, although only adjusted 
data were available for JMEI.56 This trial did not specify the variables which were 
adjusted for and this lack of information makes it difficult to assess the impact that 
these adjustments may have had on the data, and therefore the results of the MTCs. 
3. Data used to derive results for PFS was PFS assessed by central independent 
review for LUME-Lung 1,24 whereas for JMEI56 and TAILOR59 local investigator 
assessed PFS data were used; it is unclear whether the results used in the MTC 
from WSY00162 were the results from central independent review or local investigator 
assessment. However, considering the similarities in the findings from central 
independent review (HR 0.77, 95% CI: 0.62 to 0.96) and local investigator 
assessment (HR 0.78, 95% CI: 0.62 to 0.97) for LUME-Lung 1,24 it seems unlikely 
that this would greatly impact the results of the MTC. 
4. The ERG observes that the company inputted data from the primary PFS analysis for 
LUME-Lung 124 into the MTC; it would have been more informative to use the data 
from the updated analysis (HR 0.84, 95% CI: 0.71 to 1.00).  
5. The company states that trials which provided the active treatment arm with placebo 
versions of the comparator were not distinguished from trials which did not provide a 
placebo. The ERG does not consider this to be of major concern, as although the 
one trial (LUME-Lung 124) which provided a placebo is less likely to be at risk of bias 
(see also section 4.4.4 [risk of bias]), it is unlikely that this difference would introduce 
a significant amount of heterogeneity between trials. The ERG notes that due to the 
small number of studies, a comparison between the fixed and random-effects models 
to test for heterogeneity could only be conducted for the sensitivity analyses for both 
OS and PFS. The base-case analysis showed some inconsistency for both OS and 
PFS effect sizes when direct and indirect evidence was compared. The company 
suggests that this may be due to differences in EGFR mutation status across studies. 
The ERG agrees with this assessment and believes the inconsistency may also be 
caused by differences in patient populations as discussed in sections 4.3.2 and 
4.3.3.  
The ERG’s critique of AEs, including consideration of the evidence input into and derived 
from the MTC, is presented in section 4.5. 
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4.5 Critique of the adverse events data 
Comparison of adverse events from the direct evidence 
In LUME-Lung 124 AEs were collected for the full trial population and the subgroup of 
patients with a histology of adenocarcinoma. In the CS1 AEs are appropriately only 
presented for the adenocarcinoma subgroup since this is the population that is relevant to 
the decision problem.  
The company reports that treatment with nintedanib plus docetaxel resulted in additional 
AEs compared with docetaxel treatment alone. Indeed, drug-related AEs reported in Table 
59 of the CS1 were 81.3% in the nintedanib plus docetaxel arm compared to 72.4% in the 
placebo plus docetaxel arm. However, the company argues that these data must be 
considered in the context of there being longer median treatment duration in the nintedanib 
plus docetaxel arm (Table 23). The ERG notes that in clinical practice in England, the 
maximum number of docetaxel cycles is likely to be four but notes the median number in the 
nintedanib plus docetaxel arm was five. It further notes that in both arms, the maximum 
number of cycles exceeded 40.  
Table 23 Treatment exposure in the adenocarcinoma population in LUME-Lung 1 
Length of treatment and dose intensity Nintedanib + docetaxel Placebo + docetaxel 
Median duration of nintedanib/placebo treatment 
(range) 
4.2 months 
 (0.10 to 41.53) 
3.0 months 
(0.07 to 31.10) 
Mean dose intensity of nintedanib/placebo (%, SD) 91.2 (15.0) 93.8 (13.3) 
Number of docetaxel courses (median, range) 5.0 (1 to 45) 4.0 (1 to 41) 
Mean overall dose intensity of docetaxel (%, SD) 98.1 (4.5) 98.7 (3.7) 
Source: Table 53 of the CS1 
 
The most common specific types of AEs reported by adenocarcinoma patients in LUME-
Lung 124 are summarised in Table 24. Types of AEs reported by patients in the nintedinab 
plus docetaxel arm included diarrhoea (43.4%), nausea (28.4%) and vomiting (19.4%) which 
the company states were successfully managed by dose reduction, dose interruption and/or 
symptomatic treatment and led to permanent nintedanib discontinuation in <1% of patients 
(Table 25). These were identified as AESIs relating to nintedanib by the company. Other 
reported AESIs associated with nintedanib treatment included ALT/AST increase (37.8% vs  
9.3% and 30.3% vs 7.2% respectively, Table 24) which were reported to be generally 
reversible and led to permanent nintedanib discontinuation in <2% of patients (Table 25). 
For the majority of patients with adenocarcinoma requiring a dose reduction to manage AEs, 
a single dose reduction of nintedanib or placebo was sufficient (Table 25). 
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Table 24 Proportion of types of AEs in the adenocarcinoma population in LUME-Lung 1 
AEs 
Nintedanib + docetaxel Placebo + docetaxel 
% any CTCAE grade 
(% CTCAE grade ≥3) 
% any CTCAE grade 
(% CTCAE grade ≥3) 
All AEs 96.3 (75.9) 94.3 (68.5) 
Occurring in ≥5% in either arm:     
• Diarrhoea 43.4 (6.3) 24.6 (3.6) 
• Neutrophil count decrease 40.9 (36.3) 40.5 (34.8) 
• ALT increased 37.8 (11.6) 9.3 (0.9) 
• Fatigue 30.9 (4.7) 29.4 (4.2) 
• AST increased 30.3 (4.1) 7.2 (0.6) 
• Nausea 28.4 (0.9) 17.7 (0.6) 
• WBC decreased 27.8 (19.7) 28.2 (18.3) 
• Decreased appetite 23.4 (1.3) 15.6 (1.5) 
• Vomiting 19.4 (1.3) 12.3 (0.6) 
• Alopecia 17.5 (0.3) 20.4 (0) 
• Dyspnoea 16.9 (4.7) 15.6 (6.0) 
• Neutropenia 13.8 (11.9) 15.3 (13.5) 
• Cough 13.1 (0.9) 18.9 (0.6) 
• Pyrexia 12.2 (0.6) 14.1 (0.3) 
• Stomatitis 11.3 (1.3) 7.8 (0.3) 
• Haemoglobin decreased 10.9 (0.9) 13.8 (2.1) 
• Constipation 6.9 (0) 11.7 (0.3) 
SAEs 34.7 (31.3) 32.1 (26.6) 
Occurring in ≥5% in either arm:     
• Febrile neutropenia 5.6 (5.6) 1.8 (1.8) 
• Malignant neoplasm progression 3.8 (3.8) 2.4 (2.1) 
• Dyspnoea 2.8 (2.5) 5.4 (4.8) 
• Pneumonia 2.8 (2.2) 3.6 (1.8) 
• Diarrhoea 1.9 (1.6) 2.1 (1.8) 
• General physical health deterioration 1.9 (1.9) 1.5 (1.2) 
• Neutropenia 1.9 (1.6) 3.3 (3.3) 
• Asthenia 1.6 (1.3) 0.6 (0.3) 
• Respiratory failure 1.6 (1.6) 0.3 (0.3) 
• Vomiting 1.6 (0.6) 1.2 (0.6) 
• Atrial fibrillation 1.3 (0.9) 0 (0) 
• Chest pain 1.3 (0.9) 1.8 (1.5) 
• Pleural effusion 1.3 (1.3) 1.8 (1.2) 
• Sepsis 1.3 (1.3) 0.3 (0.3) 
• Pyrexia 0.6 (0) 1.2 (0) 
AEs=adverse events; ALT=Alanine aminotransferase; AST=Aspartate transaminase; CTCAE= Common Terminology Criteria 
for Adverse Events; WBC=white blood cell  
* As judged by the local investigator 
Source: adapted from Tables 62 and 63 of the CS1 
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Table 25 AEs leading to dose interruptions, reductions or discontinuations in LUME-Lung 1 
AEs 
Nintedanib + docetaxel Placebo + docetaxel 
% % 
At least 1 temporary interruption of 
nintedanib/placebo  
52.2 41.4 
At least 1 temporary interruption of 
nintedanib/placebo >14 consecutive days  
10.0 6.6 
1 dose reduction of nintedanib/placebo 17.2 6.6 
2 dose reductions of nintedanib/placebo 4.7 0 
AEs leading to dose reduction of nintedanib or 
placebo 
21.6 6.6 
AEs leading to dose reduction of nintedanib or 
placebo occurring in ≥1% in either arm: 
  
• Diarrhoea 8.1 3.3 
• ALT increased 7.8 0.6 
• AST increased 3.8 0 
• Vomiting 2.2 0.6 
• Nausea 1.3 0.3 
AEs leading to dose reduction of docetaxel 16.6 12.3 
AEs leading to permanent discontinuation of last 
study medication  
20.9 17.7 
AEs leading to permanent discontinuation of last 
study treatment occurring in ≥1% in either arm: 
  
• ALT increased 1.6 0 
• Malignant neoplasm progression 1.6 1.5 
• AST increased 1.3 0.3 
• Dyspnoea 1.3 3.3 
AEs=adverse events; ALT=Alanine aminotransferase; AST=Aspartate transaminase  
Source: adapted from Tables 54, 55, 56, 58 and 59 of the CS1 
 
 
The ERG notes from Table 24 that the incidence of AEs and SAEs was similar between 
treatment arms but the incidence of grade ≥3 AEs and SAEs was greater in the nintedanib 
plus docetaxel arm. The ERG notes grade 3 AEs tend to be particularly significant and can 
lead to drug discontinuation and hospitalisation but grade 2 AEs may also be clinically 
relevant by also impacting negatively on HRQoL. It is further noted that dose reduction 
schemes for nintedanib/placebo specified in Table 11 (pages 63 to 64) of the CS1 included 
grade 2 AEs, namely vomiting of CTCAE grade ≥2 within 3 days after docetaxel therapy, 
diarrhoea of CTCAE grade 2 for >7 consecutive days and AST or ALT elevations of CTCAE 
grade 2 in conjunction with bilirubin elevations of CTCAE grade ≥1, or AST or ALT 
elevations of CTCAE grade ≥3. CTCAE grade 2 diarrhoea was included as an AE in its 
economic model (see Table 35 in section 5.4.7). From the CTR41 (page 332, Table 
12.2.2.4.1.2: 2) the ERG observes 17.8% of patients in the nintedanib plus docetaxel arm 
reported CTCAE grade 2 diarrhoea compared to 7.2% in the placebo plus docetaxel arm; 
CTCAE grade 2 +  was 24.0% and 10.8% respectively. 
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Aside from AESIs related to nintedanib, a number of other AESIs were also identified and 
reported in the CS.1 These were generally balanced across treatment arms. Exceptions 
identified by the company were: 
• AESIs related to VEGFR inhibitor class effects: a higher frequency of any CTCAE 
grade hypertension in the nintedanib plus docetaxel arm (3.4% vs 0.6%). However, 
the incidence of CTCAE grade ≥3 hypertension was balanced across arms (0.9% vs 
0.6%) 
• AESIs based on potential associations/complications of AEs: any CTCAE grade 
dehydration only occurred in the nintedanib plus docetaxel arm (1.9% any CTCAE 
grade and 0.6 % CTCAE grade ≥3)  
• AESIs related to potential interaction with concomitant chemotherapy: mucositis was 
more common in the nintedanib plus docetaxel arm (16.6%) than the placeboplus 
docetaxel arm (11.4%); however, the incidence of grade ≥3 mucositis was balanced 
across arms (1.3 % vs 0.6% respectively) 
• AESIs selected based on competitor labelling: any CTCAE grade cutaneous skin 
reactions and any CTCAE grade rash were more common in the nintedanib plus 
docetaxel arm than placebo plus docetaxel arm (15.6% vs 10.5% and 12.5% vs 8.7% 
respectively; the incidence of both grade ≥3 cutanous skin reactions and grade ≥3 
rash was however balanced across arms (1.3 % vs 0.6% for cutaneous skin 
reactions and 0.3% and 0% for rash) 
• AESIs related to cardiac events: any CTCAE grade cardiac arrhythmias occurred at a 
slightly higher incidence in the nintedanib plus docetaxel arm (11.6%) compared with 
the placebo plus docetaxel arm (7.5%); however, the incidence of grade ≥3 cardiac 
arrhythmias was balanced across arms (2.2 % vs 1.5% respectively). 
 
Other AEs identified as AESIs by the company were interstitial lung disease, photosensitivity 
conditions and anaphylactic reaction. Frequencies of these AESIs were uncommon (1.3%, 
0.3% and 0 respectively for nintedanib plus docetaxel compared to 0.3%, 0.6% and 0.3% 
respectively in the placebo plus docetaxel arm). All were CTCAE grade <3 except for 
interstitial lung disease (0.3%) and anaphylactic reaction (0.3%) in the placebo plus 
docetaxel arm. 
The AEs reported in LUME-Lung 124 which are of greatest concern, are fatal AEs where 
some imbalances were reported between treatment arms, fatal AEs being more common in 
the nintedanib plus docetaxel arm (Table 26). The only exception was fatal AEs occurring 
within 6 weeks of treatment which the company argues were well-balanced “indicating that 
the combination therapy with nintedanib and docetaxel had no acute toxicity(42)” (page 154 of 
the CS1)  
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Table 26 Summary of fatal AEs in LUME-Lung 1 in the adenocarcinoma population 





n (%) n (%) 
All fatal AEs 56 (17.5) 32 (9.6) 
• Fatal AEs occurring within 6 weeks 13 (4.0) 12 (3.6) 
• Fatal AEs not attributed to progressive disease 20 (6.3) 8 (2.4) 
• Fatal AEs attributed to progressive disease* 36 (11.3) 24 (7.2) 
Drug-related fatal AEs 6 (1.9) 1 (0.3) 
• Sepsis 2 (0.6) 0 
• Dehydration 1 (0.3) 0 
• Diverticulum intestinale† 1 (0.3) 0 
• Ischaemic stroke 1 (0.3) 0 
• Large intestine perforation† 1 (0.3) 0 
• Neutropenic infection 1 (0.3) 0 
• Dyspnoea 0 1 (0.3) 
* Attribution to progressive disease by the local investigator, as documented on the Case Report Form 
† One patient experienced more than 1 fatal AE considered drug-related (patient with large intestine perforation and 
diverticulum intestinale) 
Source: adapted from Tables 60 and 61 of the CS1 
The company argues that data on fatal AEs are confounded in two ways. Firstly, the 
company argues the extent of exposure was longer on nintedanib plus docetaxel compared 
to docetaxel alone. As noted in Table 23, the median number of cycles of docetaxel that 
patients received was greater in the nintedanib plus docetaxel arm than in the docetaxel arm 
(5 vs 4 respectively). Therefore it is argued that the higher exposure to docetaxel may have 
contributed, at least in part, to the higher incidence of fatal AEs of sepsis caused by 
neutropenia in the nintedanib arm through the known myelotoxic effect of docetaxel. 
Consequently neutropenia and sepsis are considered possible side effects of nintedanib 
therapy in combination with docetaxel and are regarded as important identified risks for 
future monitoring and ongoing safety surveillance. Secondly, the analysis focusing on the 
on-treatment fatal AEs resulted in a skewed view of the deaths that occurred during the 
study. The company states that further review of PD and non-PD deaths occurring during the 
entire observation period revealed no other safety pattern suggestive of nintedanib 
associated toxicities.42 
The ERG considers that the number of deaths related to AEs is relatively small but agrees 
with the company that AE related deaths need to be monitored in future. The ERG considers 
that the greater number of PD related deaths in the nintedanib plus docetaxel arm could be 
related to the fact that PFS was longer in this arm and so patients were on treatment longer; 
this may also account for differences in non- PD deaths. However, the ERG does not 
consider that the greater number of cycles of docetaxel received by patients treated with 
nintedanib is likely to have been a confounder since, as reported by the National Confidential 
Confidential until published 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 65 of 139 
Enquiry into Patient Outcome and Death, most patients with life threatening toxicity tend to 
experience fatal AEs during the first cycle of treatment;64 it is reported by the company that 
dose intensity was similar between arms (98.1% vs 98.7%) .  
Comparison of adverse events from the indirect evidence 
As noted in section 4.4.1, it was only possible to conduct MTCs for safety outcomes if it was 
assumed pemetrexed and docetaxel had equal tolerability, an assumption which the ERG 
reiterates is not supported by the evidence (e.g. see JMEI56). The ERG has however 
presented the data input into the MTC as this shows AEs across two trials: LUME-Lung 124 
and WSY001.62 However, as WSY00162 it should be noted that WSY00162 is a trial of Asian 
patients conducted in China and AEs in a population in England may differ as a result of 
differences in co-morbidities, smoking history and pharmacokinetics between these 
populations. The ERG notes that the data from these trials support the generally held view 
that erlotinib is generally better tolerated than nintedanib plus docetaxel or docetaxel alone.  
Table 27 Safety results for adenocarcinoma populations of trials included in MTC base-case 
analysis 
Outcomes 











Any CTCAE grade AE: fatigue 
N 99 98 12 16 
% 30.9 29.4 19.7 25.8 
Any CTCAE grade AE: 
nausea 
N 91 59 1 15 
% 28.4 17.7 1.6 24.2 
Any CTCAE grade AE: 
diarrhoea 
N 139 82 10 2 
% 43.4 24.6 16.4 3.2 
CTCAE grade ≥3 fatigue 
N 15 14 0 0 
% 4.7 4.2 0 0 
CTCAE grade ≥3 nausea 
N 3 2 0 2 
% 0.9 0.6 0 3.2 
AE=adverse event; CTCAE= Common Terminology Criteria for Adverse Events 
Source: adapted from Table 34 of the CS1 
 
4.6 Critique of the health related quality of life data 
The company reports data on HRQoL data for LUME-Lung 124 that appears to have been 
reported in a poster presentation at the World Conference on Lung Cancer, Sydney, 
Australia, October 2013.47 It is stated that data are reported for patients with 
adenocarcinoma only although baseline data were only available for all patients, regardless 
of histology. The ERG also notes that the company states that longitudinal analysis reported 
that nintedanib plus docetaxel did not result in a change in global health status/QOL in 
patients with adenocarcinoma. Self-reported HRQoL assessments by EORTC 
Confidential until published 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 66 of 139 
questionnaires also revealed that there were no significant differences in cough, dyspnea or 
pain in patients over time or between those receiving nintedanib plus docetaxel and those 
receiving placebo plus docetaxel. Nintedanib-treated patients did however achieve 
numerically better cough and pain scores than placebo-treated patients, suggesting an 
improvement in HRQoL for these domains. Furthermore, statistically significant differences 
were observed between groups for three individual pain items (‘have pain’, ‘pain in chest’ 
and ‘pain in arm and shoulder’). On the other hand, the TTD for diarrhoea was significantly 
worsened in the nintedanib plus docetaxel arm; there was no significant difference between 
arms for nausea and vomiting, or appetite loss (Table 28). 
Table 28 Time to deterioration of nausea and vomiting, appetite loss and diarrhoea in 
patients with adenocarcinoma in LUME-Lung 1 
Symptom HR (95% CI) 
Nausea and vomiting 1.23 (1.00 to 1.51) 
Appetite loss 1.13 (0.92 to 1.38) 
Diarrhoea 1.86 (1.51 to 2.30)* 
*p<0.05 
HR=hazard ratio 
Source: Table 24 of the CS1 
The ERG notes that the response to the HRQoL questionnaire appears to be very good; the 
company states that over 80% of patients completed HRQoL questionnaires over the first 20 
cycles of treatment and approximately 70% of patients completed the questionnaire at the 
end of the treatment visit. It is noted that the main drivers of HRQoL in this population tend to 
be cancer related symptoms. Taking into account the findings for ORR and PFS (see section 
4.3.6) in which it was observed that the addition of nintedanib did not make a major 
difference to response rates but did lead to increased rates of tumour control and slower 
progression on average, it is perhaps unsurprising that dramatic differences in HRQoL were 
not seen on initiation of therapy. It is interesting to observe significant differences in pain 
symptoms as fatigue, dyspnoea and cough are often reported to be more troublesome to 
patients and their families.65 The worsened TTD for diarrhoea for patients treated with 
nintedanib plus docetaxel is unsurprising given the greater proportion of diarrhoea AEs in 
this arm (see section 4.5). The increased rates of diarrhoea did not seem have any major 
impact on global health status/QoL.  
No attempt was made by the company to compare HRQoL between nintedanib plus 
docetaxel and erlotinib. For reasons stated above (sections 2.2, 3.3 and 4.4.1), the ERG 
does not consider such a comparison is relevant to the decision problem, even if such a 
comparison were possible.  
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4.7 Conclusions of the clinical effectiveness section 
Clinical evidence has been submitted to NICE from the company in support of the use of 
nintedanib for previously treated locally advanced, metastatic or recurrent NSCLC of adult 
patients with adenocarcinoma tumour histology. The NICE scope did not specify 
adenocarcinoma nor did it refer to locally recurrent disease. This population is however in 
line with the anticipated marketing authorisation. While none of the scope, decision problem 
or anticipated marketing authorisation refer to the EGFR mutation status of NSCLC tumours, 
in England, the majority of patients (85 to 90%) are likely to be EGFR-negative. The ERG 
further notes that because patients who receive nintedanib also receive docetaxel, then 
patients who are likely to be eligible for treatment with nintedanib will also be ECOG PS 0 to 
1. 
Direct evidence is presented for nintedanib plus docetaxel vs placebo plus docetaxel from 
one RCT (LUME-Lung 124). Indirect evidence for nintedanib + docetaxel vs erlotinib is 
presented from MTCs. While both docetaxel and erlotinib are specified as comparators in 
the NICE scope, given that erlotinib is likely to be preferred when patients have a poorer 
performance status and/or have EGFR-positive tumours, or be treatment naïve for a TKI, the 
ERG agrees with the company that erlotinib is not a relevant comparator and that docetaxel 
is the only appropriate comparator for this STA.  
LUME-Lung 124 is a phase III double-blind RCT which compares nintedanib plus docetaxel 
vs placebo plus docetaxel. It is considered to have a low risk of bias. As a result of the 
exclusions of certain types of patients, the patient population appears to be fitter than would 
be found in clinical practice in England. This could partially explain why the post-study 
therapy rate is relatively high (55.8%). 
The findings from this trial suggest nintedanib plus docetaxel significantly improved PFS and 
OS in comparison to placebo plus docetaxel in the subgroup of patients with 
adenocarcinoma. After a median follow-up of 31.7 months the gain in median PFS was 1.4 
months (4.2 months vs 2.8 months) and gain in median OS was 2.3 months (12.6 months vs 
10.3 months). However, the ERG does not consider that the assumption of proportional 
hazards is consistent with the trial data, and therefore use of these results in cost-
effectiveness modelling should not be based implicitly or explicitly on this assumption. 
Nintedanib plus docetaxel also resulted in an increase in some types of AEs, particularly 
diarrhoea, nausea, vomiting and increases in ALT/AST. The majority of these AEs can be 
managed by dose reductions of nintedanib. The ERG is in agreement with the company that 
apparent improvements seen in terms of PFS and OS in the adenocarcinoma patients were 
achieved without substantial alterations in self-reported HRQoL.   
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5 COST EFFECTIVENESS 
5.1 Introduction 
This section provides a structured critique of the economic evidence submitted by 
Boehringer Ingelheim Ltd in support of the use of nintedanib in combination with docetaxel 
for the treatment of adult patients with locally advanced, metastatic or recurrent NSCLC of 
adenocarcinoma tumour histology after first-line chemotherapy. The two key components of 
the economic evidence presented in the CS1 are (i) a systematic review of the relevant 
literature and (ii) a report of the company’s de novo economic evaluation. The company also 
provided an electronic copy of their economic model that was developed in Microsoft Excel. 
5.2 ERG comment on company’s review of cost-effectiveness evidence 
5.2.1 Objective of the company’s cost-effectiveness review 
On page 175 of the CS,1 the company explains that “The scope of the systematic review is 
to review all available published data on economic evaluations of second-line therapies for 
locally advanced or metastatic NSCLC that could inform a HTA submission based on 
Boehringer Ingelheim’s second-line comparative trials of nintedanib”. This single systematic 
review was performed to identify clinical, cost-effectiveness, resource use and cost data as 
well as studies reporting utility scores for health states within the model.  
Details of the cost-effectiveness search strategies employed are included in Appendix 10 of 
the CS. Medline (via PubMed), Medline R-In Process (via PubMed), EMBASE, and The 
Cochrane Library (via NHS EED) were searched for data on economic models, costs, 
resource use associated with NSCLC, HRQoL and utilities. HEED and EconLit were 
searched for data on HRQoL and utilities. The time horizon for the search for full economic 
studies was 2000 to February 2014 and for cost analyses was 2012 to 2013. 
The search of the literature yielded no relevant studies. The ERG is satisfied with the 
company’s search strategy and is confident that the company did not miss any relevant 
published articles.  
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5.2.2 Eligibility criteria used in the study selection  
The inclusion/exclusion criteria used in the study selection are presented in Table 29. The 
ERG is satisfied that these criteria are relevant to the decision problem.  
Table 29 Economic evaluation search inclusion/exclusion criteria 
Parameter Inclusion criteria Exclusion criteria 
Population Relapsed or refractory NSCLC (RR NSCLC) (receiving 
second-line chemotherapy or relapsed/refractory to first-
line chemotherapy) 
Any patient population 
other than RR NSCLC 
 
Interventions Any second-line chemotherapy for RR NSCLC: 
• Monotherapy 
• Combination therapy with other chemotherapy 
Other interventions that are considered standard care in 
the patient population that will be relevant to the 
economic model 
Patients who were 
treatment-naїve or had 
received more than first-
line therapy 
Outcomes Economic models: 
• Cost-utility analyses 
• Cost-effectiveness analyses 
• Cost-benefit analyses 
• Cost-minimisation analyses  
No outcomes of interest 
included  
Study design Economic models: Economic studies  Not an economic model 
Language restrictions English language Non-English language 
Date Economic models: 2002 onwards  Prior to the year 2002* 
Country Any None 
*Abstracts published prior to 2011 and systematic reviews published prior to 2009 were excluded 
Source: Table 72 of CS1 
5.2.3 Included and excluded studies 
No relevant studies were identified by the company. 
5.2.4 Conclusions of the cost effectiveness review  
The ERG notes that since nintedanib in combination with docetaxel has not yet received a 
full marketing authorisation from the EMA for the second-line treatment of adult patients with 
adenocarcinoma, the lack of economic evaluations of relevance to the decision problem is 
not unexpected.  
5.3 ERG critique of the company’s literature review 
The ERG is satisfied with the company’s search strategy and stated eligibility criteria for 
inclusion/exclusion. The ERG is confident that the company did not miss any relevant 
published papers.  
The ERG acknowledges that the company reported the methods and results of a series of 
literature reviews at key points throughout the cost-effectiveness section in the CS;1 the 
ERG considered the results of these additional reviews to be very helpful. 
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5.4 Summary and critique of the company’s submitted economic 
evaluation by the ERG 
5.4.1 NICE reference case checklist  
 
Table 30 NICE Reference case checklist completed by ERG 
Attribute Reference case Does the de novo economic evaluation match the reference case? 
Decision problem The scope developed by NICE Partial - the population was limited to patients with 
adenocarcinoma 
Comparator(s) Alternative therapies routinely 
used in the NHS 
Yes 
Perspective costs NHS and Personal Social 
Services  
Partial - only NHS costs were included in the model 
Perspective benefits All health effects on individuals Yes, health effects to the individual are captured via 
QALYs 
Form of economic 
evaluation 
Cost-effectiveness analysis Cost-effectiveness analysis 
Time horizon Sufficient to capture differences 
in costs and outcomes 




Systematic review Nintedanib + docetaxel vs docetaxel: direct trial data 
from LUME-Lung 124 was used. Nintedanib + 
docetaxel vs erlotinib: hazard ratios were taken from 
the results of the company’s network meta-analysis 
(fixed-effects model) 
Outcome measure Quality adjusted life years 
(QALYs) 
QALYs were used which is appropriate 
Health states for 
QALY 
Described using a standardised 
and validated instrument 
EQ-5D was used, with data collected mainly from 
participants in LUME-Lung 1.24 Data from published 
sources66,67 were used in the sensitivity analysis 
Benefit valuation Time-trade off or standard 
gamble 
Time-trade off 
Source of preference 
data for valuation of 
changes in HRQoL  
Representative sample of the 
public 
UK preference tariff based on public sample. Data 
for assigning valuation health states were collected 
directly from trial participants 
Discount rate An annual rate of 3.5% on both 
costs and health effects  
Benefits and costs were discounted at the 3.5% rate 
Equity  An additional QALY has the 
same weight regardless of the 
other characteristics of the 
individuals receiving the health 
benefit  
All QALYs estimated by the model have the same 
weight 
Sensitivity analysis Probabilistic sensitivity analysis  Deterministic, scenario and probabilistic sensitivity 
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Table 31 Critical appraisal checklist for the economic analysis completed by ERG 
Question Critical appraisal ERG comment 
Was a well-defined question posed in 
answerable form? 
Yes  
Was a comprehensive description of the 
competing alternatives given? 
Yes  
Was the effectiveness of the programme 
or services established? 
Partial For the direct comparison of nintedanib + 
docetaxel vs docetaxel, effectiveness was 
established using data from LUME-Lung 124 
 
For the indirect comparison of nintedanib + 
docetaxel vs erlotinib, an MTC was undertaken. 
The ERG does not consider the results of the MTC 
to be valid or reliable, nor does it consider the 
comparison to be relevant to the decision problem 
Were all the important and relevant costs 
and consequences for each alternative 
identified? 
Mostly Specific issues are discussed insection 5.5 and the 
impact on the ICER is presented insection 6 of the 
ERG report 
Were costs and consequences 
measured accurately in appropriate 
physical units? 
No Specific issues are discussed insection 5.5 and the 
impact on the ICER is presented insection 6 of the 
ERG report 
Were the cost and consequences valued 
credibly? 
No Specific issues are discussed insection 5.5 and the 
impact on the ICER is presented insection 6 of the 
ERG report 
Were costs and consequences adjusted 
for differential timing? 
Yes (with 
errors) 
Specific issues are discussed insection 5.5 and the 
impact on the ICER is presented insection 6 of the 
ERG report 
Was an incremental analysis of costs 
and consequences of alternatives 
performed? 
Yes ICERs were calculated correctly 
Was allowance made for uncertainty in 
the estimates of costs and 
consequences? 
Yes Deterministic, scenario and probabilistic sensitivity 
analyses were undertaken 
Did the presentation and discussion of 
study results include all issues of 
concern to users? 
Yes  
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5.4.2 Description of the company’s economic model 
A schematic of the company’s submitted economic model is provided in the CS1 and is 
reproduced in Figure 2.The company’s cost-effectiveness model is a partitioned survival 
Markov model which comprises three health states: progression-free (on or off treatment) 
(PF); PD and death (D). All patients enter the model in the PF state. At the beginning of each 
time period patients can either remain in the same health state or progress to a worse health 
state, i.e. from PF to PD or death; or from PD to death. The model uses the partitioned 
survival (also known as area under the curve or AUC) method to determine the proportion of 
patients in each of the three health states during each model cycle. The proportion of 
patients in the PD state is estimated as the difference between OS and PFS. Estimates of 
OS and PF are based on PF and OS survival data from LUME-Lung 124 and the 
corresponding parametric survival models. The model assumes that patients receive best 
supportive care (BSC) following the discontinuation of active second-line treatment. The 
model also allows some patients in the progressed state to have subsequent treatments. 
The costs of subsequent treatment are included in the economic evaluation; however, the 
impact of subsequent therapy is not included in the model. Variants of this model structure 
have been used in the modelling of metastatic oncology for numerous STAs including two 
recent NICE STAs that considered locally advanced or metastatic NSCLC (NICE TA19214 
and NICE TA25813). 
 
Figure 2 Schematic of company’s model 
Source: Figure 24 of the CS1 
 
The model has been developed in Microsoft Excel using a 3-weekly cycle length. It includes 
a half-cycle correction and the time horizon is set at 15 years. Health effects are measured 
in QALYs. A summary of all of the variables applied in the economic model is shown in 
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Table 79 of the CS;1 details displayed in the table include the values used, range 
(distribution) and source. 
5.4.3 Population 
The company states on page 180 of the CS1 that the model population was based on the 
findings of LUME-Lung 124 and included patients with locally advanced and/or metastatic, 
stage IIIB/IV or recurrent NSCLC with adenocarcinoma histology who failed after first-line 
chemotherapy. 
5.4.4 Interventions and comparators 
The company’s base-case economic evaluation compares nintedanib plus docetaxel with 
docetaxel. The interventions are implemented in the model in accordance with their current, 
or anticipated, full marketing authorisations and doses. 
Patients receiving nintedanib plus docetaxel are assumed to take two 100mg capsules of 
nintedanib twice daily; there are 120 capsules in each 100mg pack. The assumed NHS list 
price per 30-day pack is £2151.10. The ERG notes that there is also a 150mg capsule 
available; there are 60 capsules in each 150mg pack. In response to a clarification question 
raised by the ERG, the company indicated that the price of both packs is likely to be the 
same. Nintedanib plus docetaxel therapy needs to be given for a minimum of four cycles 
before nintedanib can be administered as monotherapy. There is no administration cost 
associated with nintedanib. Patients receiving intravenous docetaxel are assumed to receive 
75mg/m2 on day 1 of a 21-day cycle. The monthly cost of docetaxel is estimated to be £49 
(using electronic Marketing Information Tool [eMIT] prices68) and has a monthly 
administration cost of £221.43 (NHS Reference Cost 2012/13).69 
The submitted economic model also permits the comparison of nintedanib plus docetaxel 
with erlotinib. In the model the dose of erlotinib is assumed to be 150mg per day and the 
MIMS 2013 price for a pack of 30 tablets is £1631.53.70 It is noted that erlotinib has an 
associated patient access scheme, which the company took into account by undertaking a 
number of sensitivity analyses in which a range of discounts were applied to the list price. 
However, the company emphasises on page 184 of the CS1 that erlotinib is not a relevant 
comparator and considers that patients treated with erlotinib are a different patient 
population. 
Some patients in the model go on to receive subsequent therapy after progression: the 
company’s external expert stipulated that 5% would receive erlotinib, 25% would receive a 
platinum doublet and 70% would receive BSC. The cost per month of BSC (£406.63 per 
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cycle [3 weeks]) is as per TA310 (Afatinib NICE submission) 15 as recommended by the 
company’s external expert.  
5.4.5 Perspective, time horizon and discounting 
The company states that the economic evaluation is undertaken from the perspective of the 
NHS and Personal Social Services. However, it should be noted that the model does not 
include all likely Personal Social Services costs. The time horizon is set at 15 years and both 
costs and outcomes are discounted at 3.5% in line with the NICE Methods Guide to 
Technology Appraisal.54  
5.4.6 Treatment effectiveness and extrapolation 
Modelling treatment effectiveness (nintedanib plus docetaxel vs docetaxel) 
Kaplan-Meier survival curves for OS and PFS for nintedanib plus docetaxel and docetaxel 
monotherapy were available from LUME-Lung 124 and show the proportion of patients in the 
model’s three health states at each time point. These data were incorporated into the cost-
effectiveness model by using full parametric approximation of the raw data in the base-case. 
In the sensitivity analyses, K-M data from LUME-Lung 124 were used to model OS (until at 
least 5% of trial patients are still at risk) and were extrapolated using parametric function as 
a tail to the Kaplan-Meier data to provide a lifetime time horizon. Survival data from LUME-
Lung 124 were mature and the proportion of censored patients in both treatment arms were 
similar. However, in order to facilitate extrapolation of trial data beyond the time horizon, OS 
and PFS data were analysed using parametric survival models. Parametric survival curves 
were fitted to PFS and OS K-M curves using two approaches: 1) joint models, statistical 
models including data for both treatment groups with a term for treatment and 2) separate 
models, statistical models fitted to each randomised treatment arm separately. 
Choice of statistical model 
The “goodness of fit” based on Akaike information criteria (AIC) indicated that joint models 
were appropriate. However, the intercept and scale parameters of the separately fitted 
curves indicated that the curves should not be forced into the same model, thus separate 
curves were selected for OS and PFS. The log-logistic model had the lowest AIC among the 
separately fitted OS models, and the Weibull model had the lowest AIC among the separate 
proportional hazard models for OS; therefore, these were selected to model the OS data. 
The log-normal model had the lowest AIC among the separate PFS fits, and the Weibull had 
the lowest AIC among the separate proportional hazard models for PFS; therefore, these 
were selected to model PFS.  
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The company states that the long-term extrapolation of trial data was validated with a group 
of UK clinicians and against data from SEER using the SEER*Stat software, as well as 
against data from LUCADA. As noted in section 5.5, no references were provided to identify 
the specific DEER and LUCADA data sets employed.  
Survivals implemented in the model 
Survival modelling options programmed into the cost-effectiveness model are displayed in 
Table 32. In the base-case, the analysis used separate models for PFS and OS, with log-
normal distribution for the PFS and log-logistic distribution for the OS.  
Table 32 Survival estimation models employed in the company’s model 
Progression-free survival Overall survival (OS) 
Separate model - Log-normal (base-case) Separate model - Log-logistic (base-case) 
Separate model - Weibull Separate model - Weibull 
Kaplan-Meier curve* Kaplan-Meier curve* 
 Kaplan-Meier curve and SEER lognormal† 
 Kaplan-Meier curve and Separate Log-logistic† 
 Kaplan-Meier curve and Separate Weibull† 
 Kaplan-Meier curve and LUCADA lognormal† 
LUCADA= National Lung Cancer Audit database; OS=overall survival; PFS=progression-free survival; SEER=Surveillance, 
Epidemiology and End Results 
* With this option, the model does not extrapolate the PFS/OS with the use of parametric models but it uses the K-M curves for 
PFS/OS obtained directly from the LUME-Lung 124 trial. Note that this option only applies for nintedanib + docetaxel and 
docetaxel monotherapy 
† With this option, the Kaplan-Meier curves from the LUME-Lung 124 trial are used for the estimation of OS until patient number 
at risk drops down to 5% of original patients, afterwards parametric models are used 
Source: Table 75 of the CS1 
Modelling treatment effectiveness of erlotinib 
As OS and PFS K-M curves for erlotinib were not available, model OS and PFS inputs for 
erlotinib were derived by applying HRs (i.e., vs nintedanib plus docetaxel) obtained from the 
mixed treatment comparisons to the OS and PFS of nintedanib plus docetaxel. The 
company considers that HRs can only be used if the survival distribution is a proportional 
hazard model such as exponential, Weibull, or Gompertz. Thus, in the model, erlotinib can 
be evaluated only if a Weibull distribution is selected for both OS and PFS. The model base-
case analysis utilised HRs from the MTC base-case. The HR for OS was 0.64 (95% CI: 0.46 
to 0.90) and the HR for PFS was 0.7 (95% CI: 0.5 to 1.0). The company used results from 
the fixed-effects model because there was one trial per comparison. 
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5.4.7 Health related quality of life 
Utility 
Health related quality of life data were collected during LUME-Lung 124 using the EQ-5D 
instrument, in line with the NICE Methods Guide to Technology Appraisal.54 Data from the 
LUME-Lung 124 were analysed using a longitudinal model adjusted for baseline ECOG 
score, prior treatment with bevacizumab, presence of brain metastases, controlling for health 
status and key adverse events. Key model utility values for PF and PD are displayed in 
Table 33. 
Table 33 Utilities for progression-free and post-progression states 
Nintedanib + docetaxel and docetaxel arms - 
Pooled 
Progression free without adverse events 
Mean Standard error 
Week 0 0.710 0.01 
Week 3 0.721 0.01 
Week 6 0.707 0.01 
Week 9 0.699 0.01 
Week 12 0.692 0.01 
Week 15 0.687 0.01 
Week 18 0.682 0.01 
Week 21 0.677 0.02 
Week 24 0.671 0.02 
Week 27 0.666 0.02 
Week 30 0.661 0.02 
Treatment arm 
Progressive disease 
Mean Standard error 
Nintedanib + docetaxel 0.64 0.01 
Docetaxel 0.64 0.01 
Source: Table 80 of the CS1 
Progression free utility estimates 
The analysis estimated utility values over time for PF patients from week 0 to week 30 in 3-
week intervals - without a treatment term. An assumption of the linear extrapolation of trend 
observed until week 30 for the PF health state is employed in the base-case to allow 
modelling of continuing change in utility in the PF state beyond the trial data. 
Progressed disease utility estimates 
In contrast to the estimation of PF utilities over time, mean PD utilities were used in the 
base-case model to accommodate the memory-less feature of the Markov approach. 
  
Confidential until published 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 77 of 139 
Utility values used in the model 
The company’s model uses the utility values derived from LUME-Lung 124 in the base-case. 
Utility values from the literature are also tested within the model. The company used utility 
values from a recently published paper by Chouaid et al66 in a sensitivity analysis. This 
paper reports utilities recorded from relevant patients in Europe, Canada, Australia and 
Turkey as well as the UK and uses the EQ-5D to obtain utilities for the health states that 
were used in the company’s model. 
Table 34 Utilities used in the sensitivity analysis (Chouaid et al66 2013) 
Health state Mean (Standard error) 
Progression free survival (PFS) 0.74 (0.03) 
Post-progression 0.46 (0.08) 
Source: Table 83 of the CS1 
Disutility 
The company’s model also incorporated the impact of AEs on HRQoL; utility decrements 
associated with each AE were applied for a period of one model cycle. The company notes 
that the model may have double counted disutilities as some patients may experience 
multiple AEs simultaneously. Disutilities due to AEs are presented in Table 35. 
Table 35 Disutilities associated with AEs 
Adverse event Disutility Sources 
ALT increased -0.05 Assumption 
Anaemia -0.07 Nafees et al67 
Diarrhoea - grade 2 -0.02 Assumption: half of the disutility for grade 3/4 diarrhoea 
Diarrhoea - grade 3/4 -0.04 Data on file, Table 18.171 
Fatigue -0.21 Data on file, Table 18.171 
Febrile neutropenia -0.09 NICE TA192,14 Nafees et al. 200867 
Infection -0.05 Assumption 
Liver-related investigations -0.05 Assumption 
Nausea and vomiting -0.05 Nafees et al67 
Neutropenia -0.09 Nafees et al67 
Neutrophil count decreased -0.09 Assumption: same as disutility of neutropenia 
Rash -0.033 Nafees et al.67  
Thrombocytopenia -0.05 NICE TA18172 
WBC count decreased -0.05 Assumption 
WBC=white blood cell 
Source: Table 84 of the CS1  
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5.4.8 Resources and costs 
Drug acquisition and administration costs 
Table 36 presents a summary of the drug and IV administration costs per cycle for each 
comparator for the active second-line treatment phase, the BSC phase and, where relevant, 
the third-line treatment phase. Adjustments in drug costs due to change in dose intensity and 
treatment discontinuation as observed in LUME-Lung 124 were included in the company’s 
model for second-line treatments. Changes in dose intensity or treatment discontinuation 
inputs only affected drug costs outcomes; they did not affect clinical outcomes (e.g. OS, PFS 
and AEs). Wastage was taken into account when calculating the cost of IV treatments. 
As nintedanib is taken orally, it is not associated with any additional administration costs.  
Table 36 Drug costs used in the company’s model 
Drug Units per administration 
Price 





























Docetaxel 75 mg/m2 £5.68 IV 1 £155 £196 
Erlotinib 150 mg £0.36 Oral 21 - £1,051 
Carboplatin† 750 mg £0.33 IV 1 
£155 
£250 
Vinorelbine† 30 mg/m2 £2.78 IV 3 £465 
IV=intravenous 
* Mean dose intensity taken into account: (nintedanib + docetaxel=98.1%, nintedanib=91.2%, docetaxel=98.7% and 
erlotinib=92%)  
† third-line treatment 
Source: Table 96 of the CS1 
Health state costs 
The company considered that there was little published literature exploring the detailed 
resource use commonly associated with NSCLC or other metastatic cancer. To estimate the 
treatment patterns in NSCLC a resource use questionnaire was constructed. This formed the 
basis of an interview with an oncologist who specialised in the treatment of patients with lung 
cancer and who had experience of working on NICE health technology assessment reports. 
A series of questions was posed separately for each different health state (stable on 
nintedanib plus docetaxel, stable on docetaxel, stable on erlotinib, stable on BSC; 
progressed on active treatment, progressed on BSC; and a one-off estimate of resource use 
at the time of progression) under the umbrella term ‘monitoring’. Three main areas of 
resource use were considered: routine follow up (type and frequency of physician visit, 
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laboratory tests, radiological scans); treatment at time of progression (hospitalisations, 
physician visits, laboratory tests, radiological scans, procedures use; and resources used 
during BSC/palliative care (initial tests, procedures, hospitalisations, physician visits, 
laboratory tests, radiological scans and procedures). Detailed descriptions of resource use 
are displayed in Tables 98 to 105 in the CS;1 in addition a full range of the unit costs 
employed is also presented in Table 106 of the CS.1 The unit costs of visit procedures and 
laboratory tests were mainly derived from the National Schedule of Reference costs 
(2012/3),69 whilst some visit costs were taken from the Personal Social Services Research 
Unit (PSSRU).73 
Adverse events costs 
A single UK consultant provided AE management costs. Estimates were generated via 
survey and face-to-face discussion. Costs for inpatient hospitalisations were taken from the 
NHS National Schedule of Reference Costs (2012/13).69 Outpatient costs were taken from 
the same source69 or from the PSSRU.73 The cost of each AE is summarised in Table 37. 
Table 37 Adverse events costs 
Type of adverse event Cost of adverse events 
ALT increased £587 
Anaemia £978 
AST increased £336 
Diarrhoea - CTCAE grade 1 and 2 £250 
Diarrhoea - CTCAE grade 3 and 4 £1796 
Fatigue £370 
Febrile neutropenia £2012 
Infection £2181 




WBC count decreased £423 
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CTCAE= Common Terminology Criteria for Adverse Events; 
WBC=white blood cell 
Source: Table 107 of the CS1  
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5.4.9 Model validation  
The company reports that a number of steps were taken to ensure that the analysis was 
validated, including: 
• External review by a leading UK clinical expert to ensure that the model adheres to the 
clinical course of the disease and is reflective of current clinical practice 
• Sensitivity analyses 
• A senior modeller within the model developers’ organisation (with no involvement in the 
model’s development) performed a detailed quality assurance check on the model 
• The company performed validation checks (varying parameter values and assumptions). 
This involved increasing and decreasing various parameters or changing assumptions in 
the model and then monitoring the impact on outputs. If the outputs were unexpected, 
further checks were made to determine whether this was the result of an error in the 
model. 
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5.4.10 Results included in the company’s model 
The incremental cost-effectiveness results generated by the company’s economic model are 
presented in Table 38 and Table 39. The ICER for nintedanib plus docetaxel vs docetaxel is 
estimated by the company to be £50,677 per QALY gained. The ICER for nintedanib plus 
docetaxel vs erlotinib is estimated by the company to be £27,008. 






















Nintedanib +  
docetaxel 
******* **** **** - - - - - 
Docetaxel ******* **** **** £11,051 0.33 0.22 £50,776 £50,776 
ICER=incremental cost-effectiveness ratio; LYG=life years gained; QALY=quality adjusted life year 
N.B. Distributions used - OS: Log-logistic; PFS: Log-normal 
Source: Table 129 of the CS1 
 





















Nintedanib +  
docetaxel 
******* **** **** - - - - - 
Erlotinib ******* **** **** £7,571 0.43 0.28 £27,008 £27,008 
ICER=incremental cost-effectiveness ratio; LYG=life years gained; QALY=quality adjusted life year 
N.B. Distributions used - OS: Weibull distributions; PFS: Weibull survival 
Source: Table 130 of the CS1 
5.4.11 Sensitivity analyses 
Deterministic sensitivity analyses 
The company carried out a wide range of deterministic sensitivity analyses. Results for the 
ten parameters showing the greatest variability for the comparisons of nintedanib plus 
docetaxel vs docetaxel and vs erlotinib are shown in Figure 3 and Figure 4 respectively. For 
the comparison of nintedanib plus docetaxel vs docetaxel, the two most influential variables 
were univariate changes in utility values after progression for both intervention and 
comparator. For the comparison of nintedanib plus docetaxel vs erlotinib, the single most 
influential variable was the HR used for OS. 
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Figure 3 One-way sensitivity analysis: nintedanib plus docetaxel vs docetaxel 




Figure 4 One-way sensitivity tornado diagram: nintedanib plus docetaxel vs erlotinib 
Source: Figure 34 of the CS1 
Probabilistic sensitivity analysis  
The company undertook probabilistic sensitivity analysis (PSA) to derive the mean ICERs 
per QALY gained for nintedanib plus docetaxel vs docetaxel and vs erlotinib. PSA was 
carried out using 5000 iterations of the cost-effectiveness model.  
The PSA result for nintedanib plus docetaxel vs docetaxel shows that nintedanib plus 
docetaxel has a 2% probability of being cost-effective at the £30,000 per QALY gained 
threshold and a 50% chance of being cost-effective at the £50,000 per QALY gained 
threshold. The cost-effectiveness plane and cost-effectiveness acceptability curve (CEAC) 
for this comparison are displayed in Figure 5 and Figure 6. 
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Figure 5 Incremental cost-effectiveness plane for nintedanib plus docetaxel vs docetaxel 
Source: Figure 35 of the CS1 
 
 
Figure 6 Cost-effectiveness acceptability curve for nintedanib plus docetaxel vs docetaxel 
Source: Figure 36 of the CS1 
 
The PSA result for nintedanib plus docetaxel vs erlotinib shows that nintedanib plus 
docetaxel has a 65% probability of being cost-effective at the £30,000 per QALY gained 
threshold and a 94% chance of being cost-effective at the £50,000 per QALY gained 
threshold. The cost-effectiveness plane and CEAC for this comparison are displayed in 
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Figure 7 Cost-effectiveness plane for nintedanib plus docetaxel vs erlotinib 




Figure 8 Cost-effectiveness acceptability curve for nintedanib plus docetaxel vs erlotinib 
Source: Figure 38 of the CS1 
 
Scenario analyses 
The company also undertook a series of scenario analyses and explored how varying 
scenarios relating to survival modelling, indirect comparisons, resource use, utility, time 
horizon and discount rate might affect the results of the economic evaluation. The results of 
these scenario analyses are displayed in Tables 135 to 140 in the CS.1 The company 
concluded that the base-case ICERs are mainly sensitive to changes in the PFS and OS 
HRs as well as the costs and utilities associated with the post-progression states. 
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5.5 Detailed critique of company’s economic model 
The model submitted by the company for this appraisal is structured as a partitioned survival 
spreadsheet model following a structure broadly similar to those used in similar 
appraisals.13,14 For most functions the assumptions and options are labelled and annotated 
where necessary. However, in some cases, the ERG has found it difficult to confirm details 
of the data sources employed.  
In line with the issues previously discussed (section 2.2 and 3.3) concerning the relevance of 
erlotinib as a comparator (largely due to the challenge of identifying a meaningful population 
for such a comparison), and the unreliability of indirect evidence of relative efficacy (section 
4.4.1 and 4.4.6), this critique is primarily focussed on the direct comparison between 
nintedanib plus docetaxel and docetaxel monotherapy in the adenocarcinoma subgroup of 
LUME-Lung 1.24  
A particular concern of the ERG relates to the analyses reported by the company of OS data 
from the SEER and LUCADA registers (Appendix 13 of CS1). No references were provided 
which identify the specific data sets employed and relevant details (such as date of 
extraction, selection criteria, duration of follow-up) are missing. The ERG has had to infer 
from the text that the SEER results appear to relate to all-cause mortality from the date of 
Stage 4 diagnosis and that the LUCADA data relate to second-line chemotherapy, but 
without any specific indication of prior treatments, PS and/or other relevant characteristics. 
The value of these analyses to support the company’s chosen parametric survival modelling 
is therefore difficult to assess, and in particular the relevance of the SEER dataset to the 
population recruited to LUME-Lung 124 must be considered weak. 
The following sections detail eleven specific issues identified by the ERG involving errors in 
data analysis, parameter values or methodology which have been identified in the submitted 
model, together with estimates made by the ERG of the impact of correcting these problems 
on the estimated ICER for nintedanib plus docetaxel compared with docetaxel. Within the 
time available to the ERG, it has not been possible to be certain that other problems do not 
remain undetected in the company’s model. 
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5.5.1 Methods used to project time-to-event outcomes 
In seeking to project OS and PFS data from LUME-Lung 124 to represent expected lifetime 
experience, the company has followed a convention of seeking to fit a variety of standard 
parametric functions to the available data, and employed the derived functions in place of 
the trial data throughout their decision model.  
The ERG considers that this approach to model calibration to be flawed on several counts: 
- The primary purpose of curve-fitting is to anticipate what is likely to happen to the 
minority of patients who remain at risk (i.e. alive with or without disease progression 
or remaining on treatment) at the time of data cut. However, the great majority of 
data events used for this purpose are drawn from patients who are unlike those 
remaining at risk at the time of data cut, since that majority were at greater propensity 
to fail (i.e. die, progress or cease treatment) than those still remaining. This is an 
example of bias against survivors and frequently results in the fitting of inappropriate 
functions and misleading projection estimates. 
- The methods used for fitting parametric functions to a survival data set are 
essentially descriptive and lack any external validity based on the appropriateness of 
an underlying disease/treatment process governing them. Therefore, the analyst may 
be content in having achieved a reasonable correspondence to the available data, 
but lacks any basis for confidence in any future projection based thereon. 
- When a single clinical trial is the primary source for cost-effectiveness assessment, it 
is important to make the maximum direct use of the available evidence. Replacing a 
large part of the trial results with a fitted model adds additional uncertainty from 
imposed modelling assumptions to the unavoidable data sampling uncertainty, so 
that rather than clarifying the underlying disease dynamic, it only serves to obscure it. 
- Most of the ‘standard’ statistical functions used by the company to model survival 
lack any logical or empirical basis for representing a biological phenomenon, being 
only selected for their analytical convenience. 
As part of the clarification process, the ERG requested detailed K-M survival analysis results 
for all of the time-to-event trial data employed in the company’s model. The ERG has, for 
each of the K-M survival analysis results, identified a projective model, using only those data 
in the period towards the end of the survival curve in which it is apparent that a long-term 
trend has become established. The early K-M data are used directly in the company’s 
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model, giving way to the projective model only to represent the segment of patient 
experience which cannot be reliably estimated otherwise. 
In projecting ToT the company’s model considers only a single parametric function 
(exponential model with fixed hazard per cycle calibrated over the whole trial period). Here, 
the same methodology flaws are present, except that no attempt has been made to assess 
the comparative validity of the exponential hazard function against possible alternatives. 
5.5.2 Overall survival estimation 
The company’s model base-case comparison of nintedanib plus docetaxel vs docetaxel 
indicates a gain in (undiscounted) overall survival of 4.7 months; only 15% (0.7 months) of 
this gain is attributed to the pre-progression phase. This is unusual in locally advanced and 
metastatic cancers where treatment benefit is largely confined to the active treatment period 
(i.e. PFS). In order to validate this claim, the ERG has carried out its own analysis of the OS 
and post-progression survival (PPS) trial data, based on K-M results provided by the 
company in response to a clarification request. 
Figure 9 shows a cumulative hazard chart for OS. After about 300 days, a simple linear trend 
is established in both trial arms and continues indefinitely. This indicates that in both arms 
OS can be estimated by use of a simple exponential projective model (i.e. there is a constant 
hazard irrespective of time). Comparing the slopes of the trend lines allows a long-term HR 
of 0.83 in favour of nintedanib plus docetaxel to be estimated. To verify this finding a similar 
cumulative hazard chart was prepared for PPS (shown as Figure 10). This confirms that 
patients in LUME-Lung 124 who survived a disease progression event continued to gain 
survival benefit from treatment with nintedanib plus docetaxel compared with those receiving 
only docetaxel. Long-term linear trends are apparent in both trial arms beyond 200 days in 
PPS, and the trends continue to diverge with an estimated long-term HR of 0.79 in favour of 
nintedanib plus docetaxel. 
Estimates of lifetime OS were obtained by the ERG by applying the K-M trial results directly 
using the area under curve (AUC) method until the long-term OS trends were established 
and then projecting remaining estimated survival using the exponential trends (as shown in 
Figure 11). Mean OS in the docetaxel arm is estimated as 453.0 days (14.9 months) 
compared with 545.7 days (17.9 months) in the nintedanib plus docetaxel arm, a net survival 
gain of 92.7 days (3.05 months) attributable to the addition of nintedanib to docetaxel. This 
result is considerably lower than the OS gain obtained from the company’s model (4.7 
months), and indicates the effect of replacing the company’s preferred Log-Logistic survival 
model to represent the whole trial data set with the ERG’s approach (direct use of 
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unadjusted trial data for the majority of patients, followed by projecting long-term survivors 
using trends evident in the trial data set). 
Replacing the company’s preferred OS model with the ERG’s approach has a major impact 
on the cost-effectiveness of nintedanib plus docetaxel compared with docetaxel alone. The 
incremental discounted cost per patient is reduced by xxx while the incremental discounted 
QALY gain is reduced by *******, resulting in the estimated ICER increasing from £50,776 
per QALY gained to £68,587 per QALY gained. 
 
Figure 9 Cumulative OS hazard plot for nintedanib plus docetaxel vs docetaxel 
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Figure 10 Cumulative PPS hazard plot for nintedanib plus docetaxel vs docetaxel 
 
Figure 11 OS plot with ERG long-term projections for nintedanib plus docetaxel vs docetaxel 
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5.5.3 Progression-free survival estimation 
The company’s model base-case comparison of nintedanib plus docetaxel vs docetaxel 
indicates a gain in (undiscounted) PFS of 28.6 days, based on calibrating a Log-Normal 
hazard distribution to each trial arm and applying these to represent patient experience until 
all patients have died or suffered disease progression. 
Examination of the PFS temporal profile (Figure 12) indicates that although the addition of 
nintedanib to docetaxel therapy generates a short-term delay in disease progression for 
some patients (i.e. the PFS curves begin to separate), subsequently this advantage 
progressively dissipates until the PFS experience of patients in the two trial arms is 
indistinguishable. Here, the extent of advantage in mean PFS can be readily estimated 
directly from the K-M analysis results by comparing the AUC estimates up to the point when 
the curves converge. The ERG identified that convergence occurred at day 375, and the 
difference in AUC at this time is 36.4 days. This suggests a small additional PFS benefit 
compared with the gain obtained in the company’s model (28.6 days).  
 
Figure 12 PFS plot with ERG common long-term projection for nintedanib plus docetaxel vs 
docetaxel 
 
In order to apply the results of this re-analysis to the company’s model, the ERG carried out 
a K-M landmark analysis for patients who were still progression-free at day 375. This 
indicated that a common long-term exponential model is appropriate for use in both 
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treatment arms from day 375 onwards, and this is shown in Figure 12. However, it should be 
noted that any projective model could be employed to both arms of the trial without any 
effect on the cost-effectiveness analysis as the incremental gain in PFS is unaffected. 
Replacing the company’s preferred PFS model with the ERG’s approach has a modest 
impact on the cost-effectiveness of nintedanib plus docetaxel compared with docetaxel. The 
incremental discounted cost per patient is increased by ******* while the incremental 
discounted QALY gain is increased by *******, resulting in the estimated ICER increasing 
from £50,776 per QALY gained to £52,445 per QALY gained. 
5.5.4 Time on treatment estimation 
The ERG has used the same approach to obtain an accurate representation of the duration 
of treatments in the arms of LUME-Lung 1.24 This approach uses the K-M results directly 
until a long-term exponential trend is established for projection until all patients have died 
(shown in Figure 13 to Figure 15). 
Replacing the company’s preferred exponential model with the ERG’s approach has a 
modest impact on the cost-effectiveness of nintedanib plus docetaxel compared with 
docetaxel. The discounted cost per patient is increased in both treatment arms, so that the 
incremental cost per patient rises by *******, resulting in the estimated ICER increasing from 
£50,776 per QALY gained to £51,930 per QALY gained. 
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Figure 13 Time on Treatment: docetaxel in control arm with ERG long-term projection 
 
 
Figure 14 Time on Treatment: docetaxel in intervention arm with ERG long-term projection 
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Figure 15 Time on Treatment: nintedanib in intervention arm with ERG long-term projection 
 
5.5.5 Incorrect mid-cycle adjustment for drug costs 
In the company’s model the costs of both docetaxel and nintedanib are calculated for the 
average number of patients on treatment across each cycle. This mid-cycle adjustment for 
docetaxel is not accurate since three-weekly docetaxel is delivered on the first day of each 
cycle. Clinical advice also indicates that nintedanib doses are also dispensed on the first day 
of each cycle. The effect of this error is to under-estimate the quantity and cost of drugs 
used throughout the trial and in both arms of the comparison. 
When this error is remedied the incremental discounted cost per patient increases by*******, 
and the estimated ICER increases from £50,776 per QALY gained to £53,839 per QALY 
gained. 
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5.5.6 Calculations for drug costs per dose 
The average cost per dose of docetaxel delivered has been calculated by the company 
according to the distribution of body surface area (BSA) within the relevant UK population as 
a whole, though neglecting the important distinction between males and females whose 
mean BSA differs sufficiently to affect the overall estimated cost per dose. In addition, only 
the cost of the full 75mg/m2 dose is estimated and adjusted using a relative dose intensity 
(RDI) index from trial data. It is more accurate to estimate the cost of a reduced dose 
(60mg/m2) and then create a weighted average cost based on the balance between full and 
reduced doses recorded in the trial. The ERG has therefore re-estimated the overall average 
cost per dose of docetaxel using separate male and female subgroups, and also re-
estimated the RDI multiplier to match the balance of full and reduced doses. 
In addition, the ERG received clinical advice from a centre currently using nintedanib 
indicating that in practice nintedanib tablets are dispensed to patients at the time of 
docetaxel administration in blister packs sufficient to self-treat until the date of the next 
docetaxel dose (i.e. for days 2 to 21 of each cycle). Any missed doses are unlikely to alter 
the dispensing pattern, and thus missed doses will not alter the amount and cost of product 
dispensed. Therefore a reduction in cost through a RDI index is inappropriate. The 
company’s method of calculating the cost per dose of nintedanib does not take account of 
the effect of three separate doses used (full dose, and two reduced doses) when part packs 
are dispensed as required at each cycle visit. Using data from LUME-Lung 124 of the 
differing balance between dose levels at each cycle, it has been possible to estimate an 
overall mean cost of treatment with nintedanib per cycle.  
Applying these revised ERG parameter values to the company’s base-case model, results in 
a ******* increase in the incremental cost per patient, and raises the estimated ICER from 
£50,776 per QALY gained to £52,587 per QALY gained. 
5.5.7 Cost of treating febrile neutropenia 
The company’s model includes an estimated cost of treatment for grade 3/4 febrile 
neutropenia of £2,012.10 per patient affected, based on clinical advice. This figure is 
substantially lower than the average cost estimated by the NICE Decision Support Unit in 
200774 which was revised for the recent MTA of second-line chemotherapy in NSCLC.75 The 
ERG further updated the DSU estimate using National Reference costs69 for 2012/13, to a 
mean cost per episode of £5,240.40 and mean cost per patient of £7,352.54 (assuming 1.4 
episodes per patient). 
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Using these revised cost estimates in the company’s model increases the incremental cost 
of nintedanib plus docetaxel vs docetaxel by £130 per patient, and raises the base-case 
ICER from £50,776 per QALY gained to £51,372 per QALY gained. 
5.5.8 Monitoring cost 
In the company’s model the ERG has observed that there is a discrepancy between the cost 
of disease monitoring in patients who are on active treatment but who have not yet suffered 
disease progression (i.e. patients with stable disease). The model assigns a cost of £188 per 
cycle to patients in the nintedanib plus docetaxel arm and assigns a value of £205 per cycle 
to patients in the docetaxel arm, when the only difference in treatment relates to self-
administered nintedanib tablets. On examination, it appears that the advice given by the 
company’s clinical expert, concerning additional physician monitoring every 2 to 3 months for 
patients who have completed active treatment but who have not yet suffered disease 
progression, has been wrongly applied to patients still on active treatment with docetaxel. 
Moreover the unit cost employed is erroneously that of a GP consultation not an oncology 
out-patient visit. 
When this misallocation is corrected, the incremental cost per QALY gained for nintedanib 
plus docetaxel vs docetaxel increases by £364, and the base-case ICER increases from 
£50,776 per QALY gained to £51,140 per QALY gained. 
5.5.9 Discounting method 
The submitted model applies discounting at a different rate for every 3-week model cycle 
based on the time elapsed. By convention in the UK, in line with the use of annual public 
sector budgets, discounting is applied annually considering the first 12 month period as 
involving current costs and each subsequent 12 month period requiring discounting for an 
additional year’s delay. In some models with extended survival and multiple future events the 
choice of discounting method may have a large impact on the modelled ICER. However, 
using annual discounting in the company’s model for this appraisal has only a minor effect, 
reducing the estimated base-case ICER from £50,776 per QALY gained to £50,532 per 
QALY gained. 
5.5.10 Disutility of fatigue related adverse events 
The key AEs identified from LUME-Lung124 were CTCAE grade 3 or 4 diarrhoea and fatigue. 
The company’s analysis of EQ-5D utility data indicates that the estimated disutility for 
diarrhoea is low (-0.04). By contrast CTCAE grade 3 or 4 fatigue appears to have the largest 
effect in terms of patient disutility, amounting to an average of -0.21 across both treatment 
arms. However, Table 24 of the company’s submitted Health Economics report71 indicates a 
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large statistically significant difference between effect sizes in the two treatment arms: -0.326 
for nintedanib plus docetaxel vs -0.101 for docetaxel, suggesting that patients experiencing 
serious fatigue on treatment are more seriously affected by the combination therapy. The 
company’s model uses the overall average disutility estimate for both regimens. The ERG 
has applied a model amendment to apply the separate disutility values, resulting in a small 
reduction in the incremental QALY gain for nintedanib plus docetaxel vs docetaxel, and a 
corresponding increase of £54 per QALY gained in the base-case estimated ICER (from 
£50,776 per QALY gained to £50,830 per QALY gained). 
5.5.11 Specification of second-line stable disease costs 
Details of health care costs incurred by patients in various health states were derived from 
evidence provided by a panel of clinical advisors. A summary of this evidence is included in 
the appendices document accompanying the CS1 (pages 70 to 77). A comparison between 
the details shown in the advisors evidence and the calculations used in the model to 
estimate average costs reveal important differences with respect to the cost of care for 
patients who have ceased active treatment and remain in a stable condition without 
evidence of further disease progression. The submitted model includes an assumption that 
these patients will require an hour of palliative nursing care every week and a bone scan 
every 3 weeks. This is in addition to a chest X-ray every 2 to 3 months and a physician visit 
once a year. The evidence of the clinical advisors only refers to the latter two items, and it 
appears that the palliative care and bone scans are included in error. Correcting this error 
substantially reduces the care costs per patient for any patient in a stable condition after 
second-line treatment. This has the effect of increasing the incremental cost per patient by 
******* and increasing the estimated ICER for nintedanib plus docetaxel vs docetaxel from 
£50,776 per QALY gained to £53,470 per QALY gained. 
5.5.12 Duration of docetaxel treatment 
The company’s base-case model follows the protocol of the LUME-Lung124 trial in permitting 
unlimited continuation of docetaxel treatment in either trial arm. One patient in the nintedanib 
plus docetaxel arm received 45 cycles of docetaxel, and one patient in the docetaxel 
monotherapy arm received 42 cycles. In the UK, standard clinical practice is to limit 
docetaxel to a maximum of four cycles per patient to avoid unacceptable AEs and 
associated poor QoL. The company’s model includes an option to restrict docetaxel therapy 
to a maximum of four cycles. However, a formula error has been detected in the company’s 
model which implements a limit of five rather than four cycles. The ERG has applied its own 
model adjustment which limits treatment to four cycles. It should be noted that this feature 
only affects the cost of drug acquisition and administration; it does not address the issue of 
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whether limiting exposure to docetaxel will impact on the prognosis of patients, nor does it 
attempt to adjust for consequent changes in AEs and the resulting cost and QoL effects. 
This modification to the company’s model reduces the base-case incremental cost per 
patient by *******, and reduces the estimated ICER for nintedanib plus docetaxel vs 
docetaxel from £50,776 per QALY gained to £48,060 per QALY gained. 
5.5.13 Comparison with erlotinib 
As noted in sections 2.2, 3.3 and 4.4.1 above, the ERG does not consider a comparison of 
nintedanib plus docetaxel to erlotinib is appropriate to the decision problem, a view also 
shared by the company. Nevertheless the company has attempted to incorporate into their 
model a facility to compare the relative cost-effectiveness of erlotinib and nintedanib plus 
docetaxel, as indicated in the NICE scope. In the absence of a trial directly comparing these 
regimes, it was necessary to attempt an MTC to generate estimated outcomes for patients 
treated with erlotinib, consistent with all relevant information in related studies. The base-
case MTC includes three RCTs56,59,62 in addition to the LUME-Lung124 trial: JMEI56 which 
compared docetaxel with pemetrexed, WSY00162 which compared pemetrexed with erlotinib 
and TAILOR59 which compared docetaxel with erlotinib (see also Figure 1, page 39). This 
provides two connection pathways linking nintedanib plus docetaxel to erlotinib: 
1) LUME-Lung124 ⇒ JMEI56 ⇒ WSY00162  
2) LUME-Lung124 ⇒ TAILOR59 
 
In principle, it is desirable to employ this network to generate HRs for each time-to-event 
outcome as a basis for estimating the corresponding survival profiles for erlotinib, consistent 
with that obtained for nintedanib plus docetaxel in the LUME-Lung124 trial.  
Time on Treatment 
Employing a network may be possible for OS and PFS, but is not feasible for ToT of 
erlotinib, since none of the connecting trial reports (for JMEI,56 WSY00162 and TAILOR59) 
report results for this outcome. Instead the company has assumed that a simple exponential 
function is appropriate for ToT in all treatments and have calibrated this function for each 
trial based on an estimated mean number of treatments per patient. It has already been 
demonstrated in section 5.5.4 that such an assumption is not correct in the case of the 
LUME-Lung124 trial and there is no reason to believe that it would be any more successful in 
the other trials in the network. In particular, the company modellers have assigned a 
parameter value for erlotinib consistent with a mean number of erlotinib cycles (i.e. 28 days) 
taken from the ERG report for NICE assessment TA162,19 without recognising that this 
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figure was obtained indirectly from PFS trial data (which may overstate ToT) and that the 
ERG on that occasion employed a 2-phase exponential model with a high risk of 
discontinuation in the first 11 weeks, and a lower risk thereafter. Without access to detailed 
patient-level ToT data for each of the studies in the MTC, it is not possible to rectify the 
substantial uncertainty associated with the estimation of drug acquisition costs in the 
company model. 
Overall survival and progression-free survival 
Meta-analysis of time-to-event data in a network relies on a number of conditions being met: 
- Within each trial the assumption of proportional hazards should apply 
- Between trials featuring the same treatment at nodes in the MTC, treatment 
outcomes should be equivalent (i.e. both proportional hazards and very similar 
outcomes at all time points) 
- If a parametric survival function is to be propagated through the network then it 
should be inherently proportional hazard compliant (i.e. Weibull or Exponential) 
For the company’s MTC of OS, a Weibull formulation was therefore used, despite this not 
appearing to give the best match to the nintedanib plus docetaxel LUME-Lung124 trial OS 
data. If all the above criteria are met, the resulting time-to-death profile should be a Weibull 
curve adjusted by an overall HR (0.64 for nintedanib plus docetaxel vs erlotinib in OS) so 
that it is consistent with the corresponding profiles for erlotinib in both the TAILOR59 and 
WSY00162 trials.  
Figure 16 compares the fitted Weibull model for erlotinib with the erlotinib Kaplan-Meier data 
from the TAILOR59 and WSY00162 trials. It is apparent that during the first 18 months there 
are large differences between the three profiles. It is also possible to test whether the 
proportional hazards assumption is violated in both arms of the network. Figures 17 and 18 
show plots of cumulative hazard data from each erlotinib trial arm against the cumulative 
hazard at the same time points from the Weibull OS model. The proportional hazards 
assumption is confirmed if the data points (corresponding to trial events) all lie close to and 
evenly spaced around the diagonal ‘proportionality’ line. It is clear that for both the erlotinib 
trials (TAILOR59 and WSY00162) the proportional hazards assumption is seriously violated. 
This is likely to have been caused by multiple problems, including non-proportional hazards 
results in LUME-Lung124 trial OS data (as discussed in Appendix 7), proportional hazards 
violations in one or more of the other three trials in the MTC and non-equivalence of trial 
arms at network nodes. 
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LI=WSY001; OS=overall survival 
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OS=overall survival; PH=proportional hazards 




LI=WSY001; OS=overall survival; PH=proportional hazards 
Figure 18 Proportionality check of Weibull erlotinib OS model vs erlotinib data from WSY001 
trial 
Confidential until published 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 101 of 139 
These diagnostic checks indicate not only that the estimated OS model estimates are 
inconsistent within the evidence network, but that the Weibull functional form calibrate from 
LUME-Lung124 trial data when transmitted through the network does not accord with the 
outcome patterns seen in other network trials. This calls into question the use of both 
Weibull parametric form and the HR for erlotinib vs nintedanib plus docetaxel estimated from 
the network. 
The potential impact of alterations in OS far outweigh all other aspects of the model (see 
5.5.2 above and Table 40 below) and therefore the importance of this finding cannot be 
over-estimated. The ERG has not been able to complete a full assessment of the PFS 
network in a similar manner due to time limitations, but early indications are that similar 
inconsistencies are present. However, PFS data are more complete and have less influence 
on cost-effectiveness results than OS. 
Unfortunately, these problems with the evidence networks are so fundamental that it is not 
possible to rectify them and modify the company’s model to provide improved estimates of 
OS, PFS and the relative cost-effectiveness of nintedanib plus docetaxel and erlotinib. 
5.6 Conclusions of the cost-effectiveness section 
Although the structure of the economic model submitted by the company is generally 
appropriate, the ERG is concerned by the number of implementation errors that have come 
to light with important consequences for the economic results generated. The ERG has 
identified eleven specific aspects of the submitted base-case model that are subject to 
challenge, or involve implementation errors. In each case an appropriate amendment has 
been introduced into the company’s model with results ranging from minor changes to 
important and substantial changes to the estimated ICER per QALY gained. 
Neither the company nor the ERG considers a comparison of nintedanib plus docetaxel to 
erlotinib to be appropriate to the decision problem. Nevertheless, this was specified in the 
NICE scope and the company has therefore undertaken such a comparison. However, the 
ERG considers that this is seriously flawed due to inconsistencies apparent in the available 
time-to-event data leading to conflicting results from the MTC. The ERG has applied other 
relevant amendments to the submitted model for this comparison, but the uncertainty in OS, 
PFS and ToT probably far outweighs all other effects but cannot be quantified. 
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6 ADDITIONAL WORK UNDERTAKEN BY THE ERG 
Table 40 summarises the effects of the various ERG amendments made to the company’s 
decision model (see also Appendix 8). The consequence of applying each proposed 
amendment is shown separately for comparison with the company’s base-case analysis. 
The joint effect of applying all ERG changes to the model simultaneously is included. In 
addition, a second summary result is provided excluding the limitation of docetaxel treatment 
to four cycles because this change reflects an issue of principle (clinical evidence vs UK 
practice), and because the impact of applying a model revision is necessarily incomplete 
(the ERG cannot estimate what the effect might be on outcomes of restricting treatment).  
Generally these amendments result in increased costs (both absolute and incremental) 
and/or reduced outcomes (survival and QALYs) and hence lead to increases in the 
estimated ICER per QALY gained. The company’s base-case ICER (£50,776 per QALY 
gained) is increased to either £85,292 per QALY gained with all revisions applied, or to 
£82,995 per QALY gained if no limit is placed on the number of cycles of docetaxel 
treatment allowed.  
The most influential change is the application of the ERG OS estimates. If this revision is not 
accepted, the revised ICER using the other ten revisions becomes £62,719 per QALY 
gained. The ERG’s estimate of the gain in undiscounted mean OS is 3.05 months. 
Cost-effectiveness results of applying the non-Time To Event ERG amendments are detailed 
in Table 41, with a full sensitivity analysis for a range of possible patient access scheme 
discounts on the list price of erlotinib in Table 42. It should be borne in mind that were it 
possible to estimate the mean OS for patients treated with erlotinib rather than docetaxel 
monotherapy in second-line chemotherapy, it is quite likely that the estimated incremental 
gain in life-years would diminish and the estimated ICER rise substantially. 
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Table 40 Cost-effectiveness results for nintedanib plus docetaxel vs docetaxel with ERG revisions to company’s base-case comparison in the 
adenocarcinoma population 
Model scenario & ERG 
revisions 
Nintedanib + docetaxel Docetaxel Incremental ICER ICER 
Cost QALYs Life years Cost QALYs Life years Cost QALYs Life years £/QALY Change 
Company’s base-case ******* ***** 1.810 ****** ***** 1.419  + £11,051  + 0.218  + 0.391 £50,776 - 
1) ERG OS estimates ******* ***** 1.493 ****** ***** 1.238  + £10,497  + 0.153  + 0.255 £68,587  + £17,811 
2) ERG PFS estimates ******* ***** 1.810 ****** ***** 1.419  + £11,527  + 0.220  + 0.391 £52,445  + £1,669 
3) ERG ToT estimates ******* ***** 1.810 ****** ***** 1.419  + £11,298  + 0.218  + 0.391 £51,930  + £1,154 
4) Mid-cycle adjustment ******* ***** 1.810 ****** ***** 1.419  + £11,717  + 0.218  + 0.391 £53,839  + £3,062 
5) Cost of treatment doses ******* ***** 1.810 ****** ***** 1.419  + £11,445  + 0.218  + 0.391 £52,587  + 1,811 
6) Febrile neutropenia cost ******* ***** 1.810 ****** ***** 1.419  + £11,180  + 0.218  + 0.391 £51,372  + £595 
7) Monitoring cost ******* ***** 1.810 ****** ***** 1.419  + £11,130  + 0.218  + 0.391 £51,140  + £364 
8) Discounting method ******* ***** 1.810 ****** ***** 1.419  + £11,189  + 0.221  + 0.391 £50,532 -£244 
9) Disutility of fatigue ******* ***** 1.810 ****** ***** 1.419  + £11,051  + 0.217  + 0.391 £50,830  + £54 
10) Stable disease costs ******* ***** 1.810 ****** ***** 1.419  + £11,637  + 0.218  + 0.391 £53,470  + £2,693 
11) Docetaxel ≤4 cycles ******* ***** 1.810 ****** ***** 1.419  + £10,452  + 0.217  + 0.391 £48,060 -£2,716 
Base-case + revisions 1-10 ******* ***** 1.493 ****** ***** 1.238  + £13,087  + 0.158  + 0.255 £82,995  + £32,219 
Base-case + all revisions ******* ***** 1.493 ****** ***** 1.238  + £13,437  + 0.158  + 0.255 £85,292  + £34,516 
Costs and QALYs discounted; Life years undiscounted 
OS=overall survival; PFS=progression-free survival; QALYs=quality adjusted life years; ToT=time on treatment 
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Table 41 Cost-effectiveness results for nintedanib plus docetaxel vs erlotinib with ERG revisions to company’s base-case comparison in the 
adenocarcinoma population 
Model scenario & ERG 
revisions 
Nintedanib + docetaxel Erlotinib Incremental ICER ICER 
Cost QALYs Life years Cost QALYs Life years Cost QALYs Life years £/QALY Change 
Company’s base-case ******* ***** 1.445 ******* ***** 0.979 £7,571 0.280 0.465 £27,008 - 
1) ERG OS estimates X X X X X X X X X X X 
2) ERG PFS estimates X X X X X X X X X X X 
3) ERG ToT estimates X X X X X X X X X X X 
4) Mid-cycle adjustment ******* ***** 1.445 ******* ***** 0.979 £7,815 0.280 0.465 £27,878  + £870 
5) Cost of treatment doses ******* ***** 1.445 ******* ***** 0.979 £7,926 0.280 0.465 £28,275  + £1,267 
6) Febrile neutropenia cost ******* ***** 1.445 ******* ***** 0.979 £7,897 0.280 0.465 £28,173  + £165 
7) Monitoring cost NA NA NA NA NA NA NA NA NA NA NA 
8) Discounting method ******* ***** 1.445 ******* ***** 0.979 £7,679 0.285 0.465 £26,927 -£81 
9) Disutility of fatigue ******* ***** 1.445 ******* ***** 0.979 £7,571 0.280 0.465 £27,020  + £12 
10) Stable disease costs ******* ***** 1.445 ******* ***** 0.979 £7,576 0.280 0.465 £27,027  + £19 
11) Docetaxel ≤4 cycles ******* ***** 1.445 ******* ***** 0.979 £7,069 0.283 0.465 £24,975 -£2,033 
Base-case + revisions 4-11 ******* ***** 1.445 ******* ***** 0.979 £8,147 0.288 0.465 £28,307  + £1,299 
Costs and QALYs discounted; Life years undiscounted 
NA = not applicable; OS=overall survival; PFS=progression-free survival; QALYs=quality adjusted life years; ToT=time on treatment; X = meaningful amendments for time-to-event estimates are not 
possible due to unreliable data network or absence of data 
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Table 42 Cost-effectiveness results for nintedanib plus docetaxel vs erlotinib with ERG revisions to company’s base-case comparison in the 
adenocarcinoma population: sensitivity of ICER to different patient access scheme discount levels for erlotinib. 
Model scenario & ERG 
revisions 
Patient access scheme discount for erlotinib  
0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50% 
Company’s base-case £27,008 £27,939 £28,870 £29,802 £30,733 £31,664 £32,596 £33,527 £34,458 £35,390 £36,321 
1) ERG OS estimates X X X X X X X X X X X 
2) ERG PFS estimates X X X X X X X X X X X 
3) ERG ToT estimates X X X X X X X X X X X 
4) Mid-cycle adjustment £27,878 £28,902 £29,926 £30,950 £31,975 £32,999 £34,023 £35,047 £36,071 £37,095 £38,119 
5) Cost of treatment doses £28,275 £29,206 £30,138 £31,069 £32,000 £32,932 £33,863 £34,794 £35,726 £36,657 £37,588 
6) Febrile neutropenia cost £28,173 £29,104 £30,035 £30,967 £31,898 £32,830 £33,761 £34,692 £35,624 £36,555 £37,486 
7) Monitoring cost NA NA NA NA NA NA NA NA NA NA NA 
8) Discounting method £26,927 £27,851 £28,775 £29,699 £30,623 £31,547 £32,471 £33,395 £34,319 £35,243 £36,167 
9) Disutility of fatigue £27,020 £27,951 £28,883 £29,815 £30,747 £31,678 £32,610 £33,542 £34,474 £35,405 £36,337 
10) Stable disease costs £27,027 £27,958 £28,890 £29,821 £30,752 £31,684 £32,615 £33,546 £34,478 £35,409 £36,340 
11) Docetaxel ≤4 cycles £24,975 £25,897 £26,820 £27,742 £28,664 £29,587 £30,509 £31,431 £32,354 £33,276 £34,198 
Base-case + revisions 4-11 £28,307 £29,314 £30,320 £31,327 £32,334 £33,341 £34,348 £35,354 £36,361 £37,368 £38,375 
Costs and QALYs discounted; Life years undiscounted 
NA = not applicable; OS=overall survival; PFS=progression-free survival; QALYs=quality adjusted life years; ToT=time on treatment; X = meaningful amendments for time-to-event estimates are not 
possible due to unreliable data network or absence of data 
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7 END OF LIFE 
The company makes a case that nintedanib plus docetaxel meets the criteria set by NICE for 
end of life treatment. Namely: 
• The life expectancy of the patient population was short (< 24 months) 
• The number of patients who would be eligible for the treatment is small 
• The increase in OS is >3 months 
 
The company states on page 288 of the CS:1 
• Patients with advanced NSCLC have a short life expectancy of less than 24 months 
on average. Using the extrapolated results from the LUME-Lung 124 trial data 
implemented in the cost-effectiveness model, the median OS of patients on 
docetaxel monotherapy (current standard of care) is 10.23 months and the mean OS 
is 15.96 months.  
• The total eligible population for nintedanib plus docetaxel in England is 703.  
• Extension to life due to nintedanib plus docetaxel vs docetaxel monotherapy in the 
target population with the base-case assumptions within the model is a mean of 3.96 
months. The extension in OS over erlotinib is a mean of 5.16 months. 
 
The ERG agrees that patients with advanced NSCLC have a short life expectancy of less 
than 24 months. It also agrees that the patients who would be eligible for the treatment is 
small. As noted in section 5.5.2, by applying the K-M trial results using the AUC method until 
the long-term OS trends were established and then projecting remaining estimated survival 
using the exponential trends, the ERG calculated the mean extension in OS to be 3.05 
months for the base-case analysis of nintedanib plus docetaxel vs docetaxel. The ERG were 
only able to carry out a partial comparison of nintedanib plus docetaxel to erlotinib for 
reasons outlined in section 5.5.13 (excluding the time-to-event outcomes known to be 
subject to the most uncertainty) and were therefore unable to derive a mean estimate for OS 
for nintedanib plus docetaxel vs erlotinib. 
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8 DISCUSSION 
The NICE scope for this STA stipulates the population should be adults with locally 
advanced or metastatic NSCLC that has progressed following prior chemotherapy. The 
decision problem differs in that it is restricted to NSCLC with adenocarcinoma histology. It 
also includes patients with locally recurrent disease. The ERG considers both differences to 
be appropriate since they reflect the relevant population stipulated by the anticipated 
licensed indication for nintedanib plus docetaxel.28 Based on the LUME-Lung 124 trial, the 
majority (94.2%) of these patients will have metastatic disease at the time of second-line 
treatment. The majority (85% to 90%) of such patients in England would be expected to 
have EGFR-negative disease,30-32 ****************************************************** 
************************* **************************************. 
The NICE scope also states that docetaxel and erlotinib are relevant comparators. The 
company notes the preliminary recommendation issued by NICE in February 2014 is that 
erlotinib should not be recommended for treating locally advanced or metastatic NSCLC that 
has progressed after non-targeted chemotherapy in people with tumours that are EGFR-
negative. The ERG also notes the same recommendation from August 2014.21 Furthermore, 
in current clinical practice in England, the majority of patients with EGFR-positive NSCLC 
receive erlotinib (or another TKI) as first-line treatment.13-15 These patients would, therefore, 
be unlikely to receive erlotinib as a second-line therapy. Because nintedanib is administered 
in combination with docetaxel, patients in receipt of nintedanib must be fit enough to receive 
docetaxel. Such patients are, therefore, likely to be assessed as ECOG PS 0 to 1. The 
general opinion of clinical advisors to both the company and ERG is that patients who are 
sufficiently fit to tolerate treatment with docetaxel will receive docetaxel rather than erlotinib. 
In view of these factors, while the decision problem does include erlotinib as a comparator 
for secondary analyses, this is nevertheless considered by the company to be an irrelevant 
comparator to nintedanib plus docetaxel. The ERG agrees with the company that erlotinib is 
not a relevant comparator for the same reasons.  
Evidence for the relative effectiveness of nintedanib plus docetaxel is derived from the 
LUME-Lung 124 trial which compares nintedanib plus docetaxel to placebo plus docetaxel. 
This, therefore, provides direct evidence for the clinical effectiveness of nintedanib plus 
docetaxel vs docetaxel alone. The trial appears to be of good quality and low risk of bias and 
reports that nintedanib plus docetaxel is superior to placebo plus docetaxel in terms of OS 
(median improvement of 2.3 months) and PFS (median improvement of 1.4 months). 
However, the ERG does not consider that the assumption of proportional hazards is 
consistent with the trial data, and therefore use of these results in cost-effectiveness 
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modelling should not be based implicitly or explicitly on this assumption. The reported gain in 
efficacy is accompanied by an increase in CTCAE grade ≥3 AEs and SAEs but these AEs 
are reported to be generally manageable. Some differences in HRQoL between treatment 
arms have been reported but none result in differences between arms in terms of overall 
global health status/QoL. The AEs of greatest concern are fatal AEs. More fatal AEs have 
been reported in the nintedanib plus docetaxel arm than in the placebo plus docetaxel arm. 
However, the numbers are small and the company is using ongoing surveillance to monitor 
this issue. Neutropenia and sepsis have also been identified as important risks.  
One potential limitation with regard to the generalisability of the findings from LUME-Lung 124 
to clinical practice in England relates to three of the exclusion criteria that the trial employed. 
First, patients with major pleural effusion were excluded. Second, patients with evidence of 
cavitary or necrotic tumours were excluded. Third, patients receiving therapeutic 
anticoagulation (except low dose heparin) or antiplatelet therapy (except for chronic low-
dose therapy with acetylsalicylic acid ≤325mg/day) were excluded. Pleural effusions50,51 and 
venous thromboembilsm 52 appear to predict poor prognosis; evidence of cavitary or necrotic 
tumours may also result in a worse prognosis, although cavitation may be a less strong 
prognostic factor.49 These exclusion criteria may partially explain why, in LUME-Lung 1,24 a 
higher proportion of patients than would be expected in clinical practice also received third-
line treatment on disease progression. This may in turn also be an indicator that patients 
included in this trial were fitter than those generally seen in NHS clinical practice. 
In order to derive an estimate for cost-effectiveness of nintedanib plus docetaxel to 
docetaxel alone, the company have developed a de novo partitioned survival Markov model, 
which incorporates data from LUME-Lung 124 alongside other published sources. The 
company’s estimate of cost-effectiveness for nintedanib plus docetaxel vs docetaxel is 
£50,766 per QALY gained. However, the ERG identified a number of weaknesses in the 
company’s model and is concerned about the number of implementation issues that it 
identified. The most important area in terms of its impact on the ICER related to OS 
estimation. Here inadequate information was provided about specific data sources used for 
SEER and LUCADA used to validate the long-term extrapolation of OS. Furthermore OS 
projection was based on the flawed assumption that there is constant hazard over time.  
In total the ERG made 11 changes to the company’s model. These related to: inappropriate 
methods used to project time-to-event outcomes (OS, PFS and time-on-treatment); mid-
cycle adjustment error; inappropriate methods used to estimate cost of treatment doses; 
underestimate of true cost of febrile neutropenia; monitoring costs; non-UK standard 
approach to discounting; overall average disutility estimate for fatigue used for both 
Confidential until published 
Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer  
Single Technology Appraisal: Evidence Review Group Report 
Page 109 of 139 
 
regimens; error in stable disease costs and erroneous restriction of docetaxel to four cycles. 
When all of the ERG’s alterations are implemented, the ERG’s revised estimate of cost-
effectiveness for the comparison of nintedanib plus docetaxel with docetaxel is £85,292 per 
QALY gained. Independently, implementing each of the ERG’s changes in the model results 
in ICERs ranging from £50,532 to £68,587 per QALY gained. The change which has the 
largest impact on the size of the ICER is the method used to estimate OS. If all of the other 
changes in the model are implemented, except replacement of the company’s OS model, the 
ICER increases to £62,719 per QALY gained.  
There is no direct evidence for the relative effectiveness of nintedanib plus docetaxel 
compared with erlotinib. In order to compare the relative clinical effectiveness for these two 
regimens, the company conducted a number of MTCs. However, the ERG has identified a 
number of uncertainties and weaknesses in relation to these MTCs. Relating to the 
generalisability of the trials to clinical practice, the ERG notes that only patients in one trial, 
LUME-Lung 1,24 had received pemetrexed as a first-line treatment and even then, this was 
only a minority (18.8%). Pemetrexed is now the treatment of choice for adenocarcinoma 
patients with EGFR-negative disease who, as noted above, constitute the majority of 
adenocarcinoma patients in England.  
There are also a number of methodological weaknesses with the conduct of the MTCs, the 
most important being that proportional hazards are presumed to hold throughout the MTC 
networks for both PFS and OS. As discussed above, the ERG has found that this is not the 
case within the LUME-Lung 124 and, as a consequence, any results generated comparing 
nintedanib plus docetaxel with erlotinib cannot be considered reliable. Important differences 
in trial and patient characteristics of trials included in the MTCs have also been observed 
which question the validity of the base-case, scenario and sensitivity analyses.  
To compare nintedanib plus docetaxel to erlotinib, the results from the MTCs have been 
incorporated into the company’s model. The company’s estimate of cost-effectiveness for 
nintedanib plus docetaxel vs erlotinib is £27,008 per QALY gained. However, as discussed 
above, there are a number of methodological issues with the conduct of the MTCs which 
undermine any confidence in this estimate. Furthermore, in addition to those discussed 
above, additional problems have been identified in relation to ToT where again the 
assumption for proportional hazards is assumed. It is impossible to ascertain whether this is 
true for any trial other than LUME-Lung 124 as these data were not available for any other 
trial. However this assumption did not hold for LUME-Lung 1.24 Furthermore, the ERG also 
established that not only is the assumption of proportional hazards for OS violated for 
LUME-Lung 124 but this is also violated for OS reported in two other trials (WSY00162 and 
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TAILOR59) included in the MTC. Thus because of concerns about the relevance of erlotinib 
as a comparator and the appropriateness of the analyses conducted, the ERG only 
considers it feasible to estimate a reliable ICER per QALY gained using the direct trial data 
from LUME-Lung 124 for patients with locally advanced, metastatic or locally recurrent 
NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. 
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9 OVERALL CONCLUSIONS 
The ERG agrees that LUME-Lung 124 is a high quality trial that demonstrates the efficacy of 
nintedanib plus docetaxel over docetaxel for patients with adenocarcinoma after first-line 
chemotherapy. Based on the clinical and cost-effectiveness evidence available, the ERG 
only considers it feasible to estimate an ICER per QALY gained using the direct trial data 
from LUME-Lung 124 for this population. The ERG concludes that the comparison of 
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11 APPENDICES 
Appendix 1: Detailed critique of the company’s search strategy 
The ERG’s critique of the company’s search strategy was undertaken in two parts: (i) An 
examination of the sources searched and the terms used to make a judgement whether the 
strategy appeared to be sufficient; (ii) The conduct of its own search strategy to determine if 
any additional relevant studies were identified. The sources searched by the company and 
the ERG are summarised in Table 43. 
Table 43 Databases searched 
Databases searched by company Databases searched by ERG 
Bibliographic databases: 
• MEDLINE and MEDLINE In-Process 
(PubMed) 
• EMBASE (Interface not stated) 
• Cochrane Library (Wiley Interscience): 
o Cochrane Database of Systematic 
Reviews  





• MEDLINE and MEDLINE In-Process (OvidSP) 
• EMBASE (OvidSP) 
• Cochrane Library (Wiley Interscience): 
o Cochrane Database of Systematic Reviews  
o Cochrane Central Register of Controlled Trials  
o Database of Abstracts of Reviews of Effects 
(DARE) 
o Health Technology Assessment Database 
(HTA) 
o NHS Economic Evaluation Database (NHS 
EED) 
The following sources were searched for grey 
literature: 
• ClinicalTrials.gov (www.clinicaltrials.gov) 
• American Society for Clinical Oncology 
(ASCO) annual meeting (www.asco.org) 
• European Society for Medical Oncology 
(ESMO) annual meeting (www.esmo.org/) 
• National Guidelines Clearinghouse  
 
In addition, reference lists of identified systematic 




The following online sources were searched for grey 
literature: 
• ClinicalTrials.gov (www.clinicaltrials.gov) 
• American Society for Clinical Oncology (ASCO) 
annual meeting (www.asco.org) 
• European Society for Medical Oncology (ESMO) 
annual meeting (www.esmo.org/) 
• National Institute for Health and Care Excellence 
(www.nice.org.uk) 
• metaRegister of Controlled Trials 
(http://www.controlled-trials.com/mrct/) 
• US Food and Drug Administration (www.fda.gov/) 
• European Medicines Agency 
(www.ema.europa.eu/) 
• National Institute for Health and Clinical Excellence 
(http://www.nice.org.uk/) 
• International Society for Pharmacoeconomics and 
Outcomes Research (www.ispor.org) 
• Scottish Medicines Consortium 
(https://www.scottishmedicines.org.uk/) 
• Summary of Product Characteristics 
(www.medicines.org.uk/emc/medicine/20929/
SPC/tyverb) 
• Medicines and Healthcare products Regulatory 
Agency (http://www.mhra.gov.uk/) 
• The European Union Clinical Trials Register 
(https://www.clinicaltrialsregister.eu/) 
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Direct evidence 
Five databases were searched by the company on 28 February 2014. These are the 
minimum specified by NICE and the ERG considers would be sufficient to identify relevant 
studies. The same search strategy was run across all databases and included free text and 
MeSH terms of lung cancer, relapsed and second line search terms and randomised 
controlled trial. The search was limited to humans. The company limited online grey 
literature searching to the past four years (from January 2011 to February 2014) as they 
stated conference proceedings older than four years of high quality can be expected to be 
published in peer viewed journals and therefore picked up in the search results. In addition 
to the databases searched, the citation lists of relevant systematic reviews published since 
2009 were also examined to identify other relevant studies. The ERG considers this search 
to be adequate although some cancer synonyms have been missed and combining search 
terms with ‘AND’ as opposed to ‘adjacency’ reduces the precision of the search.  
The ERG conducted its own searches on 8th August 2014. The ERG search strategy also 
included free text and MeSH terms, drug search terms and a search term filter to identify 
RCTs. It did not identify any additional studies. 
Indirect evidence 
The company completed MTC searches on the same date as the systematic review 
searches using the same search terms and the same databases. The ERG conducted 
searches on 21st August 2014 and searched the same databases as its previous search. 
The search terms included free text and MeSH search terms. An RCT filter was used. The 
strategy also included a drug comparison concept combined as follows: 
• Nintedinab + docetaxel vs docetaxel 
• Docetaxel vs gefitinib 
• Docetaxel vs erlotinib 
• Docetaxel vs pemetrexed 
• Pemetrexed vs gefitinib 
• Pemetrexed vs erlotinib 
• Pemetrexed vs pemetrexed + erlotinib 
• Pemetrexed + erlotinib vs erlotinib 
• Erlotinib vs gefitinib  
 
No additional studies were identified by the ERG that met the company’s eligibility criteria for 
inclusion into the MTC. 
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Appendix 2: Eligibility criteria for study inclusion into the company’s 
systematic review and MTC 
Table 44 describes the eligibility criteria employed by the company for inclusion into its 
systematic review. In addition, all non-nintedanib studies were subsequently excluded from 
the results of the search.  
Table 44 Eligibility criteria for inclusion into the company’s systematic review 
Parameter Inclusion criteria Exclusion criteria 
Population Relapsed or refractory NSCLC  
Adults with histologically or cytologically 
confirmed, locally advanced and/or 
metastatic NSCLC of stage IIIB or IV 
(according to American Joint Committee on 
Cancers) or recurrent NSCLC (all 
histologies): 
• Squamous-cell carcinoma  
• Adenocarcinoma  
• Large cell carcinoma 
Any patient population other than 
relapsed or refractory NSCLC 
 
Interventions Any second-line pharmacological treatment 
for relapsed or refractory NSCLC 
• Monotherapy 
• Combination chemotherapy  
Patients who were treatment-naїve, 
had received more than first-line 
therapy, or had received only non-
pharmacological interventions 
Outcomes Relevant outcomes for full-text inclusion: 
• Overall survival and progression-
free survival  
• Time to relapse  
• Time to death  
• Adverse events (all CTCAE grades 
and CTCAE grade 3 to 4) 
• Withdrawals  
• Mean dose and number of cycles  
of therapy received 
No outcomes of interest 
Study design Randomised controlled trials (RCTs) only Not an RCT (e.g. observational) 
Language restrictions Any language‡  
Date 2000 onwards* Prior to 2000* 
Country Any None 
NSCLC=non-small cell lung cancer 
‡ Non-English-language publications were identified for the efficacy review but none met the inclusion criteria. 
*Abstracts published prior to the year 2011 and systematic reviews published prior to the year 2009 were excluded. 
Source: Table 6 of the CS1 
 
Table 45 describes the eligibility criteria employed by the company for inclusion, with 
rationale, into its MTC. The search was also limited to include only results with abstracts.  
For both the systematic review and MTC, all abstracts obtained from the database search 
were each examined manually by two researchers applying the predefined eligibility criteria. 
Following this, a random sample of excluded abstracts was checked for accuracy by a third 
researcher to confirm the exclusion decisions. Any discrepancy in the decision to include or 
exclude a study was reviewed by and resolved between researchers. The full-text articles for 
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abstracts deemed potentially relevant during this first level of screening were retrieved in 
order to confirm their inclusion in the review. All full-text publications were independently 
reviewed by two researchers, with all disagreements being resolved by consensus. 
Table 45 Eligibility criteria for inclusion in the company’s MTC 
Parameter Inclusion criteria Exclusion criteria Rationale 
Population Relapsed or refractory 
NSCLC (RR NSCLC) 
Adults with histologically or 
cytologically confirmed, locally 
advanced and/or metastatic 
NSCLC of stage IIIB or IV 
(according to American Joint 
Committee on Cancers) or 
recurrent NSCLC (all 
histologies, including patients 




• Large cell carcinoma 
Studies not assessing 
patients with locally 
advanced or metastatic, 
stage IIIB, or IV/recurrent 
NSCLC 
The patient population 
evaluated in our MTC 
matches the population for 
which nintedanib is being 
considered for approval. 
 Additional inclusion criteria 
applied during feasibility 
assessment:  
• Study must report 
data for 
adenocarcinoma 
subgroup, or 75% or 
more of participants 
should have 
adenocarcinoma 
Additional exclusion criteria 
applied during feasibility 
assessment: 
• Study does not 
report data for an 
adenocarcinoma 
subgroup 





Interventions Any second-line 
pharmacological treatment for 
RR NSCLC: 
• Monotherapy 




Additional inclusion criteria 
applied during feasibility 
assessment: 
• Intervention should be 
licensed for use as 
second-line treatment 
for NSCLC  
• Trials evaluating 
non-second-line 
treatment (e.g., 







• Dose comparison 
studies without a 
placebo or control 
arm 
• Studies evaluating 
maintenance 
treatment 
To evaluate nintedanib vs 
currently available licensed 
interventions for the second-
line treatment of RR 
NSCLC. 
Comparators Any pharmacotherapy or no 
treatment: 
• Other second-line 
pharmacological 
treatment 
• Usual care/no 
additional intervention 
• Placebo 
None in addition to the 
above criteria 
To compare included 
interventions with common 
comparators currently 
available for the second-line 
treatment of RR NSCLC, as 
well as usual care/no 
intervention and placebo. 
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Parameter Inclusion criteria Exclusion criteria Rationale 
Outcomes Outcomes relevant to clinical 
efficacy and safety which were 






Additional inclusion criteria 
applied during feasibility 
assessment: 
• Study must report 
relevant data from at 
least one outcome 
that has been 
reported for other 
studies, thus enabling 
a comparison across 
treatments 
• Study protocols 
without outcome 
data presented 




We considered outcomes 
for which an MTC 
comparing nintedanib + 
docetaxel with other 
second-line treatments was 
feasible, and only included 
studies with published 
results for these outcomes. 
Study design Randomised controlled trials 
(RCTs) only 
Non-RCTs 
Pooled analyses of RCTs 
RCTs provide the highest 
quality clinical trial data. 
Language 
restrictions 
Any language  To minimise bias, RCTs 
published in languages 
other than English were 
included in the search, but 
no relevant non-English 
language papers were 
identified 
Date 2000 onwards 
If a study is an abstract only 
(for example, from a 
conference), it was only 
included if it was published in 
2011 or onwards 
Primary studies published 
prior to 2000, systematic 
literature reviews published 
before 2010 and conference 
abstracts published prior to 
2011 were also excluded 
Limiting the review to 
studies published from 2000 
enabled us to focus on the 
latest trials evaluating the 
second-line treatment of 
NSCLC that reflect current 
clinical practice and patient 
populations. 
Conference abstracts were 
limited to those presented in 
2011 onwards, as full text 
publications of earlier 
abstracts reporting on 
studies of a high quality 
would be expected to have 
been published.  
Systematic reviews were 
limited to those published in 
the previous 4 years, as 
these were used only to 
identify additional relevant 
primary research papers 
and therefore needed to be 
as up-to-date as possible.  
AE=adverse event; NSCLC= non-small-cell lung cancer; ORR=overall response rate; OS=overall survival; PFS=progression-
free survival; RCT=randomised controlled trial 
Source: Table 25 of the CS1 
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Appendix 3: Eligibility criteria for patient inclusion into LUME-Lung 1 
Table 46 Inclusion and exclusion criteria for selection of the trial population in LUME-Lung 1 
Eligibility criteria for LUME-Lung 1 
Inclusion 
criteria 
• Male or female patient aged 18 years or older 
• Histologically or cytologically confirmed, locally advanced and/or metastatic NSCLC of 
stage IIIB or IV or recurrent NSCLC 
• Relapse or failure of one first-line prior chemotherapy 
• At least one target tumour lesion that has not been irradiated within the past 3 months and 
that can accurately be measured 
• Life expectancy of at least 3 months 
• ECOG PS of 0 or 1 
• Patient has given written informed consent 
Exclusion 
criteria 
• More than one prior chemotherapy regimen for advanced and/or metastatic or recurrent 
NSCLC 
• More than one chemotherapy treatment regimen (either neoadjuvant or adjuvant or 
neoadjuvant + adjuvant) prior to first-line chemotherapy 
• Previous therapy with other VEGFR inhibitors (other than bevacizumab) or docetaxel for 
treatment of NSCLC 
• Persistence of clinically relevant therapy related toxicities from previous chemotherapy 
and/or radiotherapy 
• Treatment with other investigational drugs or other anti-cancer therapy, or treatment in 
another clinical trial within the past 4 weeks before start of therapy or concomitantly with 
this trial 
• Radiotherapy (except extremities and brain) within the past 3 months prior to baseline 
imaging 
• Active brain metastases or leptomeningeal disease 
• Radiographical evidence of cavitary or necrotic tumours 
• Centrally located tumours with radiographical evidence (CT or MRI) of local invasion of 
major blood vessels 
• History of clinically significant haemoptysis within the past 3 months 
• Therapeutic anticoagulation (except low dose heparin) or antiplatelet therapy (except for 
chronic low-dose therapy with acetylsalicylic acid ≤325mg/day) 
• History of major thrombotic or clinically relevant major bleeding event in the past 6 months 
• Known inherited predisposition to bleeding or thrombosis 
• Significant cardiovascular diseases  
• Inadequate safety laboratory parameters 
• Significant weight loss (>10 %) within the past 6 weeks 
• Current peripheral neuropathy greater than CTCAE grade 2 except due to trauma 
• Pre-existing ascites and/or clinically significant pleural effusion 
• Major injuries and/or surgery within the past 10 days prior to randomisation with 
incomplete wound healing 
• Serious infections requiring systemic antibiotic therapy 
• Decompensated diabetes mellitus or other contraindication to high-dose corticosteroid 
therapy 
• Gastrointestinal disorders or abnormalities that would interfere with absorption of the study 
drug 
• Active or chronic hepatitis C and/or B infection 
• Serious illness or concomitant non-oncological disease or laboratory abnormality that may 
increase the risk associated with study participation or study drug administration 
• Patients who are sexually active and unwilling to use a medically acceptable method of 
contraception during the trial and for at least 12 months after end of active therapy 
• Pregnancy or breast feeding 
• Psychological, familial, sociological, or geographical factors potentially hampering 
compliance with the study protocol and follow-up schedule 
• Patients unable to comply with the protocol 
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Eligibility criteria for LUME-Lung 1 
• Active alcohol or drug abuse 
• Other malignancy within the past 3 years other than basal cell skin cancer, or carcinoma in 
situ of the cervix 
• Any contraindications for therapy with docetaxel 
• History of severe hypersensitivity reactions to docetaxel or other drugs formulated with 
polysorbate 80 (Tween 80) 
• Hypersensitivity to nintedanib and/or the excipients of the trial drugs 
• Hypersensitivity to contrast media  
CT=computerised (or computed) tomography, CTCAE=Common Toxicity Criteria for Adverse Events. ECOG PS=Eastern 
Cooperative Oncology Group Performance Status; MRI=magnetic resonance imaging, NSCLC=non-small-cell lung cancer, 
VEGFR=vascular endothelial growth factor receptor 
Source: adapted from Table 9 of the CS1 
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Appendix 4: Clinical endpoints and statistical analyses plan in LUME-
Lung 1  
Outcomes measured are summarised in Table 47. The TSAP43 is summarised in Table 48. 
Table 47 LUME-Lung 1 Outcomes measured 
Endpoint/ assessment Details 
Primary outcome 
PFS • PFS by central review, using modified RECIST (version 1.0) criteria. Tumour 
assessments performed at baseline (within 4 weeks of randomisation), and 
every 6 weeks after first docetaxel administration  
• PFS was defined as time from date of randomisation to date of disease 
progression, or to date of death, whichever occurred earlier  
• Disease progression was defined as: 
o new lesions, including new lesions in a previously irradiated field 
o an unequivocal increase in a tumour within a previously irradiated field 
o an increase in sum of longest diameter (SLD) of the target lesions of 
20% from nadir (lowest value measured since treatment started) 
• Patients who experienced a 30% reduction from baseline in SLD of target 
lesions and a single instance of a 20% increase in SLD from nadir were 
considered as having progressed 
• The primary PFS analysis considered all data collected until the cut-off date for 
the efficacy analysis, which was the date of the 713th PFS event 
• The stratified log-rank test was used to test for the effect of nintedanib at the 2-
sided alpha-level of 0.05. The log-rank test included the four stratification 
factors used at randomisation. 
Secondary outcomes 
OS • OS was the key secondary endpoint  
• OS was defined as the time from date of randomisation to date of death 
(irrespective of cause of death). Patients who stopped active trial 
treatment were followed until death or lost to follow-up 
• Stratified log-rank test and a two-look Lan-DeMets group sequential 
design with an O’Brien-Fleming-type boundary at a two-sided cumulative 
5% level of significance. 
PFS by local investigator 
review 




Tumour response by central independent review and local investigator 
assessment, according to modified RECIST (version 1.0) criteria was assessed at 
baseline (within 4 weeks of randomisation) and every 6 weeks after first docetaxel 
administration, and categorised into one of the following categories:  
• complete response (CR) - disappearance of all target lesions and non-
target lesions 
• partial response (PR) - at least a 30% decrease in the SLD of target 
lesions, taking as reference the baseline SLD 
• stable disease (SD) - neither sufficient shrinkage of target lesions to 
qualify for PR nor sufficient increase to qualify as PD; persistence of one 
or more non-target lesions 
• progressive disease (PD):  
o new lesions, including new lesions in a previously irradiated field 
o an unequivocal increase in a tumour within a previously irradiated 
field 
o an increase in SLD of the target lesions of 20% from nadir 
(lowest value measured since treatment started) 
• unknown (UNK) 
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Endpoint/ assessment Details 
 Evaluation of tumour response was based on radiological tumour assessments (CT 
or MRI)  
• Tumour images were centrally reviewed by a panel of central independent 
radiologists. Following radiological review, all patient information was 
presented to an oncologist. The radiologists and the oncologist were 
blinded to treatment 
• Best overall response:  
o represents the best response a patient has had during their time 
in the study up until progression, last evaluable assessment in 
the absence of progression or the start of subsequent anti-cancer 
therapy.  
o for patients whose progression event is death, best objective 
response will be calculated based on data up until the last 
evaluable RECIST assessment prior to death. 
• Confirmed objective response 
o A patient was considered to have a confirmed objective response 
if a CR or PR was confirmed by imaging no earlier than 28 days 
after the first occurrence of the response 
• Disease control 
o Disease control was defined as a best overall response of CR, 
PR, or SD recorded at least 6 weeks after the date of 
randomisation 
• Time to confirmed objective response 
o Time from randomisation to first documented confirmed response 
(CR or PR) recorded at least 6 weeks after the date of 
randomisation 
• Duration of confirmed objective response 
o Time from first documented confirmed response (CR or PR) to 
progression, or death in the absence of progression 
• Duration of disease control 
o Time from randomisation to progression, or death in the absence 
of progression (whichever occurs earlier) amongst patients with 
disease control 
• Change in tumour size 
o The best change in size (i.e. SLD) of target lesions from baseline 
was analysed. The maximum SLD decrease from baseline (or 
the minimum increase in SLD for patients with no reduction in 
target lesion size) was considered as the best change of the 
target lesion size in a patient 
Clinical improvement • Clinical improvement quantified the maintenance of body weight and 
ECOG PS, by measuring the time from randomisation to deterioration in 
body weight of more than 10% from baseline, and/or increase in ECOG 
performance score of at least 1 category from baseline, whichever 
occurred earlier. Patients who died without prior deterioration were 
considered as having deteriorated at the time of death. 
• Clinical improvement was analysed until end-of treatment only 
HRQoL • HRQL was measured at the screening visit, at 21-day intervals during 
treatment, at the end of active treatment, and at the first follow-up visit by 
the following standardised self-assessment questionnaires:  
o EQ-5D health status self-assessment questionnaire 
o EORTC Quality of Life Questionnaire (EORTC QLQ-C30) 
o EORTC lung cancer specific supplementary module (EORTC 
QLQ-LC13) 
• The EQ-5D includes the following two questionnaires, which were 
analysed descriptively:  
o Five dimensions of health (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression), which are analysed 
descriptively. Each dimension comprised three levels (no 
problems, some problems, severe problems) 
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Endpoint/ assessment Details 
o A visual analogue scale (VAS) recorded the respondents self-
rated health status on a vertical graduated (0 to 100) scale 
• The EORTC QLQ-C30 questionnaire includes a global health 
status/HRQL scale, 5 functional scales, 3 symptom scales, and 6 single 
items to assess dyspnoea, insomnia, appetite loss, constipation, diarrhoea 
and financial difficulties. The QLQ-LC13 supplementary module was 
designed to be used by patients receiving chemotherapy or radiotherapy. 
It incorporates a multi-item scale to assess dyspnoea, and a series of 
single items to assess pain, coughing sore mouth, dysphagia, peripheral 
neuropathy, alopecia and haemoptysis.  
• The main HRQL endpoints were the time to deterioration for cough (QLQ-
LC13, question 1), dyspnoea (QLQ-LC13, questions 3 to 5) and pain 
(QLQ-C30, Questions 9 and 19) and were evaluated as follows: 
o Distribution of patients with improved, stable, or worsened 
scores. Improvement was defined as scores that improve by ≥10 
points (0 to 100 point scale) at any time during study. Worsening 
was defined as a worsening in EORTC scores of ≥ 10 points at 
any time in patients with no improvement. Otherwise, a patient 
was considered stable. 
o Time to deterioration: defined as time from randomisation to the 
first 10-point increase (i.e. worsening) from baseline score 
Pharmacokinetics • Pharmacokinetics of nintedanib and of its clinical relevant metabolites 
BIBF1202 and BIBF1202 glucuronide were determined from blood 
samples taken at Visit 2 of Treatment Course 2 and 3; both prior to and 
after the administration of nintedanib. 
Safety • Incidence and intensity of AEs according to the CTCAE version 3.0 
• Changes in safety laboratory parameters 
• The safety analysis included data collected until the safety cut-off date 
CR=complete response; CT=computed tomography; CTCAE=Common Terminology Criteria for Adverse Events; 
ECOG=Eastern Cooperative Oncology Group; EORTC QLQ LC=European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire (Lung Cancer Module); EMA=European Medicines Agency; EORTC= European 
Organisation for Research and Treatment of Cancer; EQ-5D=European Quality of Life-5 Dimensions; HRQL=health related 
quality of life; MRI=Magnetic resonance imaging; OS=overall survival; PD=progressive disease; PFS=progression-free survival; 
PR=partial response; QLQ=quality of life questionnaire; PRO=patient reported outcome; RECIST=Response Evaluation Criteria 
in Solid Tumours; SD=stable disease; SLD=sum of longest diameters; VAS=visual analogue scale 
Source: Table 13 of the CS1 
 






A pre-planned futility analysis was to be performed by the central independent DMC after 
approximately 50% of the PFS events needed for the primary PFS analysis had occurred (~356 
events), for the purpose of advising the sponsor as to whether or not the study should continue as 
planned. The sponsor was blinded to the results of this analysis. Although PFS by central 
independent review was the primary endpoint, PFS as assessed by the local investigator was used 
for the futility analysis because of the logistical complexity and the time it took to complete the 





The primary PFS analysis was to be performed when 713 patients had experienced a centrally 
independently assessed PFS event (cut-off date 2 November 2010). 
At this time, a protocol-defined interim analysis of OS was also to be performed. The primary 




The final analysis of OS was performed when 1,151 patients had died (cut-off date 15 February 
2013).  
At the time of the final OS analysis an updated analysis of all available PFS events was also 
performed.  
 
DMC=data monitoring committee; ITT=intention-to-treat; OS=overall survival; PFS=progression-free survival 
Source: TSAP43 
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Appendix 5: Subgroup and sensitivity analyses in LUME-Lung 1  
Subgroup analyses 
A number of subgroup analyses for the primary endpoint of PFS assessed by central review 
and for the secondary outcome OS were pre-specified in the protocol: 
• tumour histology (squamous vs non-squamous)  
• baseline ECOG PS (0 vs 1) 
• presence of brain metastases at baseline (yes vs no) 
• prior treatment with bevacizumab (yes vs no) 
• sex (male, female) 
• age (<65years, ≥65 years) 
• race (Asian vs non-Asian patients; information was derived from the race categories 
as documented on the CRF) 
• smoking status (never smoked vs currently smokes/ex-smoker) 
 
The following subgroup analyses were added post-hoc: 
• geographical region (Asia, Europe, South Africa; based on country of enrolment) 
• best response to first-line therapy (CR/PR/SD, PD, unknown/missing/NA) 
• sum of longest diameters at baseline (<7.5cm vs ≥7.5cm) 
• time since first-line therapy (<9 months vs ≥9 months) 
 
The company lists a number of baseline characteristics (CS1, p.77), which were also 
investigated for subgroup effects. However, neither the protocol53 or CTR40 specified 
whether these were pre-specified or post-hoc analyses. Therefore, the ERG asked for 
clarification on this issue and the company responded stating that three variables were pre-
specified in the protocol53 and three were included in an amendment to the TSAP44 for the 
final OS analysis of LUME-Lung 1.24  
• presence of liver metastases (yes vs no) (a priori). 
• disease stage at diagnosis (<IIIB/IV, IIIB, IV) (a priori). 
• concomitant therapy with biphosphonates at baseline (yes vs no) (a priori). 
• presence of adrenal metastases (yes vs no) (included in amendment) 
• number of metastatic organs at baseline (≤2 metastatic organs, >2 metastatic 
organs, not centrally reviewed) (included in amendment) 
• lactate dehydrogenase (LDH) level at baseline (LDH ≤1, LDH >1) (included in 
amendment) 
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Sensitivity analyses 
The following sensitivity analyses were pre-specified in the protocol for PFS: 
• Analysis using a Cox proportional hazards model fitting the four stratification factors 
as covariates 
• Analysis using a stepwise variable selection method to identify covariates that might 
be relevant to efficacy 
• Analysis replacing actual tumour imaging dates with the originally scheduled dates of 
radiological assessments 
• Analysis using an interval-censoring approach 
 
However, the ERG found that the list of covariates included in the model for the second 
sensitivity analysis were listed in the CS1 (pages 74 to 75), but were not all pre-specified in 
the protocol. The ERG asked for clarification on whether these factors were pre-specified, 
and the company responded with the following information, stating that only four out of 
twelve were pre-specified: 
• Brain metastases at baseline: predefined strata and also for this analysis in interim 
TSAP LUME-Lung 1 before unblinding of primary PFS data (a priori). 
• Prior treatment with bevacizumab: predefined strata and also for this analysis in 
interim TSAP LUME-Lung 1 (a priori). 
• Body- surface area: (post-hoc). 
• Age: Predefined in interim TSAP LUME-Lung 1 in subgroup section (a priori). 
• Duration of first-line chemotherapy: (post-hoc). 
• Time to first progression: specified in TSAP amendment (post-hoc). 
• Time since first histological diagnosis: (post-hoc). 
• Presence of ipsilateral metastases in the lung at baseline: (post-hoc). 
• Presence of contralateral metastases in the lung at baseline: (post-hoc). 
• Bone metastases at baseline: (post-hoc). 
• Adrenal metastases at baseline: specified in TSAP amendment (post-hoc). 
• Sum of target lesions at baseline: predefined in interim TSAP LUME-Lung 1 (a priori). 
 
The following sensitivity analyses were pre-specified in the protocol for OS: 
• Analysis using a Cox proportional hazards model with three of the stratification 
factors used at randomisation as covariates(ECOG PS at baseline, prior 
bevacizumab treatment, presence of brain metastases at baseline) 
• Analysis using a model which included the stratification factors and the baseline sum 
of the longest diameters (SLD) of the target lesions (mm) as covariates. 
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Appendix 6: Methods utilised by the company for making indirect 
comparisons and mixed treatment comparisons  
Mixed treatment comparisons 
MTCs were performed using the Markov chain Monte Carlo software package OpenBUGs. 
The company ran all analyses using fixed-effects models, which assume there is no 
heterogeneity in relative effects. Random-effects models were also performed if sufficient 
data was available to estimate a random-effects coefficient, i.e. there were comparisons in 
the network with evidence from more than one trial. The company chose not to fit random-
effects models in situations where the data was sparse, as the estimate of random-effects 
variation would be too reliant on the choice of prior. The company chose to use vague (non-
informative) priors for study and treatment effects, in order to enable a moderate amount of 
random-effects variation.  
Three chains were used to run the analyses, and in all cases, the first 50,000 burn-in 
simulations were discarded to allow for convergence. Estimates were then obtained from a 
further 50,000 iterations. The company performed several validation checks to ensure that 
the models had converged sufficiently and that the estimates produced were reliable. These 
included examining the Brooks-Gelman-Rubin (BGR) plots and inspection of the values of 
the Monte Carlo error (Monte Carlo standard error of the mean) to assess validity.  
Bucher indirect comparisons 
A Bucher indirect comparison is a simple method of comparing two treatments for which 
there is no direct evidence. In order to obtain an estimate of the treatment effect of A vs C, it 
is possible to look at two trials which have a common comparator, i.e. Trial 1 considering A 
vs B, and Trial 2 considering B vs C. The Bucher method does not incorporate random-
effects variance from trials elsewhere in the evidence network, i.e. trials which consider C vs 
D.  
Wherever possible, the company conducted Bucher indirect comparisons.  
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Appendix 7: Assessment of proportional hazards assumption in LUME-
Lung 1 Trial 
Both indirect comparisons and MTCs require the trials included in the analysis to conform to 
the assumption of proportional hazards for meaningful and robust results to be generated. 
This means that the hazard (i.e. the risk of an event occurring at a particular time) is in a 
constant ratio between the patterns of events observed in the two treatment arms, 
independent of the time since randomisation. This is a strong assumption which is frequently 
violated, and it is important that its validity is confirmed prior to carrying out any meta-
analysis of outcomes from multiple clinical trials. 
In this appraisal a single trial (LUME-Lung 124) compares nintedanib plus docetaxel 
treatment with erlotinib through a network of trials in which the only links are trials which 
feature docetaxel monotherapy as a treatment arm. If the proportional hazards assumption is 
not supported by the LUME-Lung 124 trial data, any estimation of the relative effectiveness of 
nintedanib plus docetaxel vs erlotinib (i.e. a calculated HR) will lack credibility and be 
effectively meaningless. In this appendix the validity of the proportional hazards assumption 
in LUME-Lung 124 is considered for two key outcomes (PFS and OS) critical to the modelling 
of cost-effectiveness. 
PFS  
Figure 19 shows clearly that the PFS survival curve LUME-Lung 124 trial arms diverge after 
about six weeks and then converge and cross after about one year, indicating that the 
patient PFS advantage from nintedanib plus docetaxel treatment is limited to the first year 
after treatment. To test the proportional hazards assumption in this data set the HR has 
been calculated at each event time in either arm of the trial and are shown in Figure 19. If 
the proportional hazards assumption is supportable the HR values should vary randomly 
about a horizontal line corresponding to the conventional estimated HR for the trial. Clearly 
this is not the case as a strong upward trend is apparent following the initial fluctuations 
(which are due to the small numbers of events recorded in the first few weeks of the trial). 
On this basis it must be concluded that any HR estimated from a meta-analysis aimed at 
comparing PFS outcomes between nintedanib plus docetaxel and any treatment other than 
docetaxel does not satisfy the essential requirement for validity and reliability, and cannot be 
considered appropriate for populating a cost-effectiveness model. 
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Figure 19 Variation in estimated PFS HR with time in the LUME-Lung 1 clinical trial 
 
OS  
Similarly the trend of OS HR estimates also show systematic variations over time (Figure 
20): from a peak of 1.1 at four months, falling to less than 0.75 at 400 to 500 days, and 
increasing thereafter. This pattern is not consistent with the presumption of a steady 
common HR independent of time, and therefore indicates that the proportional hazards 
assumption cannot be applied to the LUME-Lung 124 OS data set with confidence. 
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Figure 20 Variation in estimated OS HR with time in the LUME-Lung 1 clinical trial 
 
CONCLUSION 
Without a single robust time-invariant HR for either PFS or OS it is not possible to use 
conventional methods to link and compare the outcomes of patients treated with nintedanib 
plus docetaxel to patients treated with erlotinib in either the TAILOR59 or the WSY00162 
trials, regardless of the characteristics of the other trials in the network. Without such 
comparison meaningful cost-effectiveness analysis involving erlotinib is not possible. 
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Appendix 8: ERG Revisions to company’s model: Nintedanib STA 
All revisions are activated by a binary logic switch with 0 = unchanged, 1 (or any non-zero number) = apply ERG modification. 
Logic switches are indicated by range variables Mod_n where n = 1 - 12. The Mod numbers do not directly match the Table Row numbers, and 
one Table Row involves applying 2 similar Mod revisions simultaneously. 
A menu of revisions/Mod numbers appears on the ‘Results’ worksheet together with summary results as used to transfer to the ERG report. 




Associated detail Implementation instructions 
  ERG_Survival_Tables.xlsx Copy this worksheet as an additional sheet in the model. Ensure that the named 
ranges ERG_OS, ERG_PFS, ERG_TOT are correctly named in the model. 
 
1. ERG OS 
estimates 
Mod_7 LUME1_OS40-1-3.xlsx In Sheet ‘Survival’, 
Replace formula in cell AW119 by 
  =IF(Mod_7=0,OFFSET(AI119,0,2*ch_OS-2),VLOOKUP(B119,ERG_OS,2)) 
Copy formula in cell AW119 to range AW120:AW405 
 
Replace formula in cell AX119 by 
  =IF(Mod_7=0,OFFSET(AJ119,0,2*ch_OS-2),VLOOKUP(B119,ERG_OS,3)) 
Copy formula in cell AX119 to range AX120:AX405 
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Associated detail Implementation instructions 
2. ERG PFS 
estimates 
Mod_6 LUME1_PFS-1-1.xlsx In Sheet ‘Survival’, 




Copy formula in cell M119 to range M120:M405 
 




Copy formula in cell N119 to range N120:N405 
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Associated detail Implementation instructions 








In Sheet ‘comp1Model’,  
Replace formula in cell L15 by   
=IF(Mod_8=0,100%,VLOOKUP(E15,ERG_TOT,4)) 
Replace formula in cell L16 by 
   =IF(Mod_8=0,L15*(1-
rDiscontinuation_nine_Comp1),VLOOKUP(E16,ERG_TOT,4)) 
Copy formula in L16 to range L17:L301 
 
Replace formula in cell M15 by   
=IF(Mod_8=0,100%,VLOOKUP(E15,ERG_TOT,3)) 




Copy formula in M16 to range M17:M301 
 
In Sheet ‘comp2Model’, replace formula in cell M15 by 
   =IF(Mod_8=0,100%,VLOOKUP(E15,ERG_TOT,2)) 
Replace formula in cell M16 by 
   =IF(Mod_8=0,IF(OR(Efficacy!$F$43="no",E15<4),M15*(1-
rDiscontinuation_Comp2),0), 
VLOOKUP(E16,ERG_TOT,2))*IF(AND(Mod_4=1,E16>3),0,1) 
Copy formula in M16 to range M17:M301 
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Associated detail Implementation instructions 
4. Mid-cycle 
adjustment 
Mod_10 None In Sheet ‘comp1Model’, replace formula in cell BE16 by 
   =IF(Mod_10=0,AVERAGE(S15:S16),S15)*cDrugAdmin_doxa_Comp1 
Copy formula in BE16 to ranges BE17:BE19, BE21:BE301 




In Sheet ‘comp2Model’,  
Replace formula in cell AV16 by   
=IF(Mod_10=0,AVERAGE(S15:S16),S15)*cDrugAdmin_Comp2 
Copy formula in AV16 to ranges AV17:AV19, AV21:AV301 
Replace formula in cell AV20 by   
=IF(Efficacy!$F$43="no",IF(Mod_10=0,AVERAGE(S19:S20),S19)*cDrugAdmin_C
omp2,0) 












In Sheet ‘UnitCosts’, 
Replace formula in cell H35 by   =IF(Mod_1=0,Y37,98.480134%) 
Replace formula in cell H36 by   =IF(Mod_1=0,Y38,99.08405%) 
Replace formula in cell H37 by   =IF(Mod_1=0,Y39,99.08405%) 
Replace formula in cell I35 by   =IF(Mod_1=0,DrugCostCalc!$S$71,37.5) 
Replace formula in cell I36 by   =IF(Mod_1=0,G36*F36*BSA,37.5) 







In Sheet ‘UnitCosts’, 




Mod_2 FNcost.xlsx In Sheet ‘AdverseEvents’,   
Replace formula in cell I195 by   =IF(Mod_2=0,SUM(H196:H209),7352.543797)  
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Associated detail Implementation instructions 
7. Monitoring 
cost 
Mod_9 None In Sheet ‘ResourceUse’,  
Replace formula in cell E91 by     =100%*IF(Mod_9=0,1,0) 
Replace formula in cell F91 by     
=timeDaysInCycle/(2.5*timeDaysInMonth)*IF(Mod_9=0,1,0) 
Replace formula in cell M67 by   =IF(Mod_9=0,0,100%) 
Replace formula in cell N67 by    
=timeDaysInCycle/(2.5*timeDaysInMonth)*IF(Mod_9=0,0,1) 
Replace formula in cell P67 by     =IF(Mod_9=0,UnitCosts!$E$73,0) 
Replace formula in cell Q67 by    =IF(Mod_9=0,M67*N67*P67,0) 
8. Discounting 
method 
Mod_3 None In Sheet ‘comp1Model’,  
Replace formula in cell H16 by   =IF(Mod_3=0,H15/(1 + discCc),1/(1 + 
iDiscCost)^INT(F16)) 
Replace formula in cell I16 by     =IF(Mod_3=0,I15/(1 + discHc),1/(1 + 
iDiscHealth)^INT(F16)) 
Copy range H16:I16 to rows 17-301 
 
 
In Sheet ‘comp2Model’,  
Replace formula in cell H16 by   =IF(Mod_3=0,H15/(1 + discCc),1/(1 + 
iDiscCost)^INT(F16)) 
Replace formula in cell I16 by   =IF(Mod_3=0,I15/(1 + discHc),1/(1 + 
iDiscHealth)^INT(F16)) 
Copy range H16:I16 to rows 17-301 
 
9. Disutility of 
fatigue 
Mod_5 None In Sheet ‘Utilities’ 
Replace formula in cell E66 by  
   =(SUMPRODUCT(Utilities!$E$50:$E$62,AdverseEvents!$E$34:$E$46) + 
IF(Mod_5=0,0,(-0.326-E55)*AdverseEvents!E39))/AdverseEvents!$E$48 
Replace formula in cell E66 by 
   =(SUMPRODUCT(Utilities!$E$50:$E$62,AdverseEvents!$F$34:$F$46) + 
IF(Mod_5=0,0,(-0.101-E55)*AdverseEvents!F39))/AdverseEvents!$F$48 
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Associated detail Implementation instructions 
10. Stable 
disease costs 
Mod_12 None In Sheet ‘Resource Use’ 
Replace formula in cell M65 by        =IF(Mod_12=0,100%,0%) 
Replace formula in cell N65 by         =IF(Mod_12=0,timeWeeksInCycle,0) 
Replace formula in cell M78 by        =IF(Mod_12=0,100%,0%) 




Mod_4 None See details for #3 
 
 
 
 
